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ABSTRACT 
Hematopoietic stem cells (HSCs) regulate the process of hematopoiesis, which is the formation 
and development of all the body’s blood and immune cells. The HSCs ability to either self-renew 
or differentiate in order to produce these populations is determined by a number of known as 
well as hypothesized regulators of HSC biology in specific microenvironments, termed as 
‘niches’, in vivo. However, in order to explore their therapeutic potential, controlling HSC fate in 
vitro is important. Current culture approaches lack the capacity to incorporate combinations of 
instructive signals to guide desired HSC fate decisions. Furthermore, approaches to examine in 
detail signaling mechanisms involved in cross-talk between multiple signals are largely 
underdeveloped.  In this thesis, I describe the development of a gradient hydrogel platform that 
enables co-culture of HSCs with multiple niche components, namely exogenous niche cells, 
extracellular matrix proteins, and matrix-tethered biomolecular signals. Gradients in 
microenvironmental signals are common across the marrow; these gradients are thought to play a 
critical role in HSC signaling and migration. The biomaterial fabrication platform described here 
enables creation and subsequent analysis of gradient environments in an attempt to understand 
the effects of niche components on HSC fate. Building upon the gradient platform, we will also 
discuss the development of an approach to functionalize the biomaterial with proteins that 
provide an additional degree of instructive signals to manipulate HSC response. Finally, using a 
diffusion-limited hydrogel network we alter the balance of niche-cell mediated paracrine and 
HSC-mediated autocrine signals as a novel approach to manipulate HSC response. Balancing 
these signals in an in vitro platform may eventually offer a path for improved control over HSC 
self-renewal versus lineage specification for a range of clinical applications. An ultimate goal is 
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developing the capacity to engineer HSC fate in vitro, enabling better clinical therapies and 
providing insights into blood-related cancers and disorders.  
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CHAPTER 1: INTRODUCTION: THE HEMATOPOIETIC STEM CELL 
NICHE, ITS CLINICAL SIGNIFICANCE AND BIOMATERIAL 
PLATFORMS AS NICHE ANALOGS 
1.1 Thesis overview 
This thesis is aimed at developing biomaterial platforms to improve our ability to understand, 
and eventually mimic, the regulatory capability of the bone marrow (BM) responsible for 
controlling the process of hematopoiesis – the formation of the full complement of our blood and 
immune cells. The progenitor cells responsible for this process are hematopoietic stem cells 
(HSCs). While the genetic material required to control hematopoiesis is contained within the 
HSC, the microenvironment surrounding the HSC – the niche – provides critical signals to 
regulate this process. Understanding its mechanisms can also provide vital clues regarding blood 
disorders and cancers such as leukemia and lymphoma that originate in the marrow. Our 
comprehension of the HSC niches within the marrow has increased greatly over the years. 
However, tools to replicate the niche outside of the body, for expansion of patient-derived HSCs, 
regulated production of defined lymphoid or myeloid cells, or as a model system to investigate 
mechanisms or treatment of hematopoietic diseases, do not exist. Subsequent chapters of this 
thesis are dedicated to describing the development of a biomaterial platform capable of 
sequentially adding multiple niche components in the BM and investigating their impact on HSC 
bioactivity. Such a tool provides a pathway to developing clinically-relevant tools to guide the 
expansion or differentiation of HSCs. 
Chapter 1 provides a review of our current understanding of the BM niche, its key regulators, 
their functions, and tools currently available to engineer HSC fate in vitro. Chapter 2 describes 
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the development of a microfluidic platform to generate gradients of multiple HSC niche 
components across a three-dimensional (3D) hydrogel to enable high throughput analysis of HSC 
niche interactions. Chapter 3 discusses the development of a methacrylated gelatin hydrogel 
construct for selective delivery of instructive biomolecular cues to guide HSC response. Chapter 
4 then applies these biomaterial tools to explore the impact of using the hydrogel platform to 
regulate cell-cell signaling between HSCs and a bone marrow derived niche cell. Notably, while 
the potential for a balance between autocrine and paracrine signaling between HSCs and niche 
cells has been proposed, here we demonstrate integration of both classes of signals within a 
single hydrogel to impact in vitro culture of primary HSCs. Finally, Chapter 5 will conclude the 
thesis with a summary of accomplishments as well as recommendations for ongoing and future 
work. 
1.2 Chapter overview  
The BM niche provide microenvironmental signals responsible for maintaining a balance 
between HSC quiescence, self-renewal, and lineage specification required for life-long 
hematopoiesis. The regulatory mechanisms of the HSC niche have been subject to significant 
investigations over the past decades due to the clinical potential of hematopoietic stem cells. 
While these studies have provided significant information regarding niche components and 
signaling pathways governing HSC fate decisions, much remains to be discovered. This chapter 
highlights key aspects of the BM niche and the progress made so far in understanding its 
operations. Identifying key niche components that regulate HSC behavior in vivo will provide the 
basis for understanding the molecular cross-talk that occurs within the marrow. We will then 
review engineering approaches used to guide and direct HSC activity on an external platform 
that enables their selective expansion or differentiation. The final segment is devoted to 
3 
 
discussing the current shortfalls in this field as well as the opportunities that exist to enable a 
broader impact of clinically relevant strategies for controlling HSC biology.  
1.3 Clinical significance of HSCs 
A primary motivation for developing artificial bone marrow platforms for in vitro culture of 
HSCs lies in their significant clinical relevance. Hematopoietic stem cell transplant, more 
commonly known as bone marrow transplant (BMT) is used to reconstitute a cancer patient’s 
compromised blood and immune system after treatment with chemotherapy. Since its first 
development roughly 40 years ago, BMTs have been routinely used to treat various forms of 
leukemia, lymphoma and myeloma [4, 5]. The three main types of transplants currently in 
practice are autologous, allogeneic and umbilical cord blood. In autologous transplants, the 
patient’s own hematopoietic stem cells are isolated from the marrow; alternatively, HSCs can be 
induced to mobilize into the peripheral blood for recovery. For some forms of hematopoietic 
pathologies, it is not possible to use autologous cells; here, HSCs isolated from a matched donor 
– allogeneic HSCs – can be used [6]. Recently, matched hematopoietic progenitors isolated from 
umbilical cord blood (UCB) have also been used as an alternative source of HSCs [4, 7]. The 
basic criterion in these transplants is matching human leukocyte antigen (HLA) of the donor with 
the patient. Despite the use of matched donor cells, a wide range of side-effects significantly 
impact patient mortality such as infections, graft versus host disease (GVHD) or low/poor 
engraftment of the stem cells in patient marrow [8, 9]. Additionally, patients also require blood 
transfusions before, during and after the transplant depending on the cancer and its associated 
treatment [10]. Despite all these efforts, the survival statistics are not encouraging. Autologous 
transplants, owing to match-related donors, have a high survival rate of 80-90%. However, the 
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survival rate for allogeneic and UCB transplants vary greatly based on donor match and the type 
of cancer, anywhere between 30 – 70% over a 5 year period [11].  
As HSCs play a direct role in several blood-related disorders and cancers, the ability to engineer 
their fate in vitro for expansion or directed cell differentiation has clinical significance from the 
perspective of improved bone marrow transplants as well as development of other cell-based 
therapies. Exercising such control over HSC fate not only requires a better understanding of their 
regulation within the body, but also the ability to replicate those fate decisions in vitro using 
biomimetic culture platforms. 
1.4 HSC Functionality, Location and Identification 
HSCs have the ability to generate the body’s full complement of lymphoid (immune) and 
myeloid (blood) cells (Figure 1.1). The most primitive form of the stem cells are the long-term 
HSCs (LT-HSCs), which retain their ability to self-renew indefinitely. These are followed by 
short-term HSCs (ST-HSCs) that are more differentiated but still have the capacity to self-renew. 
During hematopoiesis, HSCs subsequently differentiate into multipotent progenitors (MPPs) 
which retain multi-lineage differentiation capacity, but which have lost the ability to self-renew. 
MPPs further specify into common myeloid progenitors (CMPs) or common lymphoid 
progenitors (CLPs). Despite their low frequency in the marrow (~0.01% [12]) HSCs are able to 
produce a large numbers of differentiated progeny. On average, this requires production of 2.5 
billion red blood cells (RBCs), 2.5 billion platelets and 1 billion granulocytes per kg of body 
weight per day [13]. Beyond maintaining hematopoietic homeostasis, HSCs are also commonly 
mobilized into the peripheral blood, either via biomolecular signals such as granulocyte colony-
stimulating factor (G-CSF) or in response to significant trauma. In such cases, HSCs exit the 
5 
 
bone marrow and circulate through the blood system. Although HSCs typically remain within the 
bone marrow, circulating HSCs are also a part of maintaining hematopoiesis and are able to 
trigger enhanced hematopoietic cell proliferation and/or differentiation in times of stress [14, 15].  
The most common method for identifying HSCs is via surface antigen expression. While no 
single unique surface antigen exists for a given hematopoietic cell subtype, combinations of 
surface antigens can be used to selectively identify hematopoietic progenitors at many stages of 
differentiation. As seen in Figure 1, HSCs can be classified ranging from long-term HSCs (LT-
HSCs) that are the most primitive progenitor type to short-term HSCs (ST-HSCs) or multi-potent 
progenitors (MPPs) that are further differentiated along the hematopoietic hierarchy. Together, 
these groups of cell types are termed as hematopoietic stem and progenitor cells (HSPCs). The 
surface antigen expression of these cells is used for the purpose of identification and analysis, 
with combinations of these surface markers used to identify progenitors in various stages of 
development [12, 16, 17]. A broad population of HSPCs can be isolated as those marrow cells 
lacking lineage (differentiated) antigens (Lin
-
), but expressing the stem cell markers c-kit and 
Sca-1
+
; these Lin
-
Sca1
+
cKit
+
 cells are often termed LSK cells. Additional surface antigens (e.g., 
Flk2, CD34, and SLAM antigens CD150, CD244, CD48) can be used to identify increasingly 
pure populations of HSCs. However, the gold standard for identifying putative HSCs remains 
determination of their marrow-reconstituting ability in vivo via a repopulation assay. Here, the 
putative stem cells are injected into the tail vein of a mouse that has had its marrow ablated via 
irradiation. A population of cells that contains long-term repopulating HSCs will be able to 
successfully home into the marrow and reconstitute the entire hematopoietic system. Such tests 
are usually performed in order to confirm that the selected populations are indeed HSCs [17]. 
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1.5 The bone marrow HSC niche 
The process of hematopoiesis first occurs during fetal development in the embryo. Thereafter, 
HSCs migrate from the aorta-gonad-mesonephrous (AGM) region of the embryo to the placenta, 
fetal liver and then spleen [18]. Eventually, hematopoiesis shifts to the marrow where it is 
maintained in what is termed as a ‘niche’. The concept of an HSC niche was introduced in 1978 
by Schofield in order to explain the differential engraftment of HSCs from the bone marrow and 
spleen of mice [13, 19]. This hypothesis permitted the analysis of stem cells as an entity that 
balanced proliferation and quiescence while residing in these specialized bone marrow niches 
that dictated their behavior. In humans, HSCs first primarily reside within the bone marrow 
cavity of the long bones (also called red marrow), especially the femur and tibia. This serves as 
the primary site for hematopoiesis. Over time, the red marrow in the long bones is replaced by 
adipose tissue (also called yellow marrow, Figure 1.2). Hematopoiesis shifts to proximal region 
of the long bones along with other sites of the axial skeleton such as cranium, sternum, ribs and 
vertebrae [20]. However, hematopoiesis remains localized within the long bones of mice, the 
primary model system used for investigating hematopoietic stem cells and their activity [20]. 
The general structure of the bone marrow is depicted in Figure 1.3. The central medullary cavity 
holds the yellow and red marrow and a dense vascular network. The endosteum forms the inner 
lining of the medullary cavity. The epiphysis at the ends of the long bones consists largely of 
spongy bone, also called trabecular bone surrounded by a layer of compact bone and periosteum. 
The entire bone marrow environment is connected by a complex network of veins and arteries 
required to deliver nutrients in and out of the marrow and provide a path for mobilization and 
homing of HSCS from and to the marrow. Given the complexity of the marrow environment, the 
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rarity of HSCs, and the relative lack of tools to examine the dynamics of hematopoiesis in situ, a 
variety of theories have been proposed regarding the location and regulatory action of niches 
within the bone marrow. While the exact nature and function of the HSC niche is still a subject 
of significant debate, two putative niche environments have been proposed as having particular 
importance in maintaining hematopoietic homeostasis: the endosteal niche near the bone 
endosteum at the edge of the marrow and the vascular niche near the sinusoidal endothelium and 
the bone marrow vasculature (Figure 1.3B) [15, 21-27].  
1.5.1 Endosteal niche  
An endosteal niche has been proposed to exist in the region of marrow found along the bone 
lining (endosteum) of the bone marrow. Here, the tissue architecture and cells commonly found 
at the bone surface, notably osteoblasts (bone-forming cells) and mesenchymal stem cells have 
been proposed as important regulators of HSC fate. Calvi et al. demonstrated a correlation 
between the number of functional HSCs in the niche and the number of osteoblasts present, using 
an osteoblast-specific parathyroid hormone (PTH) receptor [28]. Similarly, Zhang et al. showed 
that increasing the number of spindle-shaped N-cadherin expressing osteoblasts (SNO), via 
conditional inactivation of the receptor for bone morphogenic protein, BMPR1A, resulted in an 
increase in the number of HSCs [29]. However, evidence suggests that the mode of activation of 
osteoblasts is also important as simply increasing the number of osteoblasts does not necessarily 
correspond to higher HSC populations [30]. For example treatment of mice with strontium 
increased osteoblast numbers without affecting HSCs [31] whereas a reduction in osteoblast 
numbers in a chronic inflammatory arthritis model did not affect HSC numbers [32]. Nestin+ 
mesenchymal stem cells (MSCs) represent a second cell fraction often found in close association 
8 
 
with HSCs and are believed to play a critical role in their maintenance within the endosteal niche 
[33].  
The endosteal niche has been proposed to provide a series of signals important for maintaining 
HSC quiescence [34]. Notably, studies have shown that signaling pathways associated with N-
Cadherin/N-Cadherin, Tie-2/Angiopoietin-1, and thrombopoietin/Mpl interactions between 
HSCs and the surrounding niche cell environment provide critical signals driving HSC 
quiescence and maintenance [20, 35-37]. Further, biochemical signals such as CXCL-12, SCF 
and VCAM-1 critical for HSC self-renewal are also known to be expressed by osteoblast lineage 
cells [27, 38, 39]. Notch ligands such as Jagged-1 and -2, Delta-1 and -4 and Hes-1 and -5 also 
play roles in the osteoblast-HSC interaction in the niche [40]. 
Physico-chemical factors may also influence HSC homing and engraftment in the endosteal 
niche. As the endosteum is the site of bone formation and remodeling, it contains a high 
concentration of Ca
2+ 
ions. Not surprisingly, the role of Ca
2+
 and its receptor CaR in the 
lodgment of HSCs in the endosteal niches has been demonstrated [26, 27]. Similarly, the 
endosteum is known for its low blood perfusion and oxygen concentration. Analysis of the HSCs 
lodged in the bone marrow indicates a hypoxic environment with increased expression of the 
hypoxia inducible factor-1alpha (HIF-1α) and binding to chemical probes such as pimonidazole 
that detect hypoxic environments in vivo [41, 42]. However, it is interesting to note that recent 
evidence points towards the oxygen concentration to be higher in the arteries of the endosteal 
regions and lower in those of the marrow, a testimony to our ever-evolving understanding of the 
complex bone marrow environment [43]. 
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1.5.2 Vascular niche 
The vascular niche is closely associated with the perivascular endothelium surrounding the 
vessel structures within the marrow as well as the associated cells found in proximity to the 
blood vessel. The bone marrow vasculature plays an important role in the mobilization and 
homing of HSCs, likely providing biomolecular signals to mediate this process [21, 30]. HSCs 
have been observed to localize near bone marrow sinusoids in close association with the vascular 
endothelial cells [16, 38], with the soluble factor CXCL-12/SDF-1 believed to be the primary 
signaling pathway driving HSC mobilization towards the vasculature. These signals are 
commonly expressed by the CXCL-12 abundant reticular (CAR) cells as well as Nestin
+
 MSCs 
located in the vascular niche. The importance of the CXCL12 signaling pathway is emphasized 
in several studies. Sugiyama et. al. demonstrated the proximity of HSCs to the CAR cells along 
with a loss in HSC numbers with the depletion of CXCR4, the receptor to CXCL12 [38]. 
Similarly, Tzeng et. al. reported that targeted depletion of the CXCL12 gene resulted in an 
expansion in hematopoietic populations along with a loss in the long-term quiescent HSCs [44, 
45].  
Endothelial cells are also believed to significantly impact HSC maintenance and differentiation 
[24, 46-48]. Notably, Avecilla et al. demonstrated that generation of mature megakaryocytes and 
thrombopoiesis required cytokine (SDF-1, FGF-4, VCAM-1, VLA-4) mediated interaction 
between HSCs and bone marrow endothelial cells [49]. Similarly, Akt activation in endothelial 
cells has been shown to up-regulate FGF-2, IGFBP-2, Ang-1, BMP-4 and DHH expression, all 
of which play a role in HSC maintenance and proliferation [15, 50]. Perivascular mesenchymal 
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stem cells found at the periphery of endothelial cell structures have also been suggested to play 
an important role in HSC maintenance and expansion [50, 51]. 
1.5.3 Additional putative niche locations  
While two primary niche microenvironments have been proposed in literature, these two regions 
are part of a continuum of marrow environments that HSCs likely encounter. It is highly likely 
that significant cross-talk between niche signals from across the marrow may significantly 
impact HSC behavior [27, 52, 53] (Figure 1.4). For example, Kunisaki et al. demonstrated a 
potential arteriole niche that may play a significant role in HSC quiescence [54]. Using confocal 
immunofluorescence imaging and computer modelling of the mouse bone marrow, they showed 
quiescent HSCs associate with small arterioles found in the endosteal bone marrow. Whether this 
niche is an extension of the already establish endosteal niche is unclear. However, the fact 
remains that the notion of distinct niches may not be accurate. Rather, a continuum of 
environments may be important for providing the constellations of signals required to direct HSC 
fate decisions. 
1.5.4 Components of the HSC niche  
The niche signals responsible for regulating hematopoiesis can be classified into three categories: 
niche cell, extra cellular matrix (ECM); and biomolecules. The complexity of the niche in part 
arises from the large number of these regulators and their molecular cross-talk (Figure 1.4). 
While several of components in each category have been identified, their function and role in 
HSC maintenance is not completely understood and further complicated by the dynamic nature 
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of the niche. Although some components tend to be native to particular niches (e.g., osteoblasts 
in the endosteal niche), these associations need not always be exclusive.  
1.5.4.1 Niche cells 
The cellular component of the HSC niche consists of a heterogeneous population of several types 
of cells. Osteoblasts and Nestin
+
 MSCs are known regulators of the endosteal niche, although 
Nestin
+
 MSCs are also found in the perivascular niche [33, 55]. Similarly, osteoclasts (bone 
resorbing cells) secrete proteases such as MMP9 and cathespin-K which interfere with the 
CXCL12 signaling pathway, suggesting they may influencing HSPC mobilization from the 
marrow [30, 56, 57]. In addition to the osteoblastic lineage, cells of the monocytic and 
macrophage lineage are also known to impact HSC fate. As mature progeny of the HSCs, Chow 
et al. showed that reduction in their population resulted in the mobilization of HSCs into the 
blood stream [58].  
Cells near the bone marrow vasculature are believed to play a crucial role in HSC mobilization 
as well as homing. HSCs are known to localize near bone marrow sinusoids, indicating the 
presence of a perivascular stromal cell population. They are suspected to be a heterogeneous 
population consisting of multiple niche cell types such as mesenchymal stem cells and CXCL12 
abundant reticular (CAR) cells known to contribute towards HSC mobilization [30]. Vascular 
endothelial cells have long been known to be crucial in HSC engraftment [46, 59]. Finally, 
several other cell types of mesenchymal origin (chondrocytes, adipocytes, fibroblasts) as well as 
smooth muscle cells that populate the niche, are believed to influence HSC fate decisions [18].  
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1.5.4.2 The extracellular matrix (ECM) 
The ECM defines to the physical environment surrounding HSCs within the niche. It provides 
the structure to facilitate cell attachment and migration. It also provides extrinsic cues thought to 
impact differentiation, lineage specification, proliferation, and cell death [13, 60-63]. Here, HSC 
fate may be regulated not only by local expression levels of ECM component such as collagen 
types I – IV, Fibronectin, Laminin, Hyaluronic acid, Vitronectin, and Tenascin-C, but also by the 
structural organization and mechanical properties of the matrix [13]. Integrins and their ligands 
are one of the most commonly studied molecules that facilitate ECM-cell interaction [64, 65]. 
Several studies have explored the effects of integrins such as α2/4/5/6β1 on HSC functionality. 
For example, α4/5β1γ1 and α5β2γ1integrins associate with laminin and facilitate migration of 
CD34+ HSCs, while the α6 chain is involved in homing of HSCs to the bone marrow [13, 66, 
67].  Another important molecule is osteopontin (OPN), a matrix glycoprotein which is proposed 
to be a negative regulator of the HSC niche size [68, 69]. Apart from them, there are several 
other ligands such as drystoglycan and heparin sulfate proteoglycans that are involved in ECM-
based HSC regulation and further contribute to the complex dynamics observed within the niche 
[13, 70, 71]. 
1.5.4.3 Growth factors, Cytokines, and Transcription factors  
Biomolecular signals are perhaps the most extensively studied component of the HSC niche. As 
with niche cells, effects of these biomolecules are likely not isolated to one particular niche. 
Osteoblasts express several factors necessary for HSC function such as membrane-bound Stem 
Cell Factor (SCF), Angiopoietin-1 (Ang-1) and thrombopoietin (TPO) associated with HSC 
quiescence as well as CXCL-12, N-Cadherin and OPN related to HSC maintenance and retention 
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in the niche [35, 55, 72]. Nestin
+
 MSCs also express markers such as CXCL12, SCF, IL-7, 
VCAM-1 that are closely involved in HSC maintenance [55]. HSC mobilization to the peripheral 
blood has been reported to be mediated by a range of soluble biomolecules, notably CXCL-12, 
G-CSF, GM-CSF, IL-1/6/7/8/12, MIP-1, and Gro [73]. Cytokines such as SCF, TPO, EPO, 
and Flt3 have been implicated in HSC expansion both in vivo and in vitro, but may also play an 
important role in HSC engraftment, the process where HSCs home to the marrow and are 
functionally capable of successfully reconstituting the entire hematopoietic system [13, 74-76]. 
Interestingly, deletion of SCF from Tie2+ endothelial cells and Leptin-receptor (Lepr) expressing 
perivascular cells resulted in depleted HSC numbers, whereas the same deletion from osteoblasts 
or nestin+ MSCs did not affect the HSCs [24]. Similarly a wide range of studies have identified 
growth factors such as VEGF, FGF, PDGF, TGFβ, EGF, and IGF as playing key roles in HSC 
migration, mobilization, angiogenesis, quiescence, self-renewal, often times being secreted by 
multiple disparate cells within the marrow [77-82].  
The Wnt ligands and their Notch signaling have also been extensively studied with respect to 
their role in HSC as well as HPC regulation [39, 83, 84]. Notably, the canonical β-catenin 
mediated Wnt pathway negatively regulates vascular cell-adhesion molecule (VCAM-1), known 
to be involved in HSC homing to the marrow [39, 85]. Finally, transcriptional factors and gene 
regulatory networks are another important component of the niche being investigated. Factors 
such as Runx1/AML1 are known to regulate adult HSC expansion, however its role are still a 
subject of debate [86-88]. The transcription factors Bmi-1, Evi-1 and HoxB4 are known to lead 
to the maintenance and expansion of HSCs [89-93]. Additionally, factors such as Sonic 
Hedgehog/Patched (shown to induce cycling and expansion of primitive HSCs), GATA-3 
(necessary for the maintenance of the self-renewing HSC pool) and TCF7 (shown to act as a 
14 
 
regulator between self-renewal and differentiation of CD34+ HSCs) have also been investigated 
[94-96].  
1.5.5 Niche dysregulation and leukemia  
Disruption in niche-mediated regulation of hematopoiesis is believed to be related to the etiology 
and expansion of hematopoietic pathologies such as leukemia. For example, mice deficient in 
retinoic acid receptor gamma (RARγ) or retinoblastoma have exhibited microenvironment-
induced myeloproliferative-like diseases (MPDs), accompanied by reduced numbers of endosteal 
HSCs. Patients with chronic MPDs have also shown high levels of VEGF, believed to impact 
downstream hematopoietic differentiation [20, 97]. During allogeneic bone marrow transplants, 
HSCs home back to the marrow after the presumptive destruction of the malignant cancer cells 
during myeloablative therapy. Failure to home or engraft in the marrow niche for regular 
hematopoietic reconstitution can ultimately result in a failed transplant and could prove fatal.  
Finally, leukemic stem cells (LSCs) which are a proposed mediator for leukemia within the bone 
marrow are known to be in close association with HSCs as they share the same bone marrow 
environment. Although the origin, expansion, and identification of effective therapies to target 
LSCs is still being debated, it is clear that improved understanding of native HSC niches and 
mechanisms by which they impact normal hematopoiesis might help in our understanding of the 
LSCs and their regulation in the bone marrow niche [98-101].  
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1.6 Techniques for controlling HSC fate decisions 
The marrow microenvironment is complex, providing a spatially and temporally variable array 
of extrinsic signals believed to play a critical role in regulating HSC fate. A large volume of in 
vivo studies has been dedicated to understanding the roles of these niche components and their 
corresponding signaling mechanisms in the niche. These studies rely on knock-in/knock-out 
studies that delete targeted genes or transcription factors and evaluate the resultant effect on HSC 
biology in vivo. However, in order to generate clinically-relevant platforms for regulating HSC 
fate, it is essential to develop approaches to identify the niche signals at play, their mechanisms 
of action, as well as strategies to layer multiple niche signals in a regulated fashion. Towards this 
goal, recent endeavors have explored the development of two dimensional and three dimensional 
culture platforms inspired by the in vivo marrow environment.  
1.6.1 Platforms to engineer HSC fate in vitro  
Early attempts at in vitro HSC expansion have relied upon the use of soluble cytokines such as 
SCF, thrombopoietin (TPO) and interlukin-11 (IL-11) known to support stem cell populations. 
However, these strategies are unable to expand the self-renewing early progenitor populations. 
The expansion of LT-HSCs is difficult, especially on 2D substrates as the cells tend to undergo 
uncontrolled differentiation [102, 103].  
Manipulation of molecular targets has to some extent made it possible to expand HSC 
populations. For example, genetic deletion of the cell-cycle regulator p21 achieves an initial 
expansion of the HSPC population [104]. While it is possible to achieve expansion of HSC 
numbers via other genetic modifications (e.g., HOXB4, STAT3) this requires retroviral 
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transfection of the population. Such techniques also present the possibility of introducing 
malignancies in the populations, which is undesirable for clinical applications [92, 93]. Groups in 
the past have typically employed co-culture tactics with osteoblasts or MSCs in order to improve 
HSC expansion [105, 106]. Similarly, stromal cell lines (e.g., OP9) as well as endothelial cells 
have also been used to maintain the HSC repopulating ability or facilitate their expansion [48, 
107] although selective expansion of long-term repopulating HSCs has yet to be demonstrated. 
Mishima et al. reported CXCL12-dependent expansion of an HSC population via co-culture with 
an osteoblast-differentiated MSC cell line; however the repopulation capacity of these HSCs was 
not tested in vivo [108].  
Recent advances in biomaterial design have attempted to generate 3D biomaterial platforms with 
the goal of achieving greater control over spatial and temporal variations in niche-inspired 
signals. Here, a range of biomaterial constructs have been explored for their potential to present 
combination of niche-inspired biophysical and biochemical signals [109-111]. Of primary 
concern is choice of raw material – synthetic or natural derived polymers. While often easier to 
tailor the structural and mechanical properties of synthetic polymer-based biomaterials, they lack 
adhesion molecules presented by the natural polymers. Recently, investigations have explored 
the use of high throughput methods such as microfluidics and microarrays to build in vitro HSC 
platforms, which have primarily concentrated on modification of two-dimensional substrates 
[112-114]. Such approaches have inspired efforts in this thesis, where our goal is to explore the 
potential of leveraging spatially-graded three-dimensional biomaterial constructs as a novel 
approach for generating overlapping patterns of regulatory signals with the goal of better 
replicating the spatial gradations observed across the native marrow.  
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1.7 Significance of the gradient environment  
While having already described structural, compositional, and cellular components of 
hypothesized niches across the marrow, it is important to recognize that such niche environments 
are actually part of a continuum. The transition from the endosteal to the vascular niche includes 
a transition in matrix mechanics, from relatively stiff osteoid (>50 kPa) to vascular structures (3 
– 10 kPa) via a relatively soft marrow (<3 kPa) [115, 116]. Similarly, ECM protein density and 
content changes gradually, with higher levels of fibronectin found near the endosteum and higher 
laminin and collagen expression seen in the marrow and towards the vascular niche [61]. 
Expression levels of soluble factors such as Ca
2+
 (higher at the endosteum) and O2 (higher within 
the marrow closer to vessels) vary across the marrow as well [18]. Given spatial gradation in 
putative niche and hematopoietic cell populations across the marrow [41, 117, 118], there are 
likely significant gradations in soluble biomolecules between niche microenvironments. For 
example CAR cells near the sinusoids have a much higher expression of CXCL12 than 
osteoblasts near the endosteum resulting, likely contributing to the known gradations in CXCL12 
known to facilitate HSC mobilization [73]. A common theme across the marrow is the presence 
of spatial gradations niche-associated structural, biomolecular, and cellular components. These 
gradations also inspire new biomaterial approaches seeking to replicate elements of the HSC 
niche in vitro.  
Based on these observations, it is possible to begin to identify a series of design criteria for a 
biomaterial platform capable of impacting HSC fate decisions in vitro. Such a biomaterial must 
be: 1) biocompatible; 2) permit long-term cell culture; 3) permit culture and analysis of small 
numbers of cells owing to the rarity of HSCs; and in the case of developing a clinically-
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translatable construct be scalable and permit extraction of cells post-culture. Here, we describe 
development of an approach to generate overlapping patterns of niche-inspired signals across 
such a biomaterial construct. Such a platform may eventually enable greater control over HSC 
fate decisions in vitro, but may also have significant potential as a tool to improve our 
understanding of the synergies and hierarchies that may exist between multiple niche signals 
within the marrow.  
1.8 Summary and perspective 
Over the last decades, our understanding of the location and potential regulatory mechanisms 
associated with hematopoietic stem cell niches within the bone marrow niches has improved 
significantly. However, it remains an open question as to how to generate in vitro tools able to 
replicate such niches. A particularly significant need is development of approaches to 
systematically incorporate multiple niche inspired signals, or even multiple sub-niches, into one 
biomaterial platform. In this thesis, I discuss the development of a gradient hydrogel platform 
able to incorporate multiple niche-inspired signals as a platform technology for future ex vivo 
expansion of HSCs. I then describe an approach to incorporate niche-inspired biomolecular cues 
across the hydrogel platform to selectively impact HSC fate. Finally, I explore the potential for 
such a biomaterial tool to act as a rheostat controlling the relative impact of niche cell generated 
paracrine signals versus HSC generated autocrine signals on HSC fate.  
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1.9 Figures 
 
 
 
 
Figure 1.1. HSC differentiation hierarchy [1] 
The most primitive form of the HSC progenitors are the Long-term HSCs (LT-HSCs) with 
unlimited ability to self-renew. Following differentiation, this ability is lost to create more 
differentiated progenitors with high proliferation capacity.  
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Figure 1.2. Conversion of the bone marrow from red to yellow with age. [2] 
Hematopoiesis occurs within the red marrow while the yellow marrow consists mainly of 
adipose tissue.  
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Figure 1.3. A) Cross section of a bone depicting the various osteogenic and vascular 
components [3] B) Schematic depicting the endosteal and perivascular niche in the bone 
marrow 
(A) 
(B) 
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Figure 1.4 Schematic of spatial gradations across the marrow microenvironment.  
HSC fate is regulated by several niche components and can be broadly categorized as either 
niche cells, the ECM or biomolecules. Apart from them, the marrow also exhibits gradations 
in biophysical and biochemical properties such as stiffness and O2 concentration gradients 
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CHAPTER 2: GRADIENT HYDROGEL SYSTEMS AS A PLATFORM 
FOR NATIVE BONE MARROW NICHE MIMICS
1
 
2.1 Chapter overview 
Owing to the complex dynamics governing HSC behavior in the BM niche, biomaterial 
strategies are needed that decouple the niche interactions, while replicating the inherent 
complexity of the native niche. The biomaterial platform in consideration must be versatile, 
having the ability to integrate various types of niche components (cells, ECM, biomolecules) 
with the HSCs, regulating those interactions on both a local and global scale and permitting 
multiple types of functional and imaging analyses. In this chapter, we describe the development 
of a microfluidic-based biomaterial platform that generates gradients in concentration of niche 
cells and ECM. Gradients were generated for microbeads, MC3T3-E1 osteoblasts and HSCs 
along with various collagen densities (1 – 2.5 mg/mL). Different methods were used to 
characterize the gradients, ranging from overall fluorescence imaging to discrete characterization 
of individual regions via FACS. We successfully demonstrate the generation of linear opposing 
gradients of two niche components contained within a Teflon mold in small (180 µL) volumes. 
This platform also enables isolation of cells post-culture as well as in-situ imaging, giving us 
freedom in choosing the types of characterization used for analyzing the HSCs. Finally, since the 
gradient generator is microfluidics-based, there is large potential for further improvement in 
design to incorporate multiple niche cues in more complex patterns. This is the first step towards 
creating a biomaterial tool that incorporates all the niche elements in a systematic manner for 
controlled regulation of HSC fate in vitro.  
                                                 
1
 This chapter has been adapted from the following publication:  
Mahadik et.al. “Microfluidic generation of gradient hydrogels to modulate hematopoietic stem cell culture 
environment.”, Adv, Healthcare Mater. 2014, 3, 449-458 
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2.2 Introduction 
Hematopoiesis is a physiological process where the body’s full complement of blood and 
immune cells are generated from a small number of hematopoietic stem cells [21, 119, 120]. 
HSCs are primarily found in the bone marrow, a complex, three dimensional 
microenvironment consisting of cells, the extracellular matrix (ECM), as well as ECM-bound 
and soluble biomolecules [21]. This niche is believed to provide signals that dynamically 
influence HSC fate decisions, notably quiescence, self-renewal, and differentiation [121]. 
HSCs use a complex network for sensing, communication and regulation that is likely 
hierarchical and integrates multiple microenvironmental inputs. However, relatively little is 
known about how HSCs assimilate and respond to multiple extrinsic cues from its 
microenvironment.  
The endosteal (bone) and vascular regions of the bone marrow have been hypothesized to 
play crucial roles in HSC niche maintenance [21, 22, 33, 38, 122, 123]. The rarity of HSCs 
within the bone marrow [21] challenges direct identification of key niche constituents and 
underlying mechanisms of action. Previous ex vivo HSC studies have highlighted 
increasingly sophisticated approaches to probe the influence of cell-cell interactions and 
paracrine mediated signaling on HSC fate. For example, addition of soluble factors to 
activate the CXCL12/CXCR4 and SCF signaling pathways significantly alters hematopoietic 
cell motility and differentiation [124-126]. HSCs cultured in conditioned media or co-
cultured with endothelial cells and osteoblasts exhibit altered fate decisions [46, 127, 128]. 
Culture platforms have also recently been described to investigate the impact of 
combinations of growth factors [129]. While media supplementation and Transwell 
membrane experiments provide the capacity to study paracrine signaling in a limited manner, 
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they are not amenable to reproduce the 3D cellular, biophysical, and biochemical gradients 
that exist within the native bone marrow. 
While functional bone marrow mimics will likely require control over the spatio-temporal 
distribution of multiple niche constituents within a single biomaterial const ruct, they must 
also facilitate analysis of resultant fate decisions at both populational and single cell levels  
[130]. Gradient materials are particularly attractive due to their ability to both present 
homologous series of microenvironments in a single construct as well as their potential to 
mimic anatomical gradients within the bone marrow [117]. Examining recent efforts in other 
stem cell fields, gradient 2D polyacrylamide substrates have been used to investigate the 
impact of stiffness gradients on mesenchymal stem cell behavior [131]. Convective transport 
methods have also been described to create gradients within three-dimensional hydrogel 
systems [132, 133]. Microfluidic platforms have long been used to create spatial gradients of 
tethered and soluble biomolecules in 2D systems [134]. Resultant studies employing these 
gradients have been used to examine a wide range of cellular processes such as cell motility 
and polarity [135-140]. Variations of these microfluidic mixers have been used to create 
stable 2D and 3D constructs containing ECM proteins such as collagen or Matrigel to study 
the effect of chemokine gradients on cell chemotaxis [141-144]. However, such systems have 
not been applied to generate bone marrow mimics to examine how microenvironmental 
signals impact HSC behavior. 
The objective of this study was to develop a microfluidic mixing platform able to generate 
three-dimensional hydrogel constructs containing opposing gradients of multiple cell 
populations (Figure 2.1). We adapted a conventional staggered herringbone microfluidic 
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mixer [145] to generate a 3D hydrogel containing tunable, opposing gradients of cell and 
biomaterial properties from two hydrogel precursor suspensions. We show that stable multi -
cell gradients can be created independent of cell size and hydrogel density without harming 
cell viability. Using this design, the relative ratio of the two cell types, their spacing, and the 
speed of diffusive transport through the hydrogel are all variables that can be spatially 
defined.  
2.3 Materials and Methods 
2.3.1 Fabrication of the microfluidic mixer and hydrogel mold 
The microfluidic device was fabricated using standard 2 layer photolithography procedures 
on a 3” Si wafer (University Wafers, South Boston, MA) [146]. The design of the 
microfluidic diffusive mixer contains channels with a 200 µm (wide) x 100 µm (tall) cross -
section with 50 µm high staggered herringbone features. These herringbone features induce 
chaotic advection in the channel that further facilitates mixing of cells [145]. The design for 
the device was created in Freehand MXTM (Macromedia Inc.) and printed on high-resolution 
transparencies (5080 dpi, University of Illinois at Urbana-Champaign Printing Services). A 
positive relief structure of the microchannel design was obtained by covering a silicon wafer 
with a 100 µm layer of SU8-2050 negative photoresist (MicroChem Corporation, Newton 
MA) via spincoating, baking (65 °C for 5 minutes, 95 °C for 15 minutes), and subsequently 
using UV exposure (OAI 1500, 220 mJ cm
–2
) through the photomask that defines the channel 
geometry. A second 50 µm layer of photoresist was spin coated onto the microchannel 
geometry, followed by baking and UV exposure (180 mJ cm
–2
) with a herringbone 
photomask. The resulting two-layer photoresist structure was baked (65 °C for 1 minute, 95 
27 
 
°C for 6 min) and then developed using propylene glycol monomethyl ether acetate 
(PGMEA). The remaining positive relief structure was then washed away with acetone and 
iso-propyl alcohol. A monolayer of tridecafluoro-1,1,2,2-tetrahydrooctyl trichlorosilane 
(Gelest, Morrisville, PA) was deposited onto the silicon master prior to replica molding to 
prevent covalent adhesion of polydimethylsiloxane (PDMS) on the photoresist and the 
silicon surfaces. PDMS devices were then created from this master by curing a 10:1 mixture 
of monomer:crosslinking agent (RTV 615 Part A/B, General Electric, Waterford, NY) on the 
wafer at 65 °C for 1 hr. After peeling the PDMS mold off the wafer, access ports were 
punched using a 20 gauge needle. The mold was first cleaned with tape (Scotch TM 3M), and 
sealed to a plasma treated (Harrick Scientific Corp., PDC001) 3” x 2” glass slide (Fischer 
Scientific 12-550-A3), followed by annealing at 65 °C for 1 hr. 
The microfluidic mixer was designed to combine two hydrogel inputs (Component A, 
Component B) to create 10 output streams (Figure 2.2), each with a defined ratio of the 2 
inlet components. A Teflon mold with inner dimensions of 15 x 8 x 1.5 mm (~180 µL) was 
made with 10 stainless steel tubes (25 Gauge) attached to either side of the 15 mm length of 
the mold close to the top surface. The tubes were press-fit into holes punched at each outlet 
of the microfluidic mixer and into the Teflon frame to physically connect the microfluidic 
mixer and the mold. Tubes press-fit into the opposite side of the Teflon frame served as 
outlets for the displaced volume within the mold during gradient formation (Figure 2.3). 
Glass coverslips were semi-permanently attached to the top and bottom of the mold via non-
toxic, non-reactive high-vacuum grease (Dow Corning). The coverslips were placed to 
facilitate live-cell fluorescent imaging within the gradient construct as well as post-culture 
removal to facilitate access to discrete regions of the hydrogel.  
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2.3.2 MC3T3 and HSPC cell culture 
MC3T3-E1 pre-osteoblasts (MC3T3, ATCC, Manassas VA, passage 20-30) were cultured in 
T25 flasks in complete alpha-MEM media (alpha-MEM, 10% FBS, 5% Penicillin-
Streptomycin, 5% L-Glutamine). MC3T3s were cultured to confluence at which point they 
were washed in PBS and trypsinized; cells were then either re-suspended in culture for 
expansion or prepared for use in the microfluidic devices. Prior to use, cells were 
fluorescently tagged via CMFDA (green) or CMTPX (red) fluorescent dye (Invitrogen, 
Carlsbad CA) at a 1:1000 dilution in complete alpha-MEM media (15 minutes; 37 °C) [147]. 
Primary HSPCs were isolated from the bone marrow of the femur and tibia of female 
C57BL/6 mice (Jackson Labs; Ages 1 – 3 months). The bones were gently crushed with a 
mortar and pestle, washed with a solution of PBS + 2% FBS (PBS/FBS), and filtered with a 
40 µm sterile filter to isolate whole bone marrow. All subsequent steps were performed in a 
PBS/FBS solution on ice. Red blood cells were lysed with ACK lysis buffer (Invitrogen, 
Carlsbad, CA). Cells were re-suspended in PBS with Fc receptor-blocking antibody to reduce 
non-specific antibody binding. HSPCs were identified as the Lin
-
Sca-1
+
c-kit
+
 (LSK) fraction 
by incubating the remaining bone marrow cells with a cocktail of antibodies: PE-conjugated 
Sca-1 (1:100 dilution), APC-conjugated c-kit (1:100 dilution), and a 1:100 dilution of a 
FITC-conjugated Lineage (Lin) cocktail (CD5, B220, Mac-1, CD8a, Gr-1, Ter-119) [12, 148, 
149]. All antibodies were supplied by eBioscience (San Diego, CA). The LSK fraction was 
then sorted using a BD FACS Aria II flow cytometer (BD FACS Diva software) and 
collected in PBS/FBS on ice for immediate use. An average of 0.2% of total bone marrow 
cells sorted was identified as LSK, consistent with previously reported results  [12, 148, 149]. 
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All animal experiments were conducted with permission obtained from the University of 
Illinois Institutional Animal Care and Use Committee (IACUC), Protocol #09054, #12033.  
2.3.3 Preparation of collagen hydrogel solutions containing fluorescent microbeads or cells 
Type I collagen (BD Biosciences, Bedford MA) was used as the hydrogel precursor 
suspension for all experiments. Collagen solutions with defined densities (1.0, 1.5, 2.0, 2.5 
mg ml
–1
) were prepared from the stock collagen solution of approximately 9 mg ml
–1
 (lot 
specific) by mixing the collagen stock solution with complete α-MEM media and HEPES 
solution (2.5% of final volume); final suspension pH was adjusted to 7.3 – 7.5 via 0.4M 
NaOH [150]. Hydrogels containing 1-µm diameter Yellow/Green (FS-Y/G) (Excitation: 
505/15 nm; Emission: 515/15 nm) or Red (FS-R) fluorescent microbeads (Excitation: 
575/25; Emission: 610/25) (Invitrogen, Carlsbad CA) were generated by vortexing 0.1% v/v 
beads with the collagen hydrogel solution. Similarly, MC3T3s or LSK HSPCs were mixed 
into the hydrogel at a concentration of 200,000 – 400,000 cells ml-1. All steps were 
performed at 4 °C to minimize the potential for hydrogel gelation prior to mixing through the 
microfluidic mixer. 
2.3.4 Generation of multi-gradient microgels 
To prevent air bubbles from being trapped inside the device, the entire device assembly 
(microfluidic mixer, mold, connecting conduits) was immersed in water under vacuum (40 
Torr, 15 minutes). The two input solutions for the multi-gradient microgel were prepared in 1 
mL syringes that were then placed on a computer-controlled syringe pump (Harvard 
Apparatus, model 33 twin syringe pump, Holliston MA). The flow rate of the hydrogel 
precursor suspensions as well as the flow duration was tuned in accordance with the hydrogel 
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density (Table 2.1) to facilitate chaotic mixing and the formation of a smooth gradient. After 
generating the gradient hydrogel, the Teflon mold was detached from the microfluidic mixer , 
submerged in culture media in a petri dish, and maintained in an incubator for long-term 
culture. To maintain the reproducibility of the gradients, new microfluidic mixers were 
generated for each experiment.  
2.3.5 Characterizing microgel gradients 
A Typhoon 9400 fluorescence slide scanner (GE electronics) was used to assess the 2-
component gradients. Briefly, the projected fluorescence values through the thickness of the 
microgel and across the gradient were gathered, with the resultant composite image 
subdivided into 5 (standardized) equally-sized regions (1 – 5) along the gradient. As controls, 
the monolithic precursor suspensions were placed onto glass slides and scanned in order to 
normalize the fluorescence levels quantified from the gradient microgel. The mean 
fluorescence intensity (MFI) of each region was subsequently determined for al l acquired 
fluorescence channels using ImageJ in a manner previously described [118]. All fluorescence 
data was then normalized to the appropriate precursor gel solution fluorescence, yielding a 
normalized MFI for each region.  
Microgels containing fluorescently labeled (CMFDA, CMTPX) cells were alternatively 
imaged using a Zeiss 710 multiphoton confocal microscope through the coverslip under the 
microgel mold. Three-dimensional image stacks (700 x 700 µm x 170 µm deep) were 
acquired in the plane of the microgel construct from each of the 5 regions along the gradient; 
the total number of CMFDA vs. CMTPX labeled cells in each region was then quantified. 
The spectral deconvolution capabilities of the Zeiss 710 microscope were employed to image 
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discrete LSK HSPCs via cKit (APC) and Sca1 (PE) flow cytometry antibodies as well as 
Lineage
+
 (FITC) bone marrow cells within the collagen microgel. 
To analyze discrete populations within each microgel region (1 – 5) we developed a metal 
die which could be inserted into the microgel at any point during culture to mechanically 
separate the microgel into 5 equally-sized regions along the gradient (Figure 2.6B). Each 
sub-region contained 20 – 30 µL of cell-hydrogel suspension that could be individually 
collected and analyzed. The microbead or cell embedded constructs isolated from each 
microgel region were resuspended in PBS, filtered to remove the collagen and analyzed 
using a BD Flow Cytometer to quantify relative populations across the microgel gradient.  
2.3.6 Quantifying small molecule diffusion 
Hydrogel diffusivity was measured via fluorescence recovery after photobleaching (FRAP) 
experiments using FITC-conjugated Dextran (40 kDa, Sigma Aldrich) [151-154]. Here a 1 
mg ml
–1
Dextran solution in PBS was used to prepare the collagen precursor solutions of 
different densities (1 – 2.5 mg ml–1), replacing the media suspension previously described. 
The collagen solution was spread over a MatTek dish and incubated overnight (37
o
C, 5% 
CO2). FRAP measurements were performed using the Zeiss 710 Multiphoton confocal 
microscope [155]. Briefly, a 80 µm diameter spot was bleached (Laser intensity: 0.05 mW) at 
the center of the gel depth. The sample was bleached for 5 seconds and recovery for up to 15 
minutes was traced via fluorescent imaging. The half time (t1/2) of the recovery was 
calculated using the FRAP function available in the Zeiss software. The hydrogel diffusion 
coefficient (D) was subsequently calculated as: 
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where D is the diffusion coefficient, w the photobleaching beam radius, and t1/2 the recovery 
half time [151, 156]. A maximum of 3 spots were bleached per sample, spaced as far away 
from each other as possible to minimize after-effects of photobleaching on every subsequent 
measurement.  
2.3.7 Cell viability 
Cell viability within the microgels was assessed using a live/dead cytotoxicity kit 
(Invitrogen) using Calcein AM (live) and ethidium homodimer (dead) as indicators  [157]. 
Viability was quantified via fluorescence microcopy and ImageJ at 0, 6, 24, and 72 hours of 
culture analysis.  
2.3.8 Statistical analysis 
One-way analysis of variance (ANOVA) was performed on gradient measurements across 
different regions and collagen densities for the beads and cells followed by Tukey tests  
[158]. Significance was set at p < 0.05. At least n = 4 gradient gels were used for all 
analyses. In the figures, the error in each data point is reported as the standard error of the 
mean unless otherwise noted. 
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2.4 Results  
2.4.1 Microgels containing opposing gradients of fluorescent microspheres 
Opposing gradient microgels were first created using fluorescent microspheres (Figure 2.4) 
for a range of collagen hydrogel densities (1 – 2.5 mg ml–1) that best reflect both typical 
working conditions for collagen hydrogels and the soft microenvironment within the bone 
marrow [159-161]. Slightly different optimized flow parameters were identified for each 
collagen density in order to create maximally reproducible counter-gradients (Table 2.1). As 
expected, a higher flow rate (i.e., higher pressure) was required to achieve effective chaotic 
mixing for collagen suspensions of increased density. Microgels containing opposing linear 
gradients of fluorescent microspheres were used to compare three distinct analysis modalities 
with relevance for the resultant bone marrow mimics:  
(1) macroscopic analysis via fluorescent slide scanner;  
(2) microscopic analysis via confocal/two-photon imaging;  
(3) microgel segmentation and analysis via flow cytometry.  
Results from all analyses are reported in terms of 5 standardized equally-sized regions along 
the gradient (Figure 2.1). Macroscopic analysis using a slide scanner confirmed the presence 
of opposing gradients of hydrogel precursor suspensions in the final microgel construct for a 
range of collagen densities (1 – 2.5 mg ml–1). Figure 2.4A shows distinct gradients of 
Yellow/Green fluorescent microbeads (FS-Y/G) vs. Red fluorescent microbeads (FS-R) 
across a full 1.5 mg ml
–1
collagen microgel. Figure 2.4B and 2.4C show mean fluorescence 
intensity (MFI) analysis confirming the presence of opposing linear gradients of 
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microspheres for two microgel variants: 1.0 mg ml
–1
 (Figure 2.4B), 2.5 mg ml
–1
 (Figure 
2.4C). Figure 2.4D depicts the ratio of the two microsphere populations across the 5 
standardized analysis regions for all 4 microgel densities created. Critically, linear opposing 
gradients of microsphere populations were created for all tested hydrogel densities.  
While a statistically significant (p < 0.05) change in FS-Y/G and FS-R MFI between each 
region was not always observed, the overall trend was statistically significant for all hydrogel 
densities. Slight non-uniformity in the resultant gradients can be noted across many gels. 
This can be attributed to speed of gelation of the collagen system, which relies on  
temperature induced gelation processes as well as the difficulty in maintaining a uniform 
flow across a large 8 mm mold width. Shrinking the size of the resultant multi -gradient 
hydrogel and using photocrosslinkable chemistries are currently being pursued to create more 
stable opposing gradients. While previous literature has suggested that herringbone structures 
are not necessary to ensure uniform mixing, [134] the presence of heterogeneities (e.g., 
beads, cells) within our precursor suspensions required the presence of herringbone mixing 
structures to create linear gradients within the microgel (Figure 2.5). Microbead-laden 
microgels created using an identical mixer geometry that lacked the herringbone structures 
contained microbead populations concentrated to either end of the construct, but not mixed 
across the construct, suggesting that herringbone structures are required to generate stable 
opposing gradients.  
We subsequently used FACS analysis to validate the capacity to isolate distinct regions from 
within the microgel for post-culture analysis. The five standard regions along the gradient 
were isolated from the gradient microgel using a custom metal die inserted into the microgel, 
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resuspended in PBS in order to break up the gels, and analyzed via flow cytometry in order 
to confirm the presence of opposing gradients of fluorescent microbeads (Figure 2.6) 
consistent to results obtained via the slide scanner (Figure 2.4). For a representative (1.5 mg 
ml
–1
) microgel variant, region 1 contained an 85:15 FS-Y/G:FS-R ratio, region 3 contained a 
46:54 FS-Y/G:FS-R ratio, and region 5 contained a 15:85 FS-Y/G:FS-R ratio. The Y/G:R 
ratio varied from 5.6:1 to 1:5.6, slightly different from the ratios obtained via the 
fluorescence slide scanner (~4.5:1 to 1:4.5, Figure 2.4D). Such differences are likely due to 
detection efficiencies of each characterization method. However, overall these results 
demonstrate the potential to analyze either the microgel as a whole or distinct regions from 
within the microgel, a critical capacity for analyzing local vs. global cell interactions across a 
gradient biomaterial. 
2.4.2 Influence of microfluidic mixing conditions on cell viability  
Chaotic advective mixing has the potential to exert shear stresses on cells within the 
hydrogel suspension. While previous studies have indicated shear-mediated flow can be a 
negative regulator of cell viability,[162] HSCs natively mobilize into the peripheral blood 
stream and home back to the marrow, suggesting a capacity to withstand shear stresses 
associated with blood flow [15, 55, 163]. To examine the impact of flow through the mixer 
on cell viability, 1 mg ml
–1
 collagen suspensions containing MC3T3-E1 or primary LSK cells 
were alternatively placed directly into a glass-bottom MatTek dish (control) or were passed 
through the microfluidic mixer (device) into the dish. Relative cell viability was assessed up 
to 3 days (Figure 2.7 and 2.8). For both cell types, a high degree of relative viability was 
observed over the first 24 hours of culture, the period of time during which the most 
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significant effects of applied shear stress were expected [164]. While some statistically 
significant differences in viability were observed after 3 days in culture, viability remained 
high (>60%) throughout.  
Notably, these results are consistent with previous observations involving a microfluidic  
device with channel dimensions and fluid flow rates smaller than those used here [129]. This 
prior work suggested that flow induced cytotoxicity of HSPCs in microfluidic culture 
platforms is limited, in agreement with results reported here. While only examining flow-
induced changes on cell viability here, ongoing experimental efforts are examining the role 
played by channel dimension, advective mixing conditions, hydrogel density, and flow rate 
on HSPC function (e.g., self-renewal vs. proliferation). Such an approach would be critical 
for addressing the functional significance of applied shear stresses on HSPC fate or for 
investigating mechanisms by which HSPCs sense shear stresses during mobilization from the 
bone marrow into the blood stream. 
2.4.3 Microgels containing opposing gradients in cell content 
The ability to create opposing gradients of multiple cell populations within the microgel was 
demonstrated in a manner identical to that described for fluorescent microspheres. Opposing 
gradients of fluorescently tagged MC3T3s (with CMFDA-green dye and CMTPX-red dye) 
were observed via MFI analysis across all collagen hydrogel densities (1 – 2.5 mg ml–1; 
Figure 2.9). Figure 2.9A shows counter-gradients of MC3T3 cells for a representative 
microgel (1 mg ml
–1
). Figure 2.9B depicts the CMFDA:CMTPX ratio within the 5 regions 
for all hydrogel variants. Similar to the microbead gradients, a statistically significant (p < 
0.05) change in MFI was observed in the direction of the gradient across the microgel even 
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though adjacent regional differences were not always statistically significant. Differences in 
MFI ratios between cell (3:1 to 1:3, Figure 2.9B) and microsphere (4.5:1 to 1:4.5, Figure 
2.4D) laden microgels may be due to differences in chaotic mixing of ~20 µm cells and 1 µm 
microbeads. Although this is an unavoidable occurrence in the presence of cells, 
modifications in micro channel dimensions could possibly alleviate these problems.  
The stability of the cell gradients was subsequently assessed via FACS from microgels 
created using opposing gradients of unlabeled and CMFDA labeled MC3T3s in 1.0 mg ml
–1
 
collagen hydrogels (Figure 2.9C). The lowest hydrogel concentration was chosen as it was 
expected to present the least steric resistance to cell movement. The fraction of CMFDA
+
 
cells across the microgel was analyzed via FACS both immediately after microgel creation (0 
hrs) and after 1 day in culture (24 hrs). Consistent gradients were observed (Figure 2.9C), 
suggesting the microfluidic device can be used to establish stable opposing gradients of cell 
content. Notably, a statistically significant (p < 0.05) increase in CMFDA
+
 MC3T3s was 
observed across the gradient microgel at both 0 and 24 hours, with no significant difference 
in CMFDA
+
 fraction within any discrete region. While long-term remodeling is likely to 
disrupt these gradients, this current device will enable short-term analysis of cell-cell 
interactions. In addition to aiding the analysis of gradient stability, the ability to reproducibly 
isolate discrete regions from within the microgel is expected to play a particularly significant 
role in analyzing HSC fate decisions in future experiments where HSCs could be isolated 
from distinct regions of the microgel for not only FACS analysis, but also for further 
molecular biology techniques such as RT-PCR or signal transduction pathway analysis. 
As an alternative, confocal microscopy was used to examine microgels containing opposing 
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gradients of CMFDA
+
 vs. CMTPX
+
 MC3T3s without having to disrupt the microgel culture. 
Our goal was to demonstrate the ability to use 3D imaging approaches to characterize local 
regions within the gradient microgel and do so in a manner conducive to continuous, live-cell 
monitoring of individual or small groups of cells within the heterotypic microgel 
microenvironment. Qualitative assessment of image stacks acquired from each of the 
standardized microgel regions (Figure 2.10A, Region 3) suggests that confocal or multi-
photon imaging could be used to describe the local cellular microenvironment. Subsequently, 
the total number of CMFDA
+
 vs. CMTPX
+
 MC3T3s was manually counted within each 
image stack (Figure 2.10B). Linear opposing gradient were observed for all hydrogel 
densities (1 – 2.5 mg ml–1). Taken together, these results suggest that local features within 
the microgel can be described via population level analysis of the entire construct (Figure 
2.9A) or at the single cell level via fluorescent microscopy (Figure 2.9B). 
2.4.4 Diffusivity of the hydrogel matrix 
To simulate paracrine-mediated intracellular signaling, we examined small molecule 
diffusivity in monolithic collagen hydrogels (1 – 2.5 mg ml–1) using FITC-conjugated 
dextran (40 kDa). Hydrogel diffusivity was high for all hydrogel densities: 150 ± 4 (1.0 mg 
ml
–1
), 143 ± 10 (1.5 mg ml
–1
), 137 ± 6 (2.0 mg ml
–1
), and 153 ± 10 (2.5 mg ml
–1
) µm
2
 s
–1
. 
While a direct correlation between increasing collagen hydrogel density and mechanical 
integrity exists,[159] small-molecule diffusivity was not significantly affected for the range 
of collagen hydrogels explored here. Although the cells within the microgel could act as 
impermeable objects that hinder biomolecule diffusion,[165] cell densities (up to 5E6 cells 
ml
–1
) were chosen such that they comprise less than 7% of the total microgel volume. 
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However, we anticipate that the magnitude of niche cell paracrine signals reaching a HSPC 
within the network to be a function of the local diffusivity of the matrix as well as the local 
density of niche cells. While such effects are the subject of ongoing investigations, the 
platform described in this study enables study of the impact of paracrine-mediated niche cell 
signaling on HSC fate through control over both matrix diffusivity and niche cell density.  
2.4.5 Heterotypic bone marrow microenvironment mimics 
The microfluidic mixing platform was then used to generate preliminary heterotypic bone 
marrow culture environments. Here opposing gradients of primary murine LSK (HSPCs) and 
MC3T3 osteoblasts were created in 1 mg ml
–1
 collagen microgels. While MC3T3 osteoblasts 
are not expected to be functional niche cells capable of influencing hematopoiesis, the 
objective of this effort was to demonstrate that opposing linear gradients could be created 
from multiple cell types of different sizes (MC3T3 osteoblasts, ~20 µm; LSKs, ~5 µm) as the 
precursor to ongoing work using primary niche cells isolated from the bone marrow. 
Opposing gradients of LSKs and osteoblasts were quantified via whole construct 
fluorescence (Figure 2.11B, C). Notably, similar opposing gradients of MC3T3s and LSKs 
(2:1 to 1:2, Figure 2.11C) were observed as previously seen for opposing MC3T3 gradients 
in 1 mg ml
–1
 collagen (Figure 2.9A). Multi-photon microscopy was used to image individual 
LSKs and Lin
+
 (GFP
+
) bone marrow cells mixed together in a single microgel construct. 
Here, spectral deconvolution methods were capable of discerning LSKs (cKit
+
Sca1
+
) from 
mature bone marrow (Lin
+
) cells (Figure 2.10D). As expected for the LSKs, [166] Sca1 was 
expressed across the cell surface while cKit was expressed in punctuate regions. Features in 
the resulting gradient gel appear to be primarily set by in-channel mixing and fluid flow 
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through the outlets, suggesting that cell precipitation or heterogeneities in the precursor 
suspensions within the syringes may be negligible due to the speed of hydrogel mixing, often 
faster than 1 minute (Table 2.1). 
Taken together, these experiments demonstrate the capability to create heterotypic cell 
microenvironments and then to interrogate the resultant multi-cell aggregates at multiple 
scales. Notably, the multi-gradient microgel construct developed here offers the potential to 
perform HSC fate tracing assays within a model 3D microenvironment where the local 
cellular microenvironment can be systematically manipulated. Ongoing work is also 
exploiting this system to create gradients in the biophysical properties of the matrix and 
incorporating additional microfluidic layers to provide local supplementation of cues such as 
growth factors to the microgel [155]. Efficient post-culture retrieval of local subregions of 
the microgel construct offers the potential to analyze region-specific HSC gene expression, 
signaling pathway analyses, and functional capacity (colony forming unit, in vivo 
repopulation assays) [36, 85]. Future investigations leveraging this technology are 
anticipated to provide significant new information regarding how HSCs interact and respond 
to the diverse biophysical environment within the bone marrow. 
2.5 Conclusions 
We described an approach to reproducibly create heterotypic microenvironments containing 
HSCs and one or more putative niche cells in counter-gradient microgels. We have used 
multiple analytical approaches to validate the multi-gradient microgels at many scales (single 
cell to whole construct). We also described a method to extract distinct sub-regions from the 
greater microgel matrix for analysis using conventional molecular biology approaches. We 
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demonstrated fabrication and maintenance in culture of a series of microgels containing 
opposing gradients of fluorescent microspheres, cell populations of similar size, or dissimilar 
sizes. Preliminary cell culture assays with both a cell line (MC3T3s) and primary stem cell 
population (LSK) indicated that viability was not significantly affected by microfluidic 
patterning. 
The eventual goal of this effort is to develop a versatile biomaterial platform able to create 
complex patterns of niche inspired signals in order to examine the impact of biophysical cues 
and niche cell paracrine signaling on HSC fate. In addition to helping generate significant 
new knowledge regarding how micro-environmental signals help shape HSC fate decisions, 
this system may also facilitate optimization of culture platforms for ex vivo expansion of 
clinically relevant hematopoietic cell populations as well as study of the etiology, expansion , 
and treatment of hematopoietic pathologies. 
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2.6. Tables 
Collagen Density 
(mg ml
–1
) 
Flow Rate 
(µL min
–1
) 
Flow Duration 
(seconds) 
1 150 45 
1.5 180 40 
2 220 38 
2.5 270 30 
 
 
 
 
 
  
Table 2.1. Flow conditions for generating gradients  
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2.7 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. (A) Two-component opposing gradient microgel to present overlapping patterns of 
matrix chemistry, density, stiffness as well as biomolecule and cell content (B) Varying cell type, 
cell density (hence cell-cell spacing), and hydrogel density (hence diffusive transport) are 
hypothesized to create a combinatorial environment to examine the role of niche cell mediated 
paracrine signaling on HSC fate. 
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Figure 2.2. (A) Schematic of microfluidic mixer that combines two inlet solutions (A, B) 
via a computer controlled syringe pump. Geometric expansion leads to 10 outlets that enter 
a 180 µL Teflon mold. Inset: Microscopic image of mixing channel (200 µm wide x 100 
µm deep) containing a herring-bone structure (50 µm) to induce chaotic advection. (B) 
Macroscopic view of mixer containing colorized precursor suspensions. (C) Macroscopic 
view of Teflon mold containing resultant counter gradient microgel. 
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Figure 2.3. Schematic showing the attachment of the external Teflon mold into the PDMS 
mixing device. The mold had glass coverslips attached to the top and bottom of the Teflon 
frame to define the microgel volume. Stainless steel tubes are press-fit into opposite sides 
of the Teflon mold, serving as hydrogel inlets and outlets for displaced volume within the 
mold. Inlet tubes are then press-fit into the outlet ports of the PDMS device. This allows 
the hydrogel precursor solution to flow from 2 inlets of the mixer (at the top of the device), 
through the mixing channels, out of the 10 outlet ports at the bottom of the mixer, and into 
the mold cavity.  
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Figure 2.4. (A) Spectrally-separated images of the FS-Y/G vs. FS-R populations within a 
single opposing gradient microgel. (B) Normalized MFI for FS-Y/G vs. FS-R populations 
along a 1.0 mg ml
–1
 gradient microgel. (C) Normalized MFI for FS-Y/G vs. FS-R 
populations along a 2.5 mg ml
–1
gradient microgel. (D) Ratio of FS-Y/G:FS-R within 5 
standardized regions along the multi-gradient microgels (1.0, 1.5, 2.0, and 2.5 mg ml
–1
). 
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Figure 2.5 (A) Spectrally-separated images of microgels containing Y/G vs. R 
fluorescent microspheres created using a microfluidic mixing device without 
herringbone mixing structures within the microfluidic channel. (B) MFI analysis of the 
resulting microgels displays a more sigmoidal distribution of microbeads across the 
microgel, suggesting that herringbone structures aid formation of a linearly-graded 
hydrogel.  
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Figure 2.6. (A) Analysis of counter-gradient microgel composed of Y/G vs. R florescent 
microspheres via FACS. (B) Metal die insert used to divide the microgel into 5 distinct 
hydrogel regions along the gradient. (C) Characteristic FACS plots for microgel regions 
along the gradient with relative percentage of FS-Y/G (green) or FS-R (red) characteristic of 
MFI analysis results. 
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Figure 2.7. Relative viability of MC3T3 and LSK cells in 1 mg ml
–1
 collagen hydrogel 
after passing through the microfluidic mixer. 
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Figure 2.8. Live/Dead images of MC3T3-E1 osteoblasts and primary LSKs taken 1 day 
after culture in either control conditions (hydrogel alone) or after flowing through the 
device in the hydrogel matrix. Significantly greater numbers of MC3T3-E1 pre-osteoblasts 
were available for use compared to the freshly isolated primary LSK cells due to the 
relative rarity of LSK cells within the bone marrow. Scale bars: 100µm 
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Figure 2.9. (A) Normalized MFI for CMFDA vs. CMTPX labeled MC3T3 cells within 5 
standardized regions along a 1 mg ml
–1
 collagen gradient microgel. (B) Ratio of 
CMFDA:CMTPX labeled MC3T3 cells for all hydrogel densities (1.0, 1.5, 2.0, 2.5 mg ml
–
1
). (C) FACS analysis of the fraction of CMFDA
+
 MC3T3 cells (versus unlabeled 
MC3T3s) within each region of the microgel immediately after microgel formation (0 
hours) and after 24 hours of culture. 
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Figure 2.10. (A) Confocal microscope image taken within subregion 3 along the gradient 
showing the relative density of CMFDA vs. CMTPX labeled MC3T3 cells. (B) Fraction of 
CMFDA vs. CMTPX MC3T3 cells within the 5 regions along the gradient calculated from 
confocal images via manual cell counting. 
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Figure 2.11. (A) FACS schematic of Lin
-
cKit
+
Sca1
+
 isolation from the bone marrow of 
C57BL/6 mice. (B) Spectrally-separated images of the CMFDA-labeled MC3T3s versus 
CMPTX-labeled HSPCs within a single counter-gradient microgel (1 mg ml
–1
 collagen). (C) 
Normalized MFI for CMFDA
+
 MC3T3s versus CMPTX
+
 HSPCs within 1 mg ml
–1
 collagen 
microgels. (D) Non-destructive imaging of individual cKit
+
Sca1
+
 and Lin
+
 bone marrow 
cells within a 1 mg ml
–1
 collagen microgel via in situ two-photon microscopy. 
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CHAPTER 3: ENGINEERING FUNCTIONALIZED GELATIN 
METHACRYLATE HYDROGELS TO IMPACT HSC BIOACTIVITY
2
 
3.1 Chapter overview 
In the previous chapter, we described the development of a microfluidic platform capable of 
generating gradients of niche-inspired extrinsic cues. In this chapter, we describe the 
development of a methacrylated gelatin (GelMA) hydrogel functionalized with a stem cell-
specific protein, stem cell factor (SCF), for long-term HSC culture. Gelatin is a naturally 
occurring polymer with existing adhesion peptides and MMP degradation sites. 
Functionalization with methacrylate enables its polymerization under UV light to form a stable 
three-dimensional hydrogel. HSCs were cultured in the SCF-functionalized GelMA gels for up 
to 7 days in protein-free media. HSC proliferation and phenotype were characterized at multiple 
time points and compared to those cultured with or without soluble SCF. We subsequently 
employed the microfluidic platform originally developed in Chapter 2, shrinking the design to 
allow for the creation of small volume hydrogel constructs (60 µL) containing linear gradients of 
SCF across the hydrogel. The local regions within such a gradient hydrogel can isolated at 
multiple time points to identify a region-specific functional response of the HSCs to tethered 
SCF. Thus, we demonstrate a biomaterial approach that enables selective presentation of a 
biomolecule-functionalized matrix to drive pattern-specific HSC responses.  
                                                 
2
 This chapter has been adapted from the following publication:  
Mahadik et.al. “Covalent immobilization of stem cell factor supports expansion of primary murine hematopoietic 
stem cells in gelatin hydrogels.”, (in preparation)  
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3.2 Introduction 
Hematopoietic stem cells (HSCs) are of increasing interest in the field of regenerative medicine 
due to the well-characterized process by which they mediate production of the body’s blood and 
immune system.  While HSCs are responsible for producing nearly one trillion hematopoietic 
cells a day, mutations in this process can lead to a range of pathologies such as leukemia, 
myelodysplasia, or bone marrow failure. Clinically, HSC transplantation (HSCT) is used as part 
of high-intensity ablative therapies to treat blood disorders such as leukemia and lymphoma 
[167-169]. Here, whole bone marrow or a HSC fraction taken from the patient (autograft) or a 
matched donor (allograft) is infused into the patient after myeloablative therapy; these cells home 
to the marrow cavity where they then engraft in discrete niches to rebuild the marrow [170]. 
Marrow niches are believed to significantly impact differentiation, quiescence, migration and 
hematopoietic lineage specification via HSC interactions with neighboring niche cells, the 
extracellular matrix (ECM), and a host of soluble biomolecules [13, 21, 30, 44, 121, 171]. Given 
the rarity of the most primitive HSC fractions within the marrow (<0.005% of marrow) [16] as 
well as clinical complications associated with insufficient numbers of donor HSCs, biomaterial 
platforms present significant potential as niche mimics. 
In vivo studies that de-functionalize niches by removing cell or matrix constituents provide 
insight regarding: (i) niche anatomical localization (e.g., endosteal vs. perivascular) [28, 36, 55]; 
(ii) putative niche cells (e.g., Nestin
+
 mesenchymal stem cells, osteoblasts, endothelial cells) [24, 
33, 36, 55, 58, 172]; and (iii) niche-regulated signaling pathways (e.g., Fak, Jagged-1/Notch, 
CXCL12/CXCR4, Wnt) [44, 45, 84, 117, 123-126, 173-177]. Recently, the potential for 
biophysical signals in the form of matrix mechanical properties and ligand presentation have 
been suggested to directly impact primary murine and human HSC fate decisions as well as 
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downstream myeloid differentiation potential [61, 178, 179]. Recent efforts have turned towards 
the development of two and three-dimensional culture tools to explore expansion or directed 
differentiation of HSCs using microcontact printing, poly(dimethylsiloxane) (PDMS) templating, 
and hydrogel culture substrates [113, 180-182].  
While the biomolecular environment within the marrow is complex, a number of growth factors 
have been identified as playing a significant role in HSC homing (CXCL12) [38, 173, 183] as 
well as lodging (engraftment) and self-renewal (stem cell factor, SCF) [184, 185]. SCF binds to 
and activates the c-kit receptor on the HSCs and is responsible for their survival and maintenance 
within the niche [149, 186, 187]. Notably, SCF has been demonstrated to remain active in both 
soluble and matrix-bound states [13, 184, 185, 188], making it an ideal target to explore in the 
context of functionalizing biomaterial substrates to HSC culture. Efforts have demonstrated the 
potential of co-culture with SCF-decorated micro-particles on proliferation of human 
hematopoietic progenitor cells [189]. Previous efforts have also explored the feasibility of 
functionalizing culture surfaces with SCF to promote HSC expansion. Notably, Cooper-White et 
al., demonstrated expansion of M-07e human myeloid leukemia cells using physisorbed SCF on 
tissue culture plastic [184]. Recently, work by West et al., demonstrated the use of covalently 
immobilized SCF on RGD-functionalized PEG surfaces to expand murine IL-3-dependent 
myeloid cells (32D cell line) [186]. The existence of anatomical (cellular, extracellular matrix, 
mechanical) gradients across the marrow [41, 178, 190], suggests a need for approaches to 
replicate distinct niche environments and the biophysical gradations linking these niches. 
Microfluidic approaches have previously been shown to generate protein gradients on two-
dimensional culture substrates [130, 138, 180, 191]. Light-based covalent immobilization 
methods have also been recently described for covalent immobilization of biomolecules within 
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3D constructs [192, 193]. Recently, our group described a microfluidic templating tool to create 
overlapping patterns of HSCs and niche cells across a single hydrogel construct [180]. While this 
effort suggested an approach to create biomolecularly-graded microenvironments for long-term 
HSC culture, at this point we have little information regarding whether introduction of a 
spatially-graded biomolecule signal impacts HSC response.  
In this chapter we describe the impact of selective incorporation of SCF within a methacrylated 
gelatin (GelMA) hydrogel on murine hematopoietic stem and progenitor cell bioactivity. The 
GelMA hydrogel can be UV-polymerized, contains natural ligands (Fn motif RGD), and retains 
MMP-sensitive degradation sites [194, 195]. We have previously demonstrated multiple paths 
(macromer density; degree of methacrylation) for adjusting the modulus and microstructure of 
the GelMA hydrogel [155, 196]. Here we report the impact of soluble vs. immobilized SCF on 
proliferation and differentiation potential. Further, we explore the use of microfluidic templating 
to create local gradients of immobilized SCF across a single GelMA hydrogel. 
 
3.3. Materials and Methods 
3.3.1 Synthesis of methacrylated gelatin macromer 
Gelatin Methacrylate was synthesized as described previously [155]. Briefly, 10 % (w/v) gelatin 
(Type A, 300 bloom from porcine skin) was mixed with phosphate buffered saline (PBS) (Gibco, 
Grand Island, NY) at 60 °C and stirred until fully dissolved. Methacrylic anhydride (MA) 
(Sigma-Aldrich, St. Louis, MO) was added dropwise and allowed to react for 1 hour. Following 
a five-fold dilution in warm (60 °C) PBS, the mixture was dialyzed (12,000 – 14,000 M.W, 
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Fisherbrand, Pittsburgh, PA) against distilled water to remove salts and excess MA, then 
lyophilized. Addition of 20% (v/v) MA was used to generate a final GelMA macromer with 85% 
degree of MA functionalization, as previously verified via 
1
H NMR (Varian INOVA) [197].  
3.3.2 Synthesis of photoinitiator  
The lithium acylphosphinate (LAP) photoinitiator was synthesized as described previously by 
Anseth et al.[198]. 2,4,6-trimethylbenzoyl chloride (Sigma Aldrich) was added dropwise to an 
equimolar amount of continuously stirred dimethyl phenylphosphonite (Sigma Aldrich) at room 
temperature and under argon. A fourfold excess of lithium bromide in 2-butanone (Sigma–
Aldrich) was added to the reaction mixture and heated to 50 °C to form a solid precipitate. The 
mixture was cooled to ambient temperature then filtered and washed 3 times with 2-butanone to 
remove unreacted lithium bromide. Excess solvent was subsequently removed by vacuum.  
3.3.3 Pegylated Stem Cell Factor (PEG-SCF) 
3500 MW Acrylate PEG-NHS ester (JanKem Technology USA, Allen, TX)  was reacted at room 
temperature with recombinant murine SCF (PeproTech, Rocky Hill, NJ) at a molar ratio of 24:1 
(PEG-NHS: SCF) in the presence of PBS at a pH of 8.0 [199]. Unreacted PEG-NHS was 
removed using a 10K MW Pierce Concentrator PES (Thermo Scientific, Waltham, MA). The 
concentration of PEG-SCF was determined via ELISA (R&D Systems, Minneapolis, MN). To 
confirm conjugation, Western blotting was performed to compare PEG-SCF and unmodified 
SCF using a 15% Tris-HCl precast polyacrylamide gel. Primary antibody: rabbit polyclonal 
Anti-SCF; Secondary antibody: Goat polyclonal anti-rabbit IgG (H&L) conjugated to 
horseradish peroxidase. For detection, the SuperSignal West Pico Chemiluminescent Substrate 
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kit (Thermo Scientific) was used along with ImageQuant LAS 4000 (General Electric) for 
imaging. The final PEG-SCF was suspended in a solution of PBS (pH 7.4) with 0.1% BSA, 
aliquoted and stored at -80 °C for further use.  
3.3.4 GelMA Hydrogel Synthesis  
A 5% (w/v) solution of GelMA macromer and 0.1% (w/v) solution of LAP photoinitiator were 
created in Phosphate buffered saline (PBS). For PEG-SCF conjugated GelMA hydrogels, PEG-
SCF was added to the pre-polymer solution at concentrations of 100 and 400 ng/mL. A plastic 
mold consisting of wells 7 mm in diameter and 700 µm thick was 3D printed (Makerbot 
Replicator 2, Makerbot) and was sanded down to a final thickness of 500 µm. The mold was 
sandwiched between glass slides into which the GelMA solution (18 µl) was added. The solution 
was exposed to 10 mW/cm
2
 UV light (365 nm) for 15 seconds [155]. The resulting hydrogel was 
removed from the bracket and kept hydrated with either PBS (pH 7.4) or StemSpan SFEM media 
(StemCell technologies, Vancouver, Canada) in a 5% CO2 incubator at 37 °C.  
3.3.5 Fluorescence imaging of PEG-SCF 
GelMA hydrogels were created with the addition of PEG-SCF (Bound), non-functionalized 
soluble SCF (100 ng/mL) or no SCF (0 ng/mL) to the pre-polymer solution. The gels were 
placed in PBS in the incubator at 37 °C and 5% CO2. At days 2, 4 and 7, the gels were removed 
from PBS, embedded in Tissue-Tek O.C.T. Compound (Sakura, Torrance, CA) and frozen at – 
80 °C. Using a cryostat (Leica CM3050 S), 20 µm slices of the GelMA were made and deposited 
onto a SuperFrost Excell microscope slide (Thermo Scientific, Waltham, MA). The slices were 
then first stained with anti-murine SCF antibody conjugated with Biotin (Peprotech, Rocky Hill, 
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NJ) at 100 ng/mL for 1 hour followed by a secondary conjugation with AlexaFluor 633 
conjugated with Streptavidin (Life Technologies, Grand Island, NY) at 100 ng/mL for 30 mins. 
All staining steps were done at room temperature and away from light with three PBS washes 
between every step. The stained slices were then imaged with the Zeiss LSM 710 confocal 
microscope.  
3.3.6 SCF time-release profile in GelMA hydrogels 
SCF laden GelMA hydrogels were created via addition of PEG-SCF (Bound) or non-
functionalized SCF (Unbound) to the pre-polymer solution (100, 400 ng/mL). SCF-elution rates 
were determined over 7 days in PBS (37 
o
C, 5% CO2 incubator). The PBS solution was 
extracted (12 h, 2, 4, 7 days) and replaced with fresh PBS. Extracted PBS was frozen at -80 °C 
until analysis. SCF levels in the extracted PBS were quantified via ELISA (Mouse SCF Duoset, 
RnD Systems). The fraction of SCF retention in the gel was back-calculated from the amounts of 
SCF leached into the PBS from the gels.  
3.3.7 Primary murine cell isolation 
Primary HSPCs were isolated from the bone marrow of female C57BL/6 mice (Jackson Labs; 
Ages 1–3 months) as described previously [180]. Briefly, femurs and tibias of the mice were 
removed following CO2 asphyxiation. The bones were gently crushed with a mortar and pestle, 
washed with a solution of PBS + 5% FBS (PBS/FBS), and filtered with a 40µm sterile filter. All 
subsequent steps were performed in a PBS/FBS solution on ice. Red blood cells were lysed with 
ACK lysis buffer (Invitrogen, Carlsbad, CA). The cells were enriched via Lin
+
 cell depletion 
using the EasySep Mouse Hematopoietic Progenitor Cell Enrichment kit (StemCell 
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Technologies, Vancouver, Canada). HSPCs were isolated as the Lin
−
 Sca-1
+
 c-kit
+
 (LSK) sub-
fraction using a cocktail of antibodies (eBioscience, San Diego, CA): PE-conjugated Sca-1 
(1:100 dilution), APC-conjugated c-kit (1:100 dilution), and a 1:100 dilution of an FITC-
conjugated Lineage (Lin) cocktail (CD5, B220, Mac-1, CD8a, Gr-1, Ter-119). LSK cells were 
sorted using a BD FACS Aria II flow cytometer (BD FACS Diva software) and collected in 
PBS/FBS on ice for immediate use. All animal experiments were conducted with permission 
obtained from the University of Illinois Institutional Animal Care and Use Committee (Protocol 
#12033). 
3.3.8 SCF supplementation of LSK-laden hydrogels 
Freshly isolated LSK cells were mixed with the GelMA pre-polymer solution at a density of 5 × 
10
5
 cells/mL, and then polymerized as described previously. LSKs were seeded in four GelMA 
hydrogel variants (all media replaced every 2 days): 1) No SCF: GelMA hydrogel in SCF-free 
media. 2) Bound SCF: GelMA + PEG-SCF (100, 400 ng/mL) hydrogel in SCF-free media. 3) 
Continuous unbound SCF: GelMA hydrogel with 100 ng/mL SCF media. 4) Single-dose 
unbound SCF: GelMA hydrogel initially in 100 ng/mL SCF media but replaced after 2 days with 
SCF-free media (identical total dose as Bound SCF). 
3.3.9 Analysis of cell bioactivity 
LSK viability within the GelMA hydrogels was measured using the Live/Dead Cytotoxicity kit 
(Invitrogen Carlsbad, CA) [61]. Briefly, a 2 µM solution of Calcein AM and Ethidium 
homodimer-1 was prepared in PBS (pH 7.4) and added to the hydrogel (400 µL per sample) and 
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incubated for 20 mins at 5% CO2 and 37 °C. Cells were analyzed at 2, 4 and 7 days of culture 
for all conditions via a Zeiss LSM 710 Multiphoton Confocal Microscope.  
The phenotype of the cells was determined via surface antigen expression using flow cytometry 
(FACS) on a BD LSRII flow cytometer (BD Bioscience). Prior to analysis, the gels were first 
digested with a 50 U/mL of Collagenase type 2 (Worthington Biochemicals, Lakewood, NJ) 
prepared in PBS (pH 7.4) with 5% fetal bovine serum (FBS). The gels were digested for 40 mins 
in an incubator at 5% CO2 and 37 °C. The solution was then filtered with a 40 µm nylon mesh 
(Fisher Scientific, Pittsburgh, PA), the cells resuspended (1400 RPM, 6 mins) in a solution of 
PBS (pH 7.4) with 0.1% sodium azide and stained for the following cocktail of antibodies 
(eBioscience, San Diego, CA): APC-conjugated CD34 (1:20 dilution, 60 mins), PE-conjugated 
Sca-1 (1:100 dilution, 30 mins), APC-conjugated c-kit (1:100 dilution, 30 mins), and a 1:100 
dilution of an FITC-conjugated Lineage (Lin) cocktail (CD5, B220, Mac-1, CD8a, Gr-1, Ter-
119, 30 mins). The resulting data was analyzed using FCS Express 4.0 software [200]. Prior to 
the FACS analysis, microbeads (5µm, Spherotech, Lake Forest, IL) were added to the sample 
that served as a known standard of concentration in solution. The final numbers of cells in each 
sample were then calculated using the “Concentration Calculator” option in the FCS Express 4.0 
software.  
Colony forming potential was assessed via Methocult GF M3434 methylcellulose-based medium 
(StemCell Technologies, Vancouver, Canada). For this purpose, the gels were similarly digested 
as mentioned above and following filtration, were resuspended in the StemSpan SFEM media. 
Aliquots were made at one-third and one-fifth of the total sample volume, brought to a volume of 
0.1 mL and mixed with the Methocult media for a total volume of 1.1 mL per sample. The 
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samples were plated on a gridded 35 mm culture dishes (StemCell Technologies) and incubated 
for 12 days. Following incubation, the GEMM, GM, G, M, Mk, and E colonies were counted 
using an inverted microscope [164]. The results are reported as the number of colonies counted 
for each type per gel sample.  
3.3.10 Fabrication of silicon master for integrated microfluidic mixer 
We have previously described a 2-part microfluidic mixer and culture chamber system for 
creating spatially-graded hydrogels [180, 201]. Here, we modified the previous mixer design to 
both reduce the size of the final hydrogel construct (180 to 60 µL) and to integrate the hydrogel 
mold and microfluidic mixer into a single construct (Figure 3.1). The microfluidic device was 
fabricated using a standard two layer photolithography procedure on a 4″ Si wafer (University 
Wafers, South Boston, MA). The mixer contains 200 μm (wide) × 100 μm (tall) channels with 50 
μm high staggered herringbone features as previously described [180] expanding from 2 inlet 
channels. Outlet channels (10) in the new design led to a 15 x 8 mm x 500 μm (tall) well 
integrated onto the microfluidic platform. The design for the device was created in Freehand 
MXTM (Macromedia, Inc. now Adobe Systems, San Jose, CA) and printed on high-resolution 
transparencies (5080 dpi, PageWorks, Cambridge, MA). A positive relief was created by 
covering a silicon wafer with a 100 μm layer of SU8–2050 negative photoresist (MicroChem 
Corporation, Newton, MA) via spin-coating, baking (65 °C for 5 min, 95 °C for 15 min), then 
subsequently exposing with UV (OAI 1500, 220 mJ/cm
2
). A second 50 μm layer of photoresist 
corresponding to the herringbone mixing features was spin-coated onto the microchannel 
geometry, followed by baking and UV exposure (180 mJ/cm
2
) through a herringbone photomask. 
The resulting two-layer photoresist structure was baked (65 ° C for 1 min, 95 ° C for 6 min) then 
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developed using propylene glycol monomethyl ether acetate (PGMEA). The remaining positive 
relief structure was washed away with acetone and isopropyl alcohol. A monolayer of 
tridecafluoro-1,1,2,2- tetrahydrooctyl trichlorosilane (Gelest, Morrisville, PA) was deposited 
onto the silicon master prior to replica molding to prevent covalent adhesion of 
polydimethylsiloxane (PDMS) on the photoresist and the silicon surfaces.  
3.3.11 Fabrication of the PDMS device 
PDMS devices were then created from the master by curing a 10:1 mixture of monomer:cross-
linking agent (RTV 615 Part A/B, General Electric, Waterford, NY) on the wafer at 65 ° C for 1 
h. After peeling the PDMS mold off the wafers, access ports were punched into the device inlets 
using a 20-gauge blunt syringe needle. A second blank silicon wafer was used to create a PDMS 
layer of PDMS to be added on top of the culture well to hold culture media, with a scalpel used 
to cut a media well the size of the underlying hydrogel chamber. The PDMS pieces were cleaned 
with tape (Scotch™ 3M) and oxygen plasma (Harrick Plasma, Ithacya, NY) for 1 min. A 3-layer 
sanwhich was subsequently created by stacking the PDMS microfluidic mixer layer, a plasma-
cleaned, transparent polycarbonate membrane (1 µm pores; AR Brown, Pittsburg, PA), then the 
PDMS media well [201]. Prior to assembling the layers, the PDMS pieces were immersed in a 
1% solution of (3-aminopropyl)-trimethoxysilane (APTMS; Sigma-Aldrich), while the middle 
polycarbonate membrane was placed in a 1% solution of (3-Glycidoxypropyl)-
methyldiethoxysilane (GPTMS; Sigma-Aldrich); all were washed with DI water then dried on a 
lint-free cloth. The mixer-membrane-media well sandwich was subsequently aligned, then 
allowed 20 min incubation at room temperature, for formation of spontaneous APTMS-GPTMS 
bonds. The final device assembly was then incubated at 65 °C for 2 hours. 
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3.3.12 Gradient hydrogel mold fabrication and fluorescence imaging analysis 
GelMA hydrogels containing a gradient in SCF were created by mixing two pre-polymer 
solutions through the microfluidic device: 1) 5% (w/v) GelMA; 2) 5% (w/v) GelMA + 400 
ng/mL PEG-SCF. The solutions were placed into 1 mL syringes then loaded on a computer-
controlled syringe pump (Harvard Apparatus, model 33 twin syringe pump, Holliston, MA). The 
pre-polymer was then pumped through the microfluidic mixer at 100 µL/min [180], with 
gradient production completed within 25 seconds. The device was then detached from the 
syringe pump and UV polymerized (365 nm UV light; 10 mW/cm
2
; 25 seconds). Excess media 
was added into the PDMS media well layer and the entire assembly maintained in a 5% CO2 
incubator at 37 °C.  
In order to image the immobilized SCF within the GelMA hydrogel, the PEG-SCF was first 
stained with anti-murine SCF antibody conjugated with Biotin (Peprotech, Rocky Hill, NJ) at 
100 ng/mL for 1 hour followed by a secondary conjugation with AlexaFluor 633 conjugated with 
Streptavidin (Life Technologies, Grand Island, NY) at 100 ng/mL for 30 mins. All staining steps 
were done at room temperature and away from light. After polymerization, the gels were 
hydrated in PBS and imaged using the Typhoon 9400 Image Scanner (GE Electronics). Mean 
fluorescence intensity of each region was acquired using ImageJ software in a manner previously 
described [180].  
3.3.13. Statistical analysis. 
Statistical analysis was performed via one-way analysis of variance (ANOVA) tests after which 
a Tukey-HSD post-hoc test was used. Independent factors included time, SCF type (SCF-Acr, 
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SCF) and concentration. SCF immobilization and release experiments used at least n = 5 
constructs per group. Analysis of LSK cell bioactivity (viability, proliferation, surface antigen 
expression, CFU assay) used at least n = 3 constructs per group. Significance was set at p < 0.05. 
Error bars are reported as standard error of the mean unless otherwise noted. 
 
3.4. Results 
3.4.1. SCF was PEG-conjugated and its bioactivity maintained 
The conjugation of SCF to PEG was determined via Western Blot (Figure 3.2A). The native size 
of SCF is known to be 18.3 kDa as represented by the left lane. In the PEG-SCF lane, a protein 
smear was seen beginning at roughly 40 kDa, demonstrating conjugation to the PEG chains and a 
resultant increase in molecular weight. Additionally, no SCF at the 18.3 kDa position was seen, 
suggesting reaction of all SCF with PEG. Further, a broad distribution in molecular weights is 
seen instead of a sharp single band, likely owing to the polydispersity of the PEG chains and the 
potential for multiple chains to attach to any given SCF molecule [186].  
The attachment of PEG chains to a protein has the potential to alter its bioactivity, especially if 
the chains are tethered at the bioactive sites. In order to determine whether the PEG-SCF was 
bioactive towards the HSCs, HSCs proliferation was quantified in media containing: (1) no SCF; 
(2) soluble, unmodified SCF; or (3) soluble, PEG-SCF (Figure 3.3). Compared to the group that 
received no SCF, HSCs cultured in the presence of either PEG-SCF or unmodified SCF showed 
similar increase in proliferation  
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3.4.2. Retention of SCF within the GelMA matrix 
Covalent immobilization of PEG-SCF to the GelMA structure was determined via two methods; 
direct visualization and measurement of SCF concentration. While it is possible to directly stain 
the immobilized SCF within the hydrated gels, this measurement may be confounded by 
diffusion-limitations of the primary and secondary antibodies. Therefore thin cross sections were 
taken from the hydrogel and were subsequently stained. After 7 days in a PBS solution, the PEG-
SCF samples remained fluorescent indicating the presence of SCF in the GelMA hydrogel 
(Figure 3.2B). Comparatively, GelMA hydrogel fabricated with unmodified SCF shows 
significantly reduced staining, suggesting diffusive loss of the SCF from the matrix. In order to 
quantify the amount of SCF in the gel, SCF concentration in the surrounding PBS bath was 
examined via ELISA. Any unattached or non-functionalized SCF is expected to eventually 
diffusive out of the GelMA network and into the PBS solution. Therefore, measuring the SCF 
concentrations in the PBS solution can be used to calculate the amount of SCF that retained in 
the GelMA hydrogel. Figure 3.4 shows the SCF retention profile for both the PEG-SCF and 
soluble SCF for the GelMA. A drop in SCF retention is seen within the first 12 hours of gel 
polymerization, suggesting some PEG-SCF did not react during hydrogel gelation. However, 
SCF levels within the gels containing PEG-SCF are subsequently maintained at this level 
through the full 7 day culture. While some SCF is retained in the matrix in the case of non-
functionalized SCF, the overall amount of SCF present in the matrix is significantly reduced 
compared to hydrogel variants containing immobilized SCF. These results demonstrate that 
bioactive SCF can be retained within a three-dimensional GelMA hydrogel for up to 7 days.  
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3.4.3. Immobilized SCF within the hydrogel significantly influences LSK cell bioactivity  
It has been well established that the soluble versus membrane-bound proteins can differentially 
impact cell response via different mechanisms of action [186, 189, 202]. After seeding primary 
murine LSK cells within GelMA matrices containing no SCF, soluble SF, or matrix-immobilized 
SCF, we examined LSK bioactivity over the course of up to 7 days in culture. While UV 
exposure during photopolymerization can be potentially cytotoxic, we observed high cell 
viability (~80%) 12 hours after UV exposure (Figure 3.5), suggesting choice of photoiniatior 
concentration and UV exposure results in gelation conditions that did not adversely affect cell 
viability.  
Following cell proliferation in culture, we observed that the lack of SCF in the media or 
immobilized within the hydrogel leads to significant cell death.  For gels containing no SCF in 
gel or media (None 0) or with an initial dose of soluble SCF in gel but no addition soluble SCF 
in the media to replace the SCF lost through diffusion (Sol 0), LSK viability and proliferation 
was reduced significantly by day 4 in culture (Figure 3.5A, 3.6). For the immobilized SCF, 100 
ng/ml SCF added during gelation (PEG 100) leads to a decline in viability and proliferation 
whereas proliferation increases slightly when a larger SCF dose was initially immobilized (400 
ng/ml SCF, PEG 400 gels). Here, while still reduced, LSK viability remains stable over 7 days in 
culture (Figure 3.5B, 3.6). For the Sol 100 condition, which received an initial dose of SCF in 
the gel as well as continuous soluble supplementation through the culture, an increase in both 
viability and proliferation is seen. While it is no surprise that a continuous supply of SCF boosts 
cell proliferation, such continuous supplementation is extremely expensive.  
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We subsequently examined whether addition of soluble or matrix bound SCF impacts what 
fractions of hematopoietic stem and progenitor cells are expanded in culture. The relative 
fraction of CD34
–
 LSK, corresponding to a more primitive HSC fraction, was assessed via flow 
cytometry (Figure 3.7). The Sol 100 condition has the lowest fraction of LSK cells by day 7, 
likely a consequence of elevated proliferation rates. For both immobilized SCF conditions, the 
fractions of LSK cells were maintained, and were markedly higher than soluble SCF, over the 
course of the experiment. Similarly, the fraction of CD34
–
 LSK cells decrease with culture. 
Though not significant, the immobilized SCF conditions (PEG 100, 400) showed a higher 
fraction of these primitive progenitors at day 7, suggesting immobilization of SCF may enhance 
maintenance of a more primitive HSC sub-fraction.   
Owing to reduced proliferation and poor viability of cells in the Sol 0 and None 0 conditions, 
colony forming unit (CFU) assays were performed only for the immobilized SCF and the Sol 
100 gels, with the total number of colonies counted indicative of the proliferation capacity of the 
cells in culture. Although the number of colonies increases by day 4 for immobilized SCF, they 
decline by day 7 (Figure 3.8), correlating with the fold expansion data gathered via flow 
cytometry. An analysis of the individual colony types in culture indicate that GEMM colonies, 
which represent the most primitive colony type, is highest for the PEG 400 condition whereas the 
Sol 100 has little to no GEMM colonies by day 4 (Figure 3.9A). However, baring the GEMM 
colonies, the Sol 100 condition retains the highest number of colonies by day 7 for all the other 
(GM, G, M, Mk, E) colony types (Figure 3.9 B, C, D, E, F), suggesting more rapid expansion of 
differentiated hematopoietic cells in the presence of soluble SCF while maintenance of more 
primitive HSC fractions in the presence of matrix-tethered SCF. 
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3.4.4. Immobilized SCF gradients created using the microfluidic platform 
After demonstrating the impact of immobilized SCF on LSK cell bioactivity using monolithic 
hydrogels, we generated linear gradients of immobilized SCF across the GelMA hydrogel using 
a previously described [180] microfluidic templating approach. Our goal was to assess the 
potential to induce spatially-selective changes in HSC bioactivity across a single hydrogel 
construct. The microfluidic templating approach permits creation of a linear gradient of 
immobilized SCF across the GelMA hydrogel (Figure 3.10). In situ culture of cells is possible 
without extracting the gradient gel from the microfluidic device because of the porous membrane 
separating it from the PDMS layer on top. This creates a well in which media can be added and 
maintained over extended periods. Current work is focused towards encapsulating cells within 
these gradient gels and monitoring HSC functionality via viability and CFU assays.  
 
3.5. Discussion 
HSCs have been used effectively for the treatment of several cancers and blood disorders and 
continue to gain clinical significance. However, we have not been able to fully utilize their 
therapeutic potential due to our lack of understanding of their regulatory mechanisms. 
Furthermore, it is difficult to control their fate in vitro. This calls for a need to better engineer 
microenvironments that allow us to control the differentiative vs. proliferative response of HSCs 
in order to make them more clinically relevant. Currently, there are no 3D-based biomaterial 
tools that encapsulate the complexity of the native HSC niche, with the ability to incorporate the 
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various niche components. However, using bio-inspired strategies and identifying key niche 
constraints provides us with a basis for creating better HSC in vitro culture platforms.  
The effect of soluble vs. membrane bound cytokines on HSC fate is well known. Stem cell factor 
(SCF) exists in both the membrane-bound and soluble form and in the in vivo niche, absence of 
the bound form of SCF is shown to adversely affect mice [203].  Previous experiments with 
cytokines coated onto 2D substrates have shown improved hematopoietic expansion over time. 
The immobilization techniques used relied on ether physisorption on tissue culture plastic 
(TCPS) [184] or coated on microparticles [189]. Although these substrates were proven to be 
effective, neither technique is amenable for translation to a fully three-dimensional hydrogel. 
Gelatin is an attractive biomaterial substrate due to its natural origin, presence of RGD peptides, 
and presence of MMP degradation sites [194, 195]. Methacrylation of the gelatin macromer 
makes it possible to generate a wide variety of hydrogel constructs via UV-based 
photoimobilization with control over matrix stiffness, crosslinking density, and diffusivity [155]. 
However, selective attachment of a cytokine to a gelatin hydrogel requires functionalizing the 
biomolecule with an active site for UV-based photoimmobilization. Here selective peglyation 
with a Methacrylate-modified PEG molecule presents such an avenue [186, 199]. 
While possible to negatively impact the overall bioactivity of the SCF molecule, this approach 
can also be an effective way to covalently attach SCF to the matrix for extended periods of time 
(Figure 3.4). In previous studies, West et. al, achieved immobilization of SCF on a PDMS 
substrates for culture of the 32D myeloid progenitor cell line [186]. Here, though a full 3D 
visualization of the SCF attachment within GelMA was not explored due to diffusive limitation 
of the primary and secondary antibodies required to visualize SCF content, fluorescence analysis 
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of PEG-SCF immobilization from 2D slices taken at multiple depths through the hydrogel 
indicate that SCF can be immobilized in the GelMA hydrogel and that it is possible to achieve 
relatively uniform distribution of immobilized SCF throughout the hydrogel.  
One of the primary roles of SCF in the niche is the maintenance and self-renewal of HSCs [13]. 
However, in vitro the primary function of SCF is that of maintaining cell viability accompanied 
by the uncontrolled differentiation and proliferation of the HSCs. As can be seen in Figs. 3.5 and 
3.6, the presence of any form of SCF (soluble or bound) was crucial for long-term HSC culture. 
A lack of immobilization of the SCF adversely affects cell viability as the SCF is not retained 
within the GelMA hydrogel as evidenced by both SCF retention measurements (Figure 3.4) and 
cell viability (Figure 3.5A). Additionally, cell response to both viability and functionality is 
dependent on the concentration of the immobilized SCF with the higher concentration (400 
ng/mL) promoting cell expansion. While there is no evidenced linear relationship between cell 
proliferation and surface-immobilized SCF concentration, it is not surprising that the higher 
concentrations promote a greater biological response. In this case, it might simply be that a 
higher fraction of SCF is retained and is biologically active within the hydrogel with a higher 
starting concentration of the SCF. Functional response of the HSCs indicates a higher fraction of 
more primitive progenitors, both via flow cytometry analysis of the LSKCD34
–
 fraction (Figure 
3.7B) or via presence of increased numbers of the most primitive GEMM colonies via CFU 
assay (Figure 3.9A). The signaling cascades involved for the soluble and bound forms of SCF 
are likely to be different and have different effects on the HSCs. Therefore, simply increasing the 
bound SCF concentration need not mirror the effects seen via the soluble SCF. Increased 
proliferation and reduced number of GEMM colonies and CD34
– 
LSK fractions in the soluble 
SCF gels suggest that seeded LSK cells more rapidly expand and differentiate in the presence of 
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soluble SCF (Figure 3.6, 3.7A, B). The immobilization strategy utilized here therefore has the 
potential to be used in conjunction with soluble supplementation albeit at lower concentration in 
order to promote both cell expansion and maintenance of more primitive progenitors.   
The development of in vitro culture platforms that permit regulation of HSC bioactivity demands 
bio-inspired strategies with a greater control over the microenvironment. Immobilization of 
niche-relevant cytokines such as SCF may provide an initial building block for creation of such 
an artificial environment. However, effective control over the spatio-temporal properties of such 
immobilization strategies is required if the microenvironment is to be regulated. Gradient 
structures may be particularly significant for such goals, as they provide an avenue to rapidly 
generate a continuum of biomolecular environments permitting analysis of cell response at 
discrete regions of the hydrogel, but also in the context of the local gradient in properties across 
the hydrogel. Our lab has previously demonstrated the creation of gradient hydrogels for niche 
cells and hydrogels using a microfluidic platform [180]. Here, we modified the design of that 
device to create smaller hydrogel volumes (60 µL vs. 180 µL) to enable small-scale analysis of 
reduced numbers of HSCs. Using this platform gradients in concentration of immobilized SCF 
were created (Figure 3.10). Presently, a variety of techniques are used to create environments for 
HSC culture such as micropatterning of specific niche factors either via photolithography or 
microprinting [114, 182], or microfluidic approaches for creation of protein gradients on 2D 
surfaces [191, 204] or single-cell analysis techniques [113, 205]. While all of these techniques 
have their merits, there lacks the unifying element that brings together all the distinct niche 
components on a single platform, along with the ability to tune the matrix biophysical and 
biochemical properties for a broader cell response range. Therefore, generation of immobilized 
SCF gradients on a platform capable of manipulating both niche cell density as well as gel 
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density provides a huge advantage over other techniques for exercising control over stem cell 
fate. This approach may also reduce the need for constant media supplementation, allowing cells 
to be cultured for extended periods of time at lower costs as well as the potential to spatially 
modify the local environment surrounding the cells. Ongoing work for this project involves 
eliciting a region-specific HSC response based on the local concentration of the immobilized 
SCF.  
 
3.6. Conclusions 
We have demonstrated the ability to stimulate HSC behavior via introduction of a covalently 
immobilized cytokine SCF within the bulk of a 3D GelMA hydrogel. Both cell proliferation and 
differentiation capacity were impacted compared to the soluble form of the SCF, underscoring 
the importance of the method of cytokine presentation in regulating stem cell fate. The technique 
was then translated to create gradients in immobilized SCF concentration on a platform for long-
term cell culture where the cell response as a function of the SCF gradients is being studied. As 
of now, it is not possible to maintain the primitive HSC populations in culture for long periods of 
time as they tend to undergo differentiation into more mature progeny. Additionally, there is a 
dearth of biomaterial strategies that enable spatial control of niche components, particularly 
biomolecules in a 3D matrix. However, hydrogels containing spatial patterns of immobilized 
biomolecules may be particularly important for developing functional, ex vivo expansion 
platforms required to exploit the therapeutic potential of HSCs. The biomaterial platform 
described here attempts to recapitulate the inherent complexity of the HSC niche while also 
enabling HSC culture in vitro under more controlled environments for clinically relevant 
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applications. Future work for this study will explore using other combinations of niche cells, 
biomaterials and biomolecules for more specific HSC responses.   
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3.7 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 An improved microfluidic device design. 
The design enables creation of the gradient within the 
PDMS mold itself instead of an external Teflon mold. 
This reduces the volume and makes the process more 
efficient. (Scale Bar: 15 mm) 
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Figure 3.2 (A) Western Blot analysis of the soluble and conjugated form of 
SCF. (B) Fluorescence imaging of the slices of the 3D GelmA gels with 
immobilized SCF attachedindicate the functionalization of SCF and its 
attachment to the GelMA matrix. (Scale Bar: 100 µm) 
(B) (A) 
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Figure 3.3 Cell proliferation for different SCF conditions A decrease in cell numbers 
for the no SCF condition (Sol 0) emphasizes the importance of SCF whereas similar 
expansion numbers for Sol 100 and PEG 100 indicate that the functionalized PEG is 
bioactive.  
 
* indicates significance p <0.05 
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Figure 3.4 SCF retention in GelMA over 7 days indicates that a much higher fraction 
of the PEG-functionalized SCF is retained in the gel compared to the soluble SCF.  
 
* indicates significance p <0.001 
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Figure 3.5 Cell viability in GelMA gels with (A) no soluble SCF in media and gel 
(None 0) or with SCF in the gel but not in media (Sol 0) and (B) Soluble SCF in both 
gel and media (Sol 100) or the PEG-functionalized SCF (PEG 100, 400).  
 
^ indicates significance within the same condition w.r.t all other days (p<0.001) 
# indicates overall significance for a given day (p<0.001) 
* indicates significance between groups (p<0.05) 
*** indicates significance between groups (p<0.001) 
 
(A) (B) 
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Figure 3.6 Fold expansion in cell numbers for SCF in the gel but not in media (Sol 0), 
Soluble SCF in both gel and media (Sol 100) or the PEG-functionalized SCF (PEG 
100, 400). 
 
* indicates significance at p<0.05 
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Figure 3.7 (A) LSK cell fractions in the gels and (B) CD34-ve LSK, a more primitive 
sub-fraction of the LSKs within the same gels at 2, 4, 7 days of culture 
 
^ indicates significance within the same condition w.r.t all other days (p<0.01) 
* indicates significance between groups (p<0.01) 
 
(A) (B) 
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Figure 3.8 Total colony numbers for the CFU assay for each condition 
Both the PEG 100 and PEG 400 gels see a drop in colony numbers by day 7 whereas 
those for the Sol 100 condition remain steady.  
 
** indicates significance between groups (p<0.01) 
*** indicates significance between groups (p<0.001) 
 
84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (Days) 
#
 c
o
lo
n
ie
s 
/ 
1
0
0
0
 c
el
ls
 
Figure 3.9 CFU colonies formed by LSK cells expanded in GelMA hydrogels for up 
to 7 days. The numbers are reported as number of colonies counted per 1000 of the 
initial seeded cells. 
 
* indicates significance between groups (p<0.05) 
** indicates significance between groups (p<0.01) 
*** indicates significance between groups (p<0.001) 
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Figure 3.10 (A) Fluorescent images of Alexa Fluor 633-conjugated immobilized SCF 
show a gradient in concentration across the GelMA hydrogel (B) Linear gradient of 
the immobilized SCF as determined by the mean fluorescence intensity across 5 
distinct regions in the gel. (Scale bar 5 mm) 
(A) (B) 
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CHAPTER 4: INFLUENCE OF CELL DENSITY AND GEL 
ENVIRONMENT ON HEMATOPOIETIC STEM CELLS VIA 
AUTOCRINE AND PARACRINE SIGNALING MECHANISMS
3
  
4.1 Chapter overview 
The previous two chapters have described development of elements of a hydrogel biomaterial 
that presents overlapping gradients of cellular and biomolecular signals to encapsulated 
hematopoietic stem cells as part of a larger program to generate an artificial bone marrow. Here, 
we explore the ability to regulate the balance between HSC-generated autocrine feedback loops 
and niche cell generated paracrine signals as an alternative approach to regulate HSC fate. In 
particular, this chapter focuses on elucidating differences in HSC response to a Lineage positive 
(Lin
+
) niche cell population as a function of both niche cell density and the density of the 
hydrogel matrix. We demonstrate that while the overall density of niche cells within the matrix 
significantly impacts HSC activity, notably myeloid differentiation, these effects are strongly 
dependent on matrix density. Further, we demonstrate autocrine signaling loops may play an 
important role in expansion of early-stage HSC progenitors, particularly in hydrogel 
formulations with limited diffusion coefficient. Here, we were also able to abrogate the effects of 
niche cell mediated paracrine signals and HSC mediated autocrine signals via cocktails of 
canonical inhibitors of paracrine (TGFβ, TNFα, MIP-1α) or autocrine (VEGF, PDGF, EGF) 
signaling pathways. These results suggest an approach to modify the biomaterial matrix in order 
to not only present structural and biomolecular cues to encapsulated HSCs, but to potentially 
alter the balance of paracrine versus autocrine cues.  
                                                 
3
 This chapter has been adapted from the following publication:  
Mahadik et.al. “Influence of cell density and gel environment on paracrine-mediated signaling and hematopoietic 
stem cell fate.”, (in preparation) 
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4.2 Introduction 
The bone marrow niche plays a central role in the maintenance and regulation of HSCs. HSC 
fate decisions are believed to be regulated by complex signaling cascades initiated by extrinsic 
presentation of niche cells, extracellular matrix (ECM) cues, and soluble or matrix-bound 
biomolecules [25, 84, 171, 206]. Indirect cell-cell interactions between HSCs and niche cells 
(paracrine signals) or autocatalytic effects from the HSC itself (autocrine signals) are mediated 
by diffusible biomolecules [51, 77, 78, 207-210]. Direct cell-cell interactions (juxtacrine signals) 
rely on activation of membrane bound cell adhesion molecule activation, signals which have 
been exploited to impact HSC fate [105, 211, 212]. Together, these soluble and bound 
biomolecules are responsible for providing a constellation of extrinsic signals that regulate HSC 
fate decisions. Recent efforts aimed at using niche cell derived signals to direct HSC fate have 
primarily been performed in liquid culture systems using two-dimensional culture platforms 
[210, 213]. However, the potential to regulate the balance of autocrine vs. paracrine signals in 
more complex 3D systems remains poorly explored.  
HSCs are known to secrete and interact with a large number of cytokines and growth regulators 
in the in vivo niche, resulting in a complex and dynamic signaling network that determines their 
fate [79, 209]. The mode of communication between HSCs and niche cells is a function of the 
cell type as well as the secreted factor involved. Mesenchymal stem cells (MSCs) are believed to 
stimulate proliferation of HSCs through paracrine-mediated interactions via several molecules 
such as CXCL12, IL-6 and TPO [51]. Csaszar et. al. demonstrated that paracrine-mediated IL-6 
signaling can be regulated by the delta-1 ligand for improved HSC expansion [210].  
Transforming growth factor β (TGF-β) is known to act as both a paracrine signal as well as an 
HSC-generated autocrine feedback loop to inhibit HSC self-renewal and proliferation [208, 214, 
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215]. Vascular endothelial growth factor (VEGF) has been shown to impact HSC survival via 
VEGFR-1 and VEGFR-2 mediated autocrine feedback loops [78] while platelet derived growth 
factor (PDGF) can enhance proliferation [215-217]. The autocrine/paracrine-mediated signaling 
effects of other biomolecules such as Hepatocyte growth factor (HGF) and Interlukin-8 (IL-8) 
have also been explored [218, 219]. Recently, Zandstra et al. described an integrated 
computational and experimental approach to explore the impact of niche-inspired autocrine and 
paracrine signals on HSC fate [213, 215, 220]. They successfully modeled signal-response 
relationships for mixed HSC-niche cell cultures in liquid media. Notably, they demonstrated that 
selective inhibition of signal transduction pathways in HSCs was able to abrogate the effect of 
paracrine signals and autocrine feedback loops. While these studies highlight the importance of 
autocrine and paracrine signaling mechanisms, they relied on in vivo studies or two-dimensional 
culture platforms. Despite their importance, there lacks a framework for examining the balance 
of these signals within a fully-3D biomaterial platform. In this study, we explore the possibility 
of balancing diffusion-mediated autocrine and paracrine effects of niche cells in 3D collagen 
hydrogels.  
We hypothesize that the mode of cell communication in a diffusion-restricted environment is a 
function of both niche cell density, responsible for establishing the concentration of paracrine 
signals, and gel diffusivity, which impacts the delivery of paracrine signals as well as the 
diffusive loss vs. retention of HSC-generated autocrine signals (Figure 4.1). We hypothesized 
that HSC fate can therefore be guided, or eventually dynamically controlled, by providing 
specific combinations of cell density and gel diffusivity. For this purpose, HSCs were seeded 
with varying densities (1:0, 1:10, 1:100, 1:500) of Lin+ bone marrow cells to provide a broad 
range of paracrine signal concentrations. The Lin+ cells in question are a differentiated progeny 
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of the HSCs and are known to secrete a range of paracrine factors that stimulate as well as inhibit 
HSC proliferation [215]. HSC-niche cell co-cultures were cultured in collagen gels of two 
different densities (1 mg/mL, 3 mg/mL) with a 2D liquid culture as control. We show a more 
diffusion-restricted environment characterized by low niche cell densities and high gel density 
favors more primitive HSC progenitor populations, suggesting a greater influence of autocrine 
signaling mechanisms. However at higher niche cell densities and low gel density 
(corresponding to higher diffusion), more mature HSC progenitors are favored, hinting at more 
influential paracrine signaling mechanisms for these processes. To validate the observed effects, 
we added selective inhibitors of canonical paracrine and autocrine signaling pathways and 
evaluated their impact on the HSC progenitors. Inhibition of paracrine signals at low gel density 
led to an increase in the early progenitor populations whereas inhibition of the autocrine signals 
in the higher gel density condition decreased those fractions, validating our conclusions.  
These results serve as a first step towards identifying a biomaterial approach to regulate the 
balance of autocrine vs. paracrine signals within in vitro platform in order to guide stem cell fate 
decisions. Importantly, these observations suggest a path, through a greater degree of control 
over local diffusive properties of the biomaterial environment via gradient approaches previously 
described in this thesis, to more tightly regulate HSC fate decisions. 
4.3 Materials and Methods  
4.3.1 HSPC and Lin+ cell isolation 
Primary HSPCs were isolated from the bone marrow of the femur and tibia of female C57BL/6 
mice (Jackson Labs; Ages 1 – 3 months) as described previously [180]. Briefly, the bones were 
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gently crushed with a mortar and pestle, washed with a solution of PBS + 5% FBS (PBS/FBS), 
and filtered with a 40 µm sterile filter. All subsequent steps were performed in a PBS/FBS 
solution on ice. Red blood cells were lysed with ACK lysis buffer (Invitrogen, Carlsbad, CA). 
Cells were re-suspended in PBS with Fc receptor-blocking antibody to reduce non-specific 
antibody binding. HSPCs were identified as the Lin
-
Sca-1
+
c-kit
+
 (LSK) fraction by incubating 
the remaining bone marrow cells with a cocktail of antibodies (eBioscience San Diego, CA): PE-
conjugated Sca-1 (1:100 dilution), APC-Cy7 conjugated c-kit (1:100 dilution), and a 1:100 
dilution of a FITC-conjugated Lineage (Lin) cocktail (CD5, B220, Mac-1, CD8a, Gr-1, Ter-119). 
The LSK fraction was then sorted using a BD FACS Aria II flow cytometer (BD FACS Diva 
software) and collected in PBS/FBS on ice for immediate use. An average of 0.2% of total bone 
marrow cells sorted was identified as LSK, consistent with previously reported results. The Lin
+
 
cell population was simultaneously sorted, giving an average of 12% of total bone marrow cells.  
4.3.2 3D Collagen gel preparation  
Rat tail type I collagen (BD Biosciences, Bedford MA) was used to make the cell-laden collagen 
hydrogels. Collagen solutions of defined densities (1, 3 mg/mL) were prepared from the stock 
collagen solution of approximately 9 mg/mL (lot specific). The final concentrations were as 
follows: 1x M199 buffer (supplemented with 0.75% NaHCO2 and 0.01 M HEPES) in a ratio of 
1:4 with collagen stock; 1mM Dithiothreitol (DTT, Sigma); 5mM CaCl2; 0.1mM Glyoxal; 0.4M 
NaOH added to adjust pH between 7.3–7.4 [221]. Final gel volume was achieved by adding the 
desired cell-media suspension to create a 60µL solution. This was then poured into a 96 well 
plate to create 3D collagen gels. Gelation was achieved within 1 hr of placing the gels in a 
humidified incubator at 37 °C and 5% CO2.  
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4.3.3 Experimental culture conditions 
LSKs were seeded in monoculture and co-culture with Lin
+
 bone marrow cells in 2D or 3D 
culture environments under the following conditions: LSK:Lin
+
 cells at 1:0, 1:10, 1:100, 1:500 in 
2D (liquid), 1 mg/mL, 3 mg/mL collagen gels (Figure 4.2). 5000 LSK cells were used for each 
condition and cultured for 2 days prior to analysis. The cells were cultured in StemSpan SFEM 
media (Stemcell Technologies Inc., Vancouver, Canada) supplemented with 100 ng/mL Stem 
cell factor (SCF) (PeproTech, Rocky Hill, NJ).  
4.3.4 Surface antigen expression analysis to determine cell phenotype. 
The phenotype of LSK cells in mono- or co-cultures was determined via surface antigen 
expression using flow cytometry (FACS) on a BD LSRFortessa flow cytometer (BD 
Bioscience). Prior to analysis, the collagen gels were digested using a 50 U/mL solution of type 
IV collagenase (Worthington Biochemical) for roughly 30 mins in the incubator. The cells were 
then washed, filtered and resuspended in 100µL PBS with 5% FBS (PBS/FBS) and 0.1% sodium 
azide. The cell suspension was then stained with a cocktail of the following antibodies (all 
antibodies were from eBioscience unless otherwise specified): APC anti-CD34 (1:20 dilution, 60 
mins), AmCyan anti-IL7Rα (1:20, 60 mins BD Bioscience), APC-Cy7 anti-c-kit (1:100, 30 
mins), PE anti-Sca-1 (1:100, 30 mins), PE-Cy7 anti-CD16/32 (1:100, 30 mins), PE-Cy5 anti-
Flk2 (1:20, 30 mins), FITC-anti lineage cocktail (CD5, B220, Mac-1, CD8a, Gr-1, Ter-119, 
1:100, 30 mins). The surface antigen-based identification of the cells for all the progenitor sub-
fractions is given in Table 4.1.   
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4.3.5 Cell division tracking  
The cell division history of the LSK cells in different culture conditions was tracked by labeling 
them with carboxyfluorescein diacetate N-succinimidyl ester (CFSE, Invitrogen) or via 
CellTrace Violet (Invitrogen). For CFSE, the LSKs were labeled directly after isolation as per 
manufacturer instructions. Briefly, cells were washed and resuspended in PBS. CFSE was added 
in a final dye concentration of 2 µM for 10 mins at 37 °C. Cells were quenched with cold 
PBS/FBS, incubated on ice for 5 mins followed by a wash with PBS. Cell division was tracked 
after 2 days of culture using a BD LSRFortessa flow cytometer (BD Bioscience) and analyzed 
via FCS Express 4.0 software [200]. For CellTrace Violet tracking dye a protocol similar to 
CFSE as followed with the following changes: final dye concentration of 1µM with incubation 
time of 20 mins.  The CellTrace Violet dye was used in conjunction with surface antigen 
expression profiles to identify the proliferative state and phenotype of LSK progenitors seeded 
into the biomaterial constructs. Progenitor sub-fractions were then calculated as a fraction of 
initially seeded LSK cells.  
4.3.6 Apoptosis assay 
Cells undergoing apoptosis were detected via staining with APC-labeled Annexin V as per 
manufacturer protocols [200]. Briefly, cells were washed and resuspended in 100 µL of 1X 
Binding Buffer with 1% FBS and 5 µL of the dye (give concentration). The cells were stored in 
the dark at room temperature for 30 mins and analyzed within 1 hr. As a positive control, cells 
were treated with 1 µM of Staurosporine. To further distinguish between live and dead cells, co-
staining with propidium iodide (PI) was performed. A high percentage of cells that stained 
positive for Annexin V also stained positive for PI. Due to spectral interference of PI with the 
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surface antigen dyes PE-Cy7 and Cy5, only the Annexin V dye was added to distinguish between 
live and apoptotic cells. All cell samples were analyzed on a BD LSRFortessa flow cytometer 
(BD Bioscience) and using the FCS Express 4.0 software.  
4.3.7 Colony-forming unit (CF) assay 
Colony forming potential was assessed via Methocult GF M3434 methylcellulose-based medium 
(StemCell Technologies, Vancouver, Canada). For this purpose, cells were isolated from 
collagen hydrogels after culture via collagen digestion mentioned above, filtered, and then 
resuspended in StemSpan SFEM media. Aliquots were made at one-third and one-fifth of the 
total sample volume, brought to a volume of 0.1 mL and mixed with the Methocult media for a 
total volume of 1.1 mL per sample. The samples were plated on a gridded 35 mm culture dishes 
(StemCell Technologies) and incubated for 12 days. Following incubation, the GEMM, GM, G, 
M, Mk, and E colonies were counted using an inverted microscope [164]. The results are 
reported as the number of colonies counted per 100 of the original LSK cells seeded for each 
condition.  
4.3.8 Inhibitor molecules 
Small molecule inhibitors for paracrine signaling were added to the 1 mg/mL collagen condition 
while inhibitors for autocrine signaling were added to the 3 mg/mL collagen condition. Small 
molecule inhibitors and their doses are listed in Table 4.2.  
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4.3.9 Hydrogel mechanical characterization 
Bulk rheology experiments are performed using a torque-controlled rotational rheometer 
(Discovery Series Hybrid Rheometer (DHR), model HR-3, TA Instruments). A cone and plate 
geometry is used with a 40 mm cone diameter and a o1  cone angle and the temperature at the 
bottom (flat) plate is regulated by a Peltier system. The temperature at the bottom plate is 
maintained at o37 C  and fresh collagen solution (stored at o4 C ) is carefully loaded onto it. A 
solvent trap is used to encapsulate the sample in its solvent environment and prevent evaporation 
during experiments. 
Hydrogel diffusivity was measured via fluorescence recovery after photobleaching (FRAP) 
experiments using FITC-conjugated Dextran (40 kDa and 2000 kDa, Sigma Aldrich). Collagen 
solutions (1 and 3 mg/mL) were prepared as described above and incubated for 1 hr. The gels 
were incubated with FITC-conjugated Dextran solution overnight. Prior to analysis, the gels 
were gently washed with PBS. FRAP measurements were performed using the Zeiss 710 
Multiphoton confocal microscope as mentioned before [155]. Briefly, a 80 µm diameter spot was 
bleached (Laser intensity: 0.05 mW) at the center of the gel. The sample was bleached for 5 
seconds and recovery due to diffusive transport of fluorescent molceules form the surrounding 
hydrogel was tracked for up to 15 minutes via fluorescent imaging. The half time (t1/2) of the 
recovery was calculated using the FRAP function available in the Zeiss software. The hydrogel 
diffusion coefficient (D) was subsequently calculated as: 
   
  
    ⁄
                           (1) 
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where D is the diffusion coefficient, w the photobleaching beam radius, and t1/2 the recovery half 
time [152, 156]. A maximum of 3 spots were bleached per sample, spaced as far away from each 
other as possible to minimize after-effects of photobleaching on every subsequent measurement.  
The storage and loss modulus of the collagen gels was measured via a rheometer. 
4.3.10 Statistical analysis 
Statistical analysis was performed via one-way analysis of variance (ANOVA) tests after which 
a Tukey-HSD post-hoc test was used. Independent factors included niche cell density and 
hydrogel density. Analysis of LSK cell bioactivity (viability, proliferation index, surface antigen 
expression, CFU assay) used n = 5 constructs per group. Significance was set at p < 0.05. Error 
bars are reported as standard error of the mean unless otherwise noted. 
 
4.4 Results  
4.4.1 Niche cell density regulates HSC progenitor fractions in 2D cultures  
2D liquid culture was used as a control condition for all experiments examining HSC-niche cell 
interactions (diffusion-free environment). The total number of LSK cells as well as cell viability 
was determined for all niche cell densities (Figure 4.3). For both cell number and viability, the 
1:500 condition had a negative impact on the co-culture (reduced cell metabolic health). 
Therefore the 1:500 condition was dropped from future functional analyses.  
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FACS analysis of the cultures indicates dependence of the progenitor fractions on niche cell 
density. The early progenitors (LT-HSC, ST-HSC and MPP) saw an increasing fraction with 
niche cell density (Figure 4.4B, C, D) with a significant (p < 0.05) impact for the 1:100 
condition. In the case of the late progenitors (CMP, MEP, GMP), the results varied based on the 
progenitor type, with only the MEPs displaying a rise in fraction with increasing niche cell 
density (Figure 4.4 F, G, H). CFU assays were performed in order to corroborate the FACS 
results (Figure 4.5). The GEMM colonies are representative of the most primitive progenitor 
fractions followed by the GM colonies while the G, M, Mk and E colonies are the most mature 
colonies in the assay. With the exception of GEMM and Mk colonies, we see an increase in the 
number of colonies with increasing niche cell density. However, the increase is significant (p < 
0.01) only for the M colonies. Overall, we observe that niche cell density impacted LSK 
proliferation as well as differentiation and the effect was more significant for the early progenitor 
fractions.  
4.4.2 Biophysical characterization of collagen gels  
The collagen solution is allowed to polymerize for 3600 seconds under sinusoidal shear strain 
excitations at a frequency of 3 rad/s and amplitude of 1%. Subsequently, an oscillation frequency 
sweep is performed at a strain amplitude of 1%, predetermined to correspond to the linear 
viscoelastic regime from a constant frequency oscillation strain sweep. The results of the 
frequency sweep are shown in Figure 4.6A. In the limits of small frequencies, the in-phase 
elastic modulus  G   approaches an equilibrium plateau modulus 0G  corresponding to an 
evolved state of the collagen network at o37 C . This modulus is identified to be 5.5 Pa for the 
1mg/ml sample and 56 Pa for the 3 mg/ml. It is worth noting that measurements at frequencies 
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beyond 10 rad/s are affected by instrument inertia and carry no significance. The small frequency 
response in Figure 4.6A is validated using a constant stress creep test performed at 0.03 Pa, 
chosen suitably from the linear regime of a constant frequency oscillation stress sweep. A steady 
state response was attained after 3600 seconds, and the steady state compliance 
  01/J t J G    was consistent with the equilibrium moduli 0G  obtained from oscillation 
frequency sweeps for both collagen concentrations.  
Gel diffusivity measurements indicate a size dependence of diffusion through the collagen gel. 
The diffusivity for 40 kDa Dextran was roughly twice in 1 mg/mL (189 ± 40 µm
2
/sec) than in 
the 3 mg/mL (102 ± 13 µm
2
/sec) collagen (Figure 6B). However, the diffusivity for 2000 kDa 
Dextran was similar for both the gels indicating that the larger molecule is trapped within the 
collagen fibers to the same extent regardless of gel density. Most of the cell signaling molecules 
and growth factors relevant to this co-culture system fall roughly in the size range of 20 – 60 
kDa. Therefore differences in small-molecule diffusion between the two collagen gels are 
considerably relevant in the light of limiting the paracrine or autocrine-mediated signaling 
mechanisms.  
4.4.3 Early vs. Late HSC progenitor specification is dictated by collagen gel density 
Similar to the 2D liquid cultures, the collagen gel cultures were analyzed after 2 days via FACS 
analysis and the CFU assay. As with the 2D condition, niche cell density impacted all the 
progenitor fractions for both 1 and 3 mg/mL collagen (Figure 4.7, 8, 9). For the early progenitor 
fractions (LT-HSC, ST-HSC, MPP), differences in cell fractions between all niche cell densities 
are statistically significant (p < 0.05) for both 2D and 1 mg/mL conditions (Figure 4.7A). 
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However, for the 3 mg/mL condition, although the general trend exists the differences are no 
longer significant (Figure 4.7A, Figure 4.8). Conversely, the late progenitor fractions MEP and 
GMP were significantly different across all niche cell densities for the 1 mg/mL (p < 0.01) and 3 
mg/mL collagen (p < 0.05). Similar to FACS analysis, the number of CFU colonies increase with 
increasing niche cell density for both the collagen gels (Figure 4.10, 4.11). Unlike the 2D 
condition, the GEMM and Mk colonies increase with niche cell density with the change being 
more significant (p < 0.01) for the Mk colonies in the 3 mg/mL collagen.  
In order to compare differences in the progenitor fractions between the 1 and 3 mg/mL collagen 
gels, a heat map with the collagen gel values normalized to the 2D condition was created. This 
permitted us to directly compare the impact of matrix density and niche cell density (Figure 
4.7B). Interestingly, early progenitor fractions were higher for the 3 mg/ml condition at low 
niche cell densities (1:0). However with increasing progenitor maturity (CMP and GMP), the 
greatest increase shifts to the 1 mg/mL condition at high niche cell density (1:100). A similar 
heat map analysis conducted for the CFU colonies (Figure 4.12) indicate that except for the 
GEMM colonies (Figure 4.12B), the 3 mg/mL collagen condition has lower colony numbers 
than those in the 1 mg/mL condition. The higher number of mature colonies for 1 mg/mL 
collagen is consistent with higher progenitor fractions observed via FACS analysis. Together, 
these results suggest that conditions of low niche cell density and reduced gel diffusivity (1:0, 3 
mg/mL) lead to a greater increase in early progenitor fractions whereas those of high niche cell 
density and increased gel diffusivity (1:100, 1 mg/mL) lead to a greater increase in late 
progenitor fractions.  
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Based on these findings, we hypothesized that autocrine signaling mechanisms may have a 
greater impact in the diffusion-limited 3 mg/mL collagen, giving rise to a higher fraction of early 
progenitors whereas paracrine signaling with the mature Lin+ cells is more dominant for the 1 
mg/mL collagen and at higher niche cell densities. In order to test this hypothesis, we inhibited 
multiple paracrine signaling pathways in the 1 mg/mL condition in order to curb the increase in 
late progenitor populations and/or increase the early progenitor fractions (Figure 4.13A). 
Similarly, we inhibited multiple autocrine signaling pathways in the 3 mg/mL condition in order 
to increase the numbers of late progenitor fractions and/or decrease the early progenitor fractions 
(Figure 4.17A).  
4.4.4 Inhibition of paracrine signaling factors increases early progenitor fractions  
Paracrine signaling was blocked for the TGF-β, MIP-1α and TNFα factors, which are known to 
negatively impact HSC progenitor populations [215]. While the cell fraction dependence on 
niche cell density was qualitatively similar to that observed in case of the 1 mg/mL condition 
(Figure 4.14), the early progenitor fractions (LT-HSC, ST-HSC) however are no longer 
significantly different (Figure 4.11B, C). The CFU colonies exhibit a similar trend of increasing 
numbers; however the significant differences observed in case of the 1 mg/mL condition were 
also lost (Figure 4.15). A heat map analysis of the 1 mg/mL collagen gel vs. the paracrine 
inhibited condition (Figure 4.13B) indicates that the biggest change versus uninhibited cultures 
was seen for the LT-HSC and ST-HSC fractions at low niche cell densities. Compared to the 
uninhibited condition, the CMP fractions increased whereas the more mature GMP fractions 
decreased as per our hypothesis. A similar comparison of the CFU data (Figure 4.16) indicates 
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that only the most primitive GEMM colonies exhibited a rise in number whereas all the other 
mature colonies decreased after paracrine inhibition. 
4.4.5 Inhibition of autocrine signaling factors affects early but not late progenitors  
Autocrine signaling was blocked for the VEGF, PDGF and FGF receptors in the 3 mg/mL 
condition. These growth factors are known to induce HSC proliferation and expansion, therefore 
their inhibition is expected to reduce the early progenitor fractions, especially at low niche cell 
densities while promoting the late progenitors via increased paracrine signaling (Figure 4.17A). 
FACS analysis of all the populations indicates increasing progenitor fractions with niche cell 
density, similar to what is seen for the 3 mg/mL condition (Figure 4.18). However, unlike in the 
3 mg/mL condition where the early fractions bear no significant differences across all niche cell 
densities, the populations for the autocrine inhibited conditions increase significantly, especially 
between 1:0 and 1:100 (p < 0.005) for all progenitor types. The CFU results showed a similar 
trend of increasing numbers; however the significant differences observed in case of the 3 
mg/mL condition without autocrine blocking were lost (Figure 4.19). A heat map-based 
comparison between the autocrine inhibited progenitor fractions with the uninhibited 3 mg/mL 
condition indicates a reduction in all early progenitor fractions (LT-HSC, ST-HSC, MPP) for the 
autocrine inhibited condition, especially at low niche cell densities (Figure 4.17B). However, a 
corresponding increase in the late progenitor fractions (CMP, MEP or GMP) is not seen. A 
similar comparison of the CFU colonies indicates little to no changes in the mature colony types 
with only a slight increase in GEMM colonies for the higher niche cell densities (Figure 4.20).   
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4.5 Discussion  
Signaling molecules play a central role in regulating stem cell fate in the in vivo HSC niche. 
Several growth factors, cytokines, biomolecules and their pathways have been extensively 
explored and their mechanisms have been established via either paracrine or autocrine pathways 
or a combination of both. However these interactions have not been translated to 3D in vitro 
HSC systems.  
One of the main challenges on this front is the interdependence of stiffness and diffusivity. 
Matrix stiffness is a function of the crosslinking density, which also controls small molecule 
diffusion through its fiber network with higher stiffness corresponding to lower diffusion [194]. 
While it is not possible to completely decouple the effects of stiffness and diffusion, proper 
selection of the range of these physical properties can help mitigate their effects. For the matrix 
stiffness range explored for the 1 and 3 mg/mL collagen gels, no significant variation in HSC 
response has been reported in literature. Choi et. al. have demonstrated the dependence of HSC 
fate on substrate elasticity as it is varied roughly between 1kPa to 196 kPa. For much softer 
substrates (<100 Pa), no significant dependence of matrix elasticity is seen [61]. Additionally, as 
shown by Discher et. al., CD34+ HSCs exhibited different morphologies when cultured on 
substrates with a 100x difference in stiffness (0.3 kPa vs 34 kPa) [178]. The collagen gel 
stiffness explored here fall well below these ranges (5.5 and 56 Pa). These results therefore 
suggest the results observed here arose due to differences in small molecule diffusion rather than 
the mechanical environment.  
For the 2D diffusion-free cultures explored here, we observe an impact of increasing niche cell 
numbers on various progenitors, ranging from the most primitive LT-HSCs to the more 
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differentiated GMPs and MEPs. For the short time periods investigated here (2 days), the trend 
of increasing fractions is consistent with previous research [215]. For the 1:0 condition, due to 
the absence of any niche cells we see a significantly smaller fraction of all early progenitors as 
they are involved in further differentiation and proliferation. For the late progenitors, we see little 
to no differences in fractions as a function of niche cell density (Figure 4.4F, G, and H). A 
plausible explanation for this is these effects between niche cell densities are limited in the 
diffusion-free 2D culture environment. This is supported by their fractions in the collagen gels 
(Figure 4.7G, H and Figure 4.8G, H) with diffusion-limited signaling, where we see significant 
(p values ranging from < 0.005 to < 0.05) increase in fractions for the late GMPs and MEPs as a 
function of niche cell density. Interestingly, fractions of early progenitors (LT-HSC, ST-HSC, 
and MPP) increase significantly with increasing niche cell densities for the 2D (Figure 4.4B, C, 
D) and 1 mg/mL collagen (Figure 4.8B, C, D) but lose the significance for the 3 mg/mL 
condition (Figure 4.9B, C, D) even though the trend is maintained. This finding implies that the 
influence of increasing niche cell density (and its associated paracrine signaling) is mitigated by 
the more diffusion-limited 3 mg/mL gel environment. Direct comparisons of the progenitor sub-
fractions in the two collagen gels (Figure 4.7B) also indicate higher fraction of early progenitors 
(LT-HSC, ST-HSC, MPP) for the 3 mg/mL collagen whereas the 1 mg/mL exhibits higher late 
progenitor fractions (CMP, GMP), especially in co-culture with Lin
+
 niche cells. Owing to the 
fact that the co-culture cells in question are Lin
+
 cells known to inhibit early progenitor 
expansion of HSCs, these observations lead to the formation of our hypothesis that the inhibitory 
paracrine signaling effects are more dominant for highly diffusive conditions whereas the 
autocrine signaling effects largely dictate progenitor expansion for low diffusivity and low niche 
cell density conditions.  
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We tested this hypothesis by inhibiting specific paracrine and autocrine signaling molecules with 
known effects on the HSCs. TGFβ, MIP-1α and TNFα are known inhibitors of HSC proliferation 
acting via paracrine-mediated mechanisms  [215]. Therefore inhibiting these pathways would be 
expected to negatively impact the numbers of late hematopoietic progenitors and/or increase the 
number of early progenitor fractions. The increase in the LT-HSC and ST-HSC fractions for the 
paracrine inhibited cultures (Figure 4.13B) is consistent with this hypothesis. The biggest impact 
of inhibition was seen for the niche cell free (1:0) condition while inhibition does not 
significantly impact early progenitor cell populations in the presence of niche cells. A possible 
explanation for this could be that the concentration of the inhibitors chosen is not enough to 
inhibit paracrine signals at the range of selected niche cell densities. However examining mature 
progenitors, a decrease in the GMP and increase in the CMP fractions occur at the 1:100 
condition in the presence of paracrine blocking cocktail. This finding is supported by the CFU 
assay, where the biggest impact for paracrine inhibition is seen for the 1:100 condition in the 
most mature (GM, G, M, Mk, E) colonies (Figure 4.16C, D, E, F, G). The more primitive 
GEMM colonies consistently increase across all niche cell densities with the 1:100 having the 
highest number, consistent with the hypothesis (Figure 4.13B). 
For the autocrine inhibition, receptors for the growth factors VEGF, PDGF and FGF were 
inhibited in the 3 mg/mL collagen gel. Although the early progenitor fractions decrease after the 
inhibitions compared to the 3 mg/mL condition, the late progenitor fractions were not affected 
(Figure 4.17B), a result that was also seen for the mature CFU colonies (Figure 4.20). The 
behavior of the GEMM colonies proves to be an exception, with slightly increased colony 
numbers for the 1:10 and 1:100 densities. While this appears to be inconsistent with the 
hypothesis for reduced primitive fractions in autocrine inhibited conditions, we must note that 
104 
 
the GEMM colonies seem to mirror the trends of CMP fractions more than other early 
progenitors (Figure 4.13B and Figure 4.16B). Considering this, higher GEMM colony numbers 
seem to suggest an increase in the mature progenitors in the autocrine inhibited cultures, which 
follows the result expected of the hypothesis. The extent of the inhibitory effects is likely also a 
function of the concentration of the inhibitors used. Therefore it is entirely conceivable that 
higher concentrations would lead to a greater impact on the cell cultures, something to be 
pursued in future experiments building from this work. However, the trends and effects seen here 
are sufficient to indicate that disruption in the autocrine signaling mechanisms affect the early 
progenitor populations.  
In using a cocktail of multiple factors for autocrine or paracrine inhibition, while we observed 
significant effects across the range of niche cell and hydrogel densities tested, the specificity of 
each signaling pathway cannot be resolved. For example, use of paracrine inhibition cocktail 
induced opposite behaviors in GMP versus CMP fractions; though both are mature progenitors 
and show a response to inhibition of paracrine signals, it is impossible at present to identify 
whether it was inhibition of a single pathway versus the coordinated inhibition of multiple 
pathways that led to this change in phenotype. Future studies targeted at specific molecules with 
known effects on progenitor populations would provide better resolution of the signaling 
dynamics associated with paracrine vs. autocrine signals shaping HSC fate. Finally, in terms of 
statistical significance, variations in niche cell density had a greater effect on progenitor sub-
fractions than changes in collagen density (1 mg/mL vs. 3 mg/mL). This suggests the possibility 
that larger differences in gel diffusivities than considered here may be required to compete with 
higher magnitudes of niche cell signals. Ongoing efforts are using the methacrylated gelatin 
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platform described in Chapter 3 as the basis to create a hydrogel construct with tighter control of 
matrix mechanics yet having a wider range of gel diffusivities.  
4.6 Conclusions 
The dynamic and complex interaction of HSCs with niche cells within the bone marrow involves 
a host of biomolecules involved in autocrine, paracrine and juxtracrine-contact associated 
signaling. Here we introduce a relatively simple approach via co-varying hydrogel density and 
the density of niche cells in co-culture with HSCs. We show that niche cell density has a greater 
impact in hydrogels with increased small molecule diffusivities while paracrine signaling is not 
hindered. Comparatively, autocrine signaling was most important for hydrogels with limited 
diffusivity and without niche cell co-culture, and whose effects could be reduced by selective 
inhibition of autocrine signaling molecules. Together, these results suggest the exciting 
possibility that future biomaterial platforms may be able to exploit the balance of paracrine 
versus autocrine signals in order to gain improved control of HSC fate during in vitro culture. 
Although the system used here is relatively simple with very low matrix elasticity, the principle 
is expected to extend to other hydrogels as well. Its significance can be seen in more advanced 
biomaterials with, for e.g. immobilized biomolecules that alter the signaling pattern in the gels, 
or in the presence of gradients in niche cells or matrix diffusivity, all of which are explored in 
earlier chapters of this thesis.  
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4.7. Tables 
 
Cell type Abbreviation Progenitor 
Type 
Surface antigens References 
Lineage
-
 c-kit
+
 Sca-
1
+
 
LSK 
 
LSK  
Long-term HSC LT-HSC 
Early 
Progenitors 
LSKCD34
lo
Flk2
lo/-
 [12, 17, 46] 
Short-term HSC ST-HSC LSKCD34
hi
Flk2
lo/-
 [12, 17, 87] 
Multipotent 
Progenitor 
MPP LSKCD34
hi
Flk2
hi
 [17] 
Common Myeloid 
Progenitor 
CMP 
Late 
Progenitors 
Lin
–
c-kit
+
Sca-1
–
CD34
+
CD16/32
–IL7rα– 
[12, 222] 
Megakaryocyte-
Erythroid Progenitor  
MEP Lin
–
c-kit
+
Sca-1
–
CD34
–
CD16/32
–IL7rα– 
[12, 222] 
Granulocyte-
Macrophage 
Progenitor 
GMP Lin
–
c-kit
+
Sca-1
–
CD34
+
CD16/32
+IL7rα– 
[12, 222] 
Table 4.1. Surface antigen identification for progenitor sub-fractions 
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Gel Target factor Inhibitor Supplier References 
1 mg/mL TGF SB431542, (1 
µM) 
EMD Millipore, Darmstadt, 
Germany 
[223, 224] 
TNF- TNF- inhibitor, 
(2 µM) 
EMD Millipore, Darmstadt, 
Germany 
[74, 225] 
MIP-1 Maraviroc, (7.2 
nM) 
Selleckchem, Houston, TX [213] 
3 mg/mL PDGFR, 
VEGF, FGFR 
SU 6668, (1 µM) Tocris, Minneapolis, MN [226] 
Table 4.2. Type and concentrations of autocrine and paracrine signaling inhibitors 
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4.8 Figures 
 
 
 
 
 
 
 
 
  
Figure 4.1. Schematic describing the paracrine-mediated HSC-niche cell interaction 
which is a function of cell density and matrix diffusion. Similarly, the autocrine 
mechanisms of the HSCs are a function of matrix diffusion and together determine 
stem cell fate 
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Figure 4.2. Setup for the co-culture experiments. Primary murine HSCs were 
isolated as LSK cells from the bone marrow along with the more mature Lin+ 
populations and cultured in either or 2D (liquid) or 3D (1 mg/mL and 3 mg/mL 
Collagen) conditions at different cell densities  
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Figure 4.3. 2D cell culture viability (A) Total number of LSK cells in 2D culture (B) 
Viability of the LSK progenitors. Both indicate a drop in cell number and viability 
for the 1:500 condition 
*** p < 1E-4 
 
(A) (B) 
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Figure 4.4. HSC progenitor analysis for 2D liquid conditions. (A) The HSC 
differentiation pathway indicating the various progenitor types B – H) Fractions of 
the progenitors in culture 
*   p < 0.05 
** p < 0.01 
*** p < 0.005 
NS = No significance  
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Figure 4.5. CFU Colonies for 2D liquid conditions. (A) The HSC differentiation 
pathway indicating the position of the various colony types (B – G) Number of 
colonies per 1000 cells seeded 
*   p < 0.05 
** p < 0.01 
*** p < 0.005 
NS = No significance  
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Figure 4.6. (A) Collagen rheology measurements indicating bulk modules of 1 
mg/mL and 3 mg/mL collagen to be 5.5 Pa and 56 Pa respectively. (B) Diffusion of 
Dextran through the two collagen gels indicating significant differences for the 
smaller molecular weight (40 kDa) dextran. 
 
*** p < 0.005 
(A) (B) 
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Figure 4.7. Heat Map based analysis of 1 and 3 mg/mL collagen for progenitor fractions. 
(A) Individual fractions of the early progenitors for all conditions (B) Heat map of the 
relative fractions for all progenitors  
 
* denotes significant difference w.r.t. 2D culture 
# denotes significant difference w.r.t. 1 mg/mL culture 
 
(A) 
(B) 
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Figure 4.8. HSC progenitor analysis for 1 mg/mL Collagen. (A) The HSC differentiation 
pathway indicating the various progenitor types (B – H) Fractions of the progenitors in 
culture 
*   p < 0.05 
** p < 0.01 
*** p < 0.005 
NS = No significance  
 
116 
 
 
 
 
 
 
Figure 4.9. HSC progenitor analysis for 3 mg/mL Collagen. (A) The HSC differentiation 
pathway indicating the various progenitor types (B – H) Fractions of the progenitors in 
culture 
*   p < 0.05 
** p < 0.01 
*** p < 0.005 
NS = No significance  
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Figure 4.10. CFU Colonies for 1 mg/mL collagen. (A) The HSC differentiation 
pathway indicating the position of the various colony types (B – G) Number of 
colonies per 1000 cells seeded 
*   p < 0.05 
** p < 0.01 
*** p < 0.005 
NS = No significance  
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Figure 4.11. CFU Colonies for 3 mg/mL collagen. (A) The HSC differentiation 
pathway indicating the position of the various colony types (B – G) Number of 
colonies per 1000 cells seeded 
*   p < 0.05 
** p < 0.01 
*** p < 0.005 
NS = No significance  
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0.20 0.40 0.60 0.80 1.0 1.2 1.4 1.6 1.8 2.0
MPPST-HSCLT-HSC
GMPMEPCMP
Figure 4.12. A heat map of the CFU assay results with the colonies for 1 and 3 
mg/mL collagen normalized to the 2D condition. (A) The HSC differentiation 
pathway indicating the position of the various colony types (B – G) Comparisons for 
the various colony types 
* denotes significant difference w.r.t. 2D culture 
# denotes significant difference w.r.t. 1 mg/mL culture 
*   p < 0.05 
** p < 0.01 
*** p < 0.005 
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Uninhibited Paracrine Inhibition 
Figure 4.13. (A) Schematic of the effects of uninhibited and paracrine inhibited conditions on 
HSC differentiation (B) Heat map analysis comparing the 1 mg/mL collagen condition to the 
Paracrine inhibited 1 mg/mL collagen  
 
** p < 0.01 
*** p < 0.005 
 
(A) 
(B) 
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Figure 4.14. HSC progenitor analysis for paracrine-inhibited 1mgf/mL collagen. (A) The 
HSC differentiation pathway indicating the various progenitor types (B – H) Fractions of 
the progenitors in culture 
*   p < 0.05 
** p < 0.01 
*** p < 0.005 
NS = No significance  
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Figure 4.15. CFU Colonies for paracrine-inhibited 1 mg/mL collagen. (A) The HSC 
differentiation pathway indicating the position of the various colony types (B – G) 
Number of colonies per 1000 cells seeded 
NS = No significance  
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***
****
***
0.30 0.60 0.90 1.2 1.5 1.8 2.1 2.4 2.7 3.0
G
GEMM GM
M
Mk E
Paracrine - CFU comparison for Uninhibited/Inhibited conditions
Figure 4.16. A heat map of the CFU assay results with the colonies for 1 mg/mL 
collagen and its corresponding paracrine-inhibited condition, normalized to the 2D 
condition. (A) The HSC differentiation pathway indicating the position of the various 
colony types (B – G) Comparisons for the various colony types 
* denotes significant difference w.r.t. 2D culture 
*   p < 0.05 
** p < 0.01 
*** p < 0.005 
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#*
GMPMEPCMP
LSK
MPPST-HSC
0.20 0.40 0.60 0.80 1.0 1.2 1.4 1.6 1.8 2.0
UnInhibited heat map
LT-HSC
*
** #
Uninhibited Autocrine Inhibition 
Figure 4.17. (A) Schematic of the effects of uninhibited and autocrine inhibited conditions on 
HSC differentiation (B) Heat map analysis comparing the 3 mg/mL collagen condition to the 
Paracrine inhibited 3 mg/mL collagen  
 
(A) 
(B) 
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Figure 4.18. HSC progenitor analysis for autocrine-inhibited 3mgf/mL collagen. (A) The HSC 
differentiation pathway indicating the various progenitor types (B – H) Fractions of the 
progenitors in culture 
*   p < 0.05 
** p < 0.01 
*** p < 0.005 
NS = No significance  
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Figure 4.19. CFU Colonies for autocrine-inhibited 3 mg/mL collagen. (A) The HSC 
differentiation pathway indicating the position of the various colony types (B – G) Number of 
colonies per 1000 cells seeded 
NS = No significance  
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Figure 4.20. A heat map of the CFU assay results with the colonies for 3 mg/mL collagen 
and its corresponding autocrine-inhibited condition, normalized to the 2D condition. (A) The 
HSC differentiation pathway indicating the position of the various colony types (B – G) 
Comparisons for the various colony types 
* denotes significant difference w.r.t. 2D culture 
*   p < 0.05 
** p < 0.01 
*** p < 0.005 
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CHAPTER 5: CONCLUSIONS AND FUTURE WORK 
5.1 Conclusions 
At the beginning of this thesis, we discussed the need of a comprehensive biomaterial platform 
that facilitates engineering of HSC fate for a range of clinical and more basic science 
applications. The ideal platform should be able to integrate the several components of the HSC 
niche as well as provide flexibility to manipulate the resulting interactions that dictate stem cell 
behavior.  To this end, in Chapter 2 we discussed the development of a microfluidic-based 
device that generates gradients in concentrations of niche components in an external Teflon-
based mold. The gradient design helps simulate some of the spatial patterns of components found 
within the native niche, while also providing a controlled, systematic environment for HSC 
culture. The herringbone design within the microchannels enabled mixing of any heterogeneity 
while the solutions mixed via diffusion. Linear opposing gradients were generated using 
different densities of collagen as well as microbeads, HSCs and niche cells (osteoblasts) 
representing a wide range in particle sizes. Select regions of the hydrogel could also be isolated 
in order to perform further functional analysis of the cells in culture. Overall, this served as a 
first step towards a chip-based system that enables HSC-niche co-culture in a controlled 
environment.  
In Chapter 3, this idea was taken a step further for enhanced biomaterial functionality and on-
chip utility. We developed a GelMA based protein-functionalized biomaterial platform for long-
term HSC culture. GelMA can be photopolymerized with UV light in presence of a 
photoinitiator. The biocompatibility of GelMA is complimented by its chemistry which enables 
cross-linking with other functional groups. This enabled us to cross-link it with the protein SCF 
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that was functionalized with PEG (PEG-SCF). HSCs were shown to be maintained in monolithic 
gels at different concentrations of PEG-SCF for up to 7 days without the presence of soluble SCF 
in media. Although HSC proliferation was reduced for the PEG-SCF gels compared to the 
soluble SCF condition, they exhibited a higher fraction of the primitive progenitors. The 
microfluidic platform described in Chapter 2 was utilized to culture HSCs in gradients of PEG-
SCF within the GelMA matrix. Being able to control and maintain cytokine-mediated effects in a 
gradient platform expands the possibilities of using such a system for other target molecules for 
HSC culture.  
The notion of regulating niche signals in a 3D system was explored in Chapter 4 which involved 
the co-culture of HSCs with niche cells. At low matrix stiffness, HSC response is primarily a 
function of the diffusion-mediated paracrine and autocrine signaling that occurs between HSCs 
and Lin+ niche cells. We established that HSC bioactivity is a function of both niche cell density 
as well as matrix diffusivity and affects the fractions of early vs. late progenitor populations in 
culture. In a more diffusion-restricted environment, autocrine signaling dominated HSC 
response. At higher niche cell densities, regardless of gel diffusivity, paracrine signaling 
dominated HSC response. This was further tested by adding molecules that inhibited the 
paracrine effect at higher gel diffusivity and the autocrine effect at lower gel diffusivity. These 
results lead us to believe that signaling mechanisms in a 3D environment are a function of 
diffusion and overall signal concentration. This brings us back to the gradient platform that 
offers us the means to create a range of microenvironments on a single platform for a both active 
and passive way to manipulate HSC fate.  
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The work presented in this thesis serves as a step towards a comprehensive biomaterial strategy 
for regulating HSC fate in vitro. These developments can be applied towards clinical applications 
relevant to bone marrow transplants, directed cell differentiation and immune therapies while 
simultaneously providing new ways to better understand the niche interactions.  While only a 
select few aspects of the HSC-niche interactions have been explored here, there is vast potential 
to expand the cell, matrix and biomolecule component base to simulate some of the more 
complex behaviors and fate decisions induced by changes in the microenvironment. In the next 
section, we discuss some of the possibilities presented by this platform for enhanced HSC-niche 
interrogation.  
5.2 Future Work 
The development of a viable biomaterial platform for HSC culture opens up several possibilities 
for extended applications. Below we discuss ways in which this culture platform can be 
improved upon and applied to both extend our knowledge of HSC niche interactions as well as 
further our abilities to control stem cell fate in vitro.  
5.2.1 Improved microfluidic culture platform  
The microfluidic chip on which the HSCs are cultured is a crucial part of the biomaterial 
platform redesign strategy. Currently, the device consists of two inputs and can generate linear 
gradient gels roughly 60 µL in volume. The cells can be cultured long-term on this platform as 
well. However, there are opportunities to further improve the design for a broader spectrum of 
culture techniques and analyses; for example real-time imaging of cells in culture in a smaller 
volume can enable us to track key processes and interactions of the cells with their niche 
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environment via fluorescence. Given below are some examples of further improvements to the 
platform.  
1. Multiple (>2) inputs with linear and non-linear gradients: 
The current design limits us to linear gradients. However, there exist other environments (e.g. 
tumors) with non-linear gradient profiles. Simulating these conditions on the chip will add an 
extra dimension to the kinds of environment that can be recreated. Such an endeavor will likely 
require computational modeling of channel mixing to create the necessary designs as well as 
photolithography fabrication processes to realize them in practice. Similarly, the possibility of 
integrating the linear components with non-linear component profiles adds greater flexibility to 
the platform.  
2. Smaller culture volumes  
Given the extremely rare population of HSCs (<0.01%) in the bone marrow, it is important to use 
them conservatively for in vitro cultures, reducing the sorting time and decreasing the associated 
costs. Preliminary results not reported here suggest it is possible to create smaller culture 
volumes (up to 12 µL) by shrinking the well in which the gradient is created. Similarly, 
modifications in the microfluidic device design are needed in order to reduce the mixing volume 
as well. With the smaller culture volumes, it might not be possible to perform traditional HSC 
functional analyses such as FACS and CFU which require larger cell numbers. Therefore in-situ 
imaging or single cell analysis techniques will be required.  
3. Multi-layered and multi-directional cultures for migration and stem cell mobilization  
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The current setup allows for gradients in the orthogonal direction. In case of thicker gels, a 
gradient in both orthogonal as well as lateral direction provides more options for directing 
signaling cues for cell migration. Multi-layered cultures can also potentially serve as 3D versions 
of transwell migration assays where 2 different gradient gels are separated by a porous 
membrane that permits cell movement. Conditions in the two gels can be dynamically controlled 
to guide chemotaxis one way or another.  
5.2.2 Role of MSCs and CXCL12 in guiding HSC mobilization 
In Chapter 1, we discussed the significant effects of MSCs and the CXCL12 cytokine on stem 
cell mobilization and homing. The biomaterial platform provides us the ability to simulate some 
of the conditions involved in HSC mobilization in vivo by creating similar gradient profiles on 
the chip. The cytokine CXCL12 can be functionalized on the biomaterial backbone, much like 
with the SCF enabling the generation of concentration gradients of the CXCL12-funtionalized 
GelMA. The directional cues provided by such gradients have the potential to be used to guide 
and mobilize HSCs in vitro. This effect can be magnified or reduced by the introduction of 
MSCs or CAR cells with gradient profiles in the same or opposite directions. These experiments 
can provide further insights into the mechanisms that dictate stem cell mobilization and the 
individual vs. concerted impact of each component.  
5.2.3. Advanced functional analyses and repopulation assays 
Throughout this thesis, HSC analysis has been restricted to FACS and CFU assays. Although 
they provide a wealth of information regarding HSC biology, information about intracellular 
transcription factors or single cell fate decisions is lost. Gene expression analysis of key genetic 
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markers can further improve our understanding of the HSC biology within these constructs. The 
up- or down- regulation of genes could be linked with cell migration techniques discussed in the 
previous section to further illuminate the gene network signaling that regulates HSC fate. 
Similarly, for smaller (12 µL) platforms enhanced imaging techniques can also let us actively 
monitor cell fate in real-time via live cell imaging. This can be analyzed in combination with 
fluorescent markers that are triggered based on specific environmental cues controlled by the 
gradient platform. Our lab has begun work on other as-yet unconventional techniques such as 
TOF-SIMS [227] and Raman Spectroscopy [228] for single-cell analysis which could also be 
used to determine HSC functionality. Such techniques have an enormous potential to decode 
stem cell signaling mechanisms along with its associated intra-cellular regulatory networks. 
Finally, the repopulation assay is a prominent method used to test the ‘stemness’ of the HSCs. 
Techniques for the expansion of the HSC population on-chip can be rigorously tested using this 
assay to determine the repopulation potential of the cultured HSCs.  
5.2.4 Screening combinations of niche inspired cell/matrix/biomolecule signals 
One of the biggest advantages of this biomaterial platform developed here is its adaptability. 
This approach enables us to consider a large library of biomaterials (natural and synthetic) that 
can be used as potential platforms for HSC culture. Similarly the different kinds of niche cells 
and their relevant biomolecules can be studied in further detail. For example, the effect of a 
concentration gradient of vascular endothelial cells on HSCs in the presence or absence of a 
similar gradient of functionalized VEGF or CXCL12 can be explored. In Chapter 4, we 
discussed the paracrine/autocrine signaling mechanisms in a 3D system. One important 
limitation there was our inability to change the diffusivity without changing matrix elasticity. 
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Different biomaterial types, such as hyper-branched polyglycerols [229], may also allow us to 
further tailor hydrogel precursor suspension viscous properties as well as the balance of matrix 
mechanics and diffusivity. This will enable a much greater control over diffusion-limited 
signaling mechanisms for various niche cell types. Introducing the element of gradient profiles 
adds an extra layer of complexity within the system.  
5.3 Final thoughts 
Translation of research from bench top to a hospital bed is and will always remain a primary 
motivating factor for all tissue engineering related research. The work presented here attempts to 
improve upon the existing development within the HSC field. Understanding the interactions that 
regulate stem cell behavior in vivo is just as crucial as the ability to control its fate in vitro for 
clinical applications. As discussed in the earlier section, there is room for improvement and we 
will always witness the development of newer and better techniques in the domain of stem cell 
research. Therefore it is important to take these new developments in stride as we continue to 
strive for better biomaterials or methods for improving the clinical impact of research, knowing 
that the ultimate goal is to improve patient life.  
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APPENDIX A: CELL CULTURE PROTOCOLS 
A.1 Incubator disinfection protocol  
 
Supplies 
 Steris Staphene spray (Cat. No. 14-415-15, Fisher Scientific, Hanover Park, IL) 
 70% ethanol 
 
Procedure 
 
1. Shut off the CO2 tanks and turn off the incubator 
 
2. Prepare the sterile hood by covering the inside with bench-coat 
 
3. Cover the chemical fume hood with fresh bench-coat 
 
4. Disassemble all removable parts from the incubator chamber. Spray all pieces from the 
incubator inside the chemical fume hood with Staphene (Fisher Scientific). Spray the inside of 
the inside of the incubator with Staphene. Let stand for 15 minutes with the incubator door 
cracked open ~2 inches.  
 
5. Spray the inside of the incubator with 70% ethanol. Wipe off the excess Staphene with paper 
towels.  
 
6. Spray all internal pieces of the incubator in the chemical fume hood with 70% ethanol and 
wipe off the excess Staphene. Spray each part generously with ethanol again and place into the 
sterile hood to dry. Do not wipe anything down. Allow all parts to air dry for 15 – 30 minutes.  
 
7. Spray the inside of the incubator with 70% ethanol and allow all parts to dry for 15 – 30 
minutes; do not wipe anything down.  
 
8. Reassemble all internal pieces of the incubator, taking care to move each piece from the sterile 
hood to the incubator as quickly as possible.  
 
9. Spray the inside of incubator again with 70% ethanol. Shut the foot and allow all parts to dry; 
do not wipe anything down.  
 
10. Turn on the incubator power and open the valves on the CO2 tanks. Allow the incubator to 
ventilate with the CO2 on for 24 hours before using again.  
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A.2 Bone Marrow Harvest protocol without lineage negative enrichment  
 
Animals to sac: 
WT: Jax C57B6 mouse strain 
 
FACS Antibodies:  
Lineage cocktail [CD5 (Cat #11-0051), CD45R (B220) (Cat #11-0452), CD11b (Mac-1) (Cat 
#11-0112), Gr-1 (Ly-6G/C) (Cat #11-5931), Ter-119 (Cat #11-5921), CD8a ((Cat. #11-0081)] 
Sca-1 (Cat. #12-5981-83) 
c-Kit (Cat. #47-1172-82) 
Propidium Iodide (PI) (P3566, Life Technologies, Grand Island, NY)  
 
All antibodies from eBioscience unless otherwise specified) 
 
Supplies 
70% ethanol solution 
Surgical tools (autoclaved) – scissors, tweezers 
Mortar/Pestle 
Timer 
Pen 
Petri dish 
Vacuum chamber – vacuum flask, plastic tubing, and glass pipettes for aspiration 
Syringe 
Pre-cooled reagents– ACK lysis buffer, separation buffer, PBS/5%FBS (at 4°C) 
PBS/5%FBS: 1 tube with ~10ml to store bones, ~40mL for filtering out bone pieces, 
45mL for quenching after and rest for miscellaneous use  
 Have ~120mL ready  
40 µm cell strainer for 50 mL tubes (Cat #352340, BD Bioscience, Bedford, MA) 
Polypropylene tubes for cell handling (Cat #352002, BD Bioscience, Bedford, MA) 
35 µm cell trainer caps taken from Polystyrene ties (Cat #352235, BD Bioscience, Bedford, MA) 
 
Procedure 
 
Isolation of BM cells from mouse: 
1. Sacrifice mouse via CO2 inhalation. (Make sure to bring 70% ethanol solution, surgical 
scissors and tweezers, gloves, and a pen to the animal facilities lab.) 
 
2. Remove tibia and femur (entire length incl. head of femur) from both sides. Remove any 
attached muscle (via gentle Kim-wipe rubbing). Place into PBS+2%FBS solution. 
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3. Place bones into (cleaned/autoclaved) mortar with some PBS+2%FBS.Gently crush the bones 
using a pestle. Do not grind with continuous motion: use a gentle up-and-down motion. 
 
4. Place PBS+5%FBS + ground bones through a 40m cell strainer into 50ml conical tube; rinse 
mortar and pestle with ~25–40 mL of PBS+2%FBS buffer through strainer as well. 
 
5. Centrifuge cells: 1400 rpm, 5 minutes, 4
o
C. Aspirate supernatant. 
6. Resuspend cells in 5ml ACK lysis buffer, vortex well. Let stand 5 min (no more!) on ice. 
Quench with 35ml PBS+5%FBS 
 
7. Centrifuge cells: 1400 rpm, 5 minutes, 4
o
C. Aspirate supernatant. 
 
Work fast, keep cells on ice, and use pre-cooled (4 – 8C) reagents) 
 
FACS analysis/sorting for further enrichment in LSK population: All steps done on ice 
 
1. Resuspend cells in 800L PBS/FBS in a FACS tube and make sure there are no clumps. Add 
more 200L to clean out any remaining cells. Usually comes to 1 mL.  
 
2. Add 5 L of 0.5 mg/mL Fc receptor blocking antibody to achieve of 0.5 g/mL (Note: the 
actual concentration upon adding 5 L is much higher but is done as precaution). Sit 10’ on ice.  
 
3. Quench with 1 mL of PBS/FBS. Spin down: 1400 rpm; 5 minutes; 4C. Aspirate the 
supernatant. Resuspend in 500 L of PBS/FBS.  
 
4. Make control and sorting samples: 1E6 cells per control and the rest for sorting. Typically 
comes to about 5 L of original sample per tube for controls. Dilute with PBS/FBS for a final 
volume of 100 L.  
 
5. Add antibody cocktails to the sample (Lin, Sca-1, and c-Kit); Sit 20’ on ice. 
 
Lin cocktail Dilution For 100 L cocktail 
CD5 1:200 0.5 
B220 1:300 0.33 
Mac-1 1:320 0.31 
CD8a 1:200 0.5 
Gr-1 1:350 0.29 
Ter-119 1:320 0.31 
PBS + 2% FBS  97.76 
  Note.  Dilutions when antibodies are at 0.5 mg/mL. 
 
# Control Volume of 
control (μL) 
1 Unstained 0 
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2 PI 2 
3 APC Cy7 1 
4 PE 1 
5 FITC 1 
 
Antibody cocktail Volume (μl) 
Lin cocktail 4  
Sca-1-PE 4  
c-kit-APC Cy7 4  
 
6. Make a 1:40 PI working solution from the purchased stock solution with PBS+5% FBS. Add 
15µL of the PI working solution to PI control and WBM.  
 
# FACS Tube Contents 
1 Unstained control WBM 
2 PI control WBM, PI 
3 APC Cy7control WBM, Sca-1-PE 
4 PE control WBM, c-kit-APC Cy7 
5 FITC control WBM, Lin-FITC 
6 WBM WBM, PI, c-kit-PE, Sca-1-APC, Lin-FITC 
 
7. Wash in 1 mL PBS/5% FBS. 
 
8. Centrifuge cells: 1400 rpm, 5 minutes, 4
o
C. 
 
9. For controls, resuspend in 500 L PBS+5% FBS; pipette up/down, vortex to generate single 
cell suspension.  
 
10. For sorting sample, resuspend in PBS+5% FBS to achieve concentration of 10E6 cells/mL; 
pipette up/down, vortex to generate single cell suspension (typically comes to about 2.5 mL).  
 
11. Filter into new tubes. 
 
12. Flow analysis/sorting on each population.  
 
For Sorting: 10E6 cells/mL 
For Analysis: 2E6 cells/mL 
 
13. Filter the cells through a 35 μm cell strainer for easier sorting 
 
14. Place the sorting tube in an ice bath for better results. 
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A.3 Bone Marrow Harvest protocol with lineage negative enrichment  
 
Animals to sac: 
WT: Jax C57B6 mouse strain 
 
FACS Antibodies:  
Lineage cocktail [CD5 (Cat #11-0051), CD45R (B220) (Cat #11-0452), CD11b (Mac-1) (Cat 
#11-0112), Gr-1 (Ly-6G/C) (Cat #11-5931), Ter-119 (Cat #11-5921), CD8a ((Cat. #11-0081)] 
Sca-1 (Cat. #12-5981-83) 
c-Kit (Cat. #47-1172-82) 
Propidium Iodide (PI) (P3566, Life Technologies, Grand Island, NY)  
 
All antibodies from eBioscience unless otherwise specified) 
 
Supplies 
70% ethanol solution 
Surgical tools (autoclaved) – scissors, tweezers 
Mortar/Pestle 
Timer 
Pen 
Petri dish 
Vacuum chamber – vacuum flask, plastic tubing, and glass pipettes for aspiration 
Syringe 
Pre-cooled reagents– ACK lysis buffer, separation buffer, PBS/5%FBS (at 4°C) 
PBS/5%FBS: 1 tube with ~10ml to store bones, ~40mL for filtering out bone pieces, 
45mL for quenching after and rest for miscellaneous use  
 Have ~120mL ready  
40 µm cell strainer (Polystyrene tubes, Cat #352340, BD Bioscience, Bedford, MA) 
Polypropylene tubes for cell handling (Cat #352002, BD Bioscience, Bedford, MA) 
35 µm cell trainer caps taken from Polystyrene ties (Cat #352235, BD Bioscience, Bedford, MA) 
 
Enrichment kit: 
EasySep Mouse Hematopoietic Progenitor Cell Enrichment Kit (Stem Cell Technologies, Cat # 
19756) 
EasySep Magnet (Stem Cell Technologies, Cat # 18000) 
 
Procedure  
 
Isolation of BM cells from mouse: 
1. Sacrifice mouse via CO2 inhalation. (Make sure to bring 70% ethanol solution, surgical 
scissors and tweezers, gloves, and a pen to the animal facilities lab.) 
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2. Remove tibia and femur (entire length incl. head of femur) from both sides. Remove any 
attached muscle (via gentle Kim-wipe rubbing). Place into PBS+2%FBS solution. 
 
3. Place bones into (cleaned/autoclaved) mortar with some PBS+2%FBS.Gently crush the bones 
using a pestle. Do not grind with continuous motion: use a gentle up-and-down motion. 
 
4. Place PBS+5%FBS + ground bones through a 40m cell strainer into 50ml conical tube; rinse 
mortar and pestle with ~25–40 mL of PBS+2%FBS buffer through strainer as well. 
 
5. Centrifuge cells: 1400 rpm, 5 minutes, 4
o
C. Aspirate supernatant. 
6. Resuspend cells in 5ml ACK lysis buffer, vortex well. Let stand 5 min (no more!) on ice. 
Quench with 35ml PBS+5%FBS 
 
7. Centrifuge cells: 1400 rpm, 5 minutes, 4
o
C. Aspirate supernatant. 
 
If necessary: 
 
1. Resuspend cells in 4ml PBS + 5% FBS 
2. Count live cells from 10L aliquot (+10L Trypan blue).  Dilute by a factor of 5 (instead 
of usual 2) for easy counting as there will be a lot of cells. 
 WT 
Avg. count (hemacytometer grid)  
Total # cells/4mL  
 
FACS analysis/sorting for further enrichment in LSK population: All steps done on ice 
 
1. Resuspend at a concentration of 1x10
8
cells/mL. (You typically get 50 million per mouse). 
 
2. Add Normal Rat Serum at 50µL per mL of cell suspension. 
 
3. Add EasySep Mouse Hematopoietic Progenitor Cell Enrichment Cocktail at 50µL/mL of 
cells. Mix and incubate on ice for 15 minutes.  
 
4. Add EasySep Biotin Selection Cocktail at 100µL/mL. Incubate on ice for 15 minutes.  
 
5. Vortex the magnetic microparticles for 30 seconds and add them at 50µL/mL of cells. 
Incubate on ice for 10 minutes.  
 
6. Bring the cell suspension to a total volume of 2.5 mL Mix the cells in the tube and place the 
tube in the magnet for 3 minutes. 
 
7. Pick up the magnet and gently pour off the supernatant liquid suspension into another tube in 
one single motion. Do not stop midway and do not shake or dab off drops on the mouth of 
the tube.  
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8. The enriched cells are in the new tube whereas the Lin
+
 cells are in the tube inside the magnet.  
9. Make control and sorting samples: 0.5E6 cells per control and the rest for sorting.  
  Note.  Dilutions when antibodies are at 0.5 mg/mL. 
 
# Control Sample volume 
(µL) 
Antibody 
volume (µL) 
1 Unstained 100 0 
2 PI 100 2 
3 APC-Cy7 100 1 
4 PE 100 1 
5 FITC 100 1 
 
10. Resuspend cells in a total of 500µL of PBS/FBS 
 
11. Add antibody cocktails (Lin, Sca-1, and c-Kit); Sit 20’ on ice. 
 
Antibody cocktail Amount 
Sca-1-PE  4 µL 
Lin-FITC 4 µL 
c-kit-APC-Cy7 4 µL 
 
12. Make a 1:40 PI working solution from the purchased stock solution with PBS+5% FBS. Add 
15µL of the PI working solution to PI control and WBM 
 
# FACS Tube Contents 
1 Unstained control WBM 
2 PI control WBM, PI 
3 APC control WBM, Sca-1-PE 
4 PE control WBM, c-kit-APC 
5 FITC control WBM, Lin-FITC 
6 WBM WBM, PI, c-kit-PE, Sca-1-APC, Lin-FITC 
 
13. Wash in 1 mL PBS/5% FBS. 
 
14. Centrifuge cells: 1400 rpm, 5 minutes, 4
o
C. 
 
15. For controls, resuspend in 500 L PBS+5% FBS; pipette up/down, vortex to generate single 
cell suspension.  
 
16. For sorting sample, resuspend in PBS+5% FBS to achieve concentration of 10E6 cells/mL; 
pipette up/down, vortex to generate single cell suspension (typically 1.5 mL).  
17. Filter cells through a 35 μm cell strainer for easier sorting 
 
18. Flow analysis/sorting on each population.  
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For Sorting: 10E6 cells/mL 
For Analysis: 2E6 cells/mL 
 
19. Filter the cells through a 40 μm cell strainer for easier sorting 
 
20. Place the sorting tube in an ice bath for better results. 
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A.4 MC3T3-E1 pre-osteoblasts complete MEM-α medium protocol 
 
REFERENCES:  Refer to ATCC page 
(http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?AT
CCNum=CRL-2593&Template=cellBiology) 
 
Supplies 
Component Company Catalog No. Volume Concentration 
MEM-α Gibco A10490-01 440 mL -- 
FBS (heat inactivated) Gibco 16140-071 50 mL 10% 
L-Glutamine (100x) Gibco 25030 5 mL 2mM 
Pen-Strep Gibco 15140 5 mL 100 U/ml Pen 
100 μg/mL Strep 
Table A.1.  MEM-α medium recipe for the MCETE-E1 Subclone 4 cell line 
 
Complete Medium: 
1.  Use the 500 ml MEM-α medium 
 
2.  pH the medium to 0.1 – 0.3 below the desired final pH of the complete MEM- α medium 
using NaOH. The pH rises due to the sterile filtering step. Desired final pH range: 7.2 – 7.4  
 
3. Add the appropriate amounts of FBS, L-glutamine, and Penicillin-Streptomycin (Table 1) 
 
4. Sterile filter the complete medium (0.2 μm filter), and store at 4 °C.  
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A.5 MC3T3-E1 pre-osteoblasts feeding and passaging protocol 
 
MC3T3-E1 Cell Feeding Protocol 
 
Supplies 
 Complete MEM-α medium (See A.4) 
 Sterile PBS 
 
Procedure 
 
1. Warm complete MEM-α medium and PBS in a water bath at 37 °C. 
 
2. When the medium is warm, wipe the bottle dry with a paper towel and spray with 70% ethanol 
before placing it into the sterile hood 
 
3. Remove the old medium from each T75 (or T25) flask, taking care not to scrape cells with 
pipette tip. 
 
4. Add 10 ml of sterile PBS (or 5 ml for a T25 flask); tilt the flask gently to ensure the PBS 
spreads all over the flask, Pipette out.  
 
4. Add 15 ml of complete MEM- medium into each T75 flask (or 4 ml for a T25 flask) using a 
sterile pipette tip.  
 
5. Return cells into incubator. Check for confluence every 24 hours and feed cells every 48 
hours.  
 
MC3T3-E1 Cell Passaging Protocol 
 
Supplies 
 Complete MEM-α medium (See A.4) 
 Sterile Phosphate Buffered Saline (PBS, Cat No. 20012-043, Invitrogen Inc., Carlsbad, 
CA) 
 Trypsin-EDTA (Cat. No. 25300-062, Invitrogen) 
 Trypan Blue (Cat. No. SV3008401, Fisher Scientific) 
 
Equipment 
 Hausser Phase Contrast Hemacytometer  
 Inverted phase contrast microscope 
 Tabletop centrifuge 
 
Procedure 
 
1. Warm complete MEM-α medium, sterile PBS (Invitrogen), and 4 ml Trypsin (Invitrogen) per 
T75 flask to be passaged in a water bath at 37 C.  
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2. When the medium, PBS and Trypsin are warm, wipe them dry with paper towel and spray 
with 70% ethanol before placing in the sterile hood.  
 
3. Remove all old medium from each flask, taking care not to scrape the cells with pipette tip. 
 
4. Add 10 ml of PBS per flask and leave the PBS in the flask to rinse the cells for 30 seconds. 
Swirl gently to remove any excess medium from the cells. (For a T25 flask, use 5 ml PBS) 
 
5. Remove the PBS and add 3 ml of Trypsin per flask (for a T25 flask, use 1.5 ml Trypsin). 
Return the flasks to the incubator for 4 minutes to allow for the cells to detach from the tissue 
culture plastic. If the cell suspension is not cloudy after 5 mins, shake the flask in order to detach 
the cells. Keep shaking until the trypsin solution turns cloudy.  
 
6. Add 6 ml of complete medium to each flask to neutralize the Trypsin and to flush cells off of 
the tissue culture plastic. (for a T25 flask, use 4 ml PBS) 
 
7. Remove the Trypsin, additional medium, and cells from the flask and put into a conical tube. 
Centrifuge the cells at 130 rcf for 7 minutes.  
 
8. Aspirate off the medium supernatant and add a total of 3 – 5 ml of medium to the conical 
tubes. This amount varies depending on how many conical tubes are used (i.e. how many flasks 
are passaged).  
 
9. Remove the 10 μl aliquot from the cell suspension.  
 
10. Mix the 10 μl cell suspension aliquot with 10 μl of Trypan Blue (Fisher Scientific). Pipette 
several times to mix the stain and cell suspension.  
 
11. Place a cover slip on the hemacytometer (Fisher) and pipette 10 μl of the stain/cell 
suspension into the hemacytometer. 
 
12. Cell counts are performed in as many of the nine separate regions of the hemacytometer as is 
feasible. Average number of cells per region is used to calculate the total cell population. For this 
calculation, the dilution factor is typically 2 (1:1 ratio of cell suspension to Trypan Blue). 
 
Total Cell Population = (Mean Cells per Region) * Dilution * 10,000 * (Cell Suspension 
Volume) 
 
13. Add 14 ml of complete MEM-α medium to each new T75 flask to be seeded (or 4 ml for a 
T25 flask). Add the appropriate volume of the concentrated cell solution to place approx 0.8 
million cells in the T75 (to be passaged after a week). For the near-future use, seed 1 million 
cells in a T25 flask. They will be ready (confluent) the day after.  
 
14. Place the flask(s) into the incubator. Check the confluence every 24 hours and feed cells 
every 48 hours.  
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A.6 MC3T3-E1 pre-osteoblasts freezing protocol 
 
Supplies 
 Cell freezing medium  
 Trypsin-EDTA (Cat. No. 25300-062, Invitrogen) 
 Trypan Blue (Cat. No. SV3008401, Fisher Scientific) 
 DMSO (Cat. No. D2650 100ml, Sigma-Aldrich) 
 Fetal Bovine Serum (FBS, Cat. No. 16140-071, Invitrogen) 
 
Equipment 
 Hausser Phase Contrast Hemacytometer  
 Inverted phase contrast microscope 
 Tabletop centrifuge 
 
Procedure 
 
1. MC3T3-E1 cells can be stored in liq. N2 vapor for extended periods of time. Perform the 
freezing procedure under sterile conditions and warm all solutions to 37° C prior to use to 
maintain cell viability.  
 
2. Isolate the cell population to be frozen from 90% confluent flasks using standard cell 
passaging procedures. 
 
3. Count the cells using standard cell counting procedures.  (Include protocol/section for cell 
counting) 
 
4. Resuspend the cells in the cell freezing medium at a density of 2 x 10
6
 cells/mL. For MC3T3-
E1 cells, the appropriate freezing medium is 60% MEM-α, 30% FBS and 10% DMSO.  
 
5. Distribute 1 ml of the cells in the freezing medium into each cryovial. Ensure that the 
cryovials are sealed.  
 
6. Place the cryovials into a Styrofoam container with walls ~ 15 mm thick and pack the 
contained with cotton gauze. Seal the container with tape and place it into a liquid N2 dewar.  
 
7. Wait 4 hours for the cell suspension to freeze and then transfer the cryovials to a plastic box in 
the dewar racks in a liquid N2 tank.  
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A.7 MC3T3-E1 pre-osteoblasts thawing protocol 
 
Supplies 
 Complete MEM-α medium (See A.4) 
 T75 tissue culture flasks (BD Falcon Tissue Culture Flasks with Vented Cap, Cat. No. 
BD353136, VWR Scientific, Inc., Bridgeport, NJ) 
 
Equipment 
 Tabletop centrifuge  
 
Procedure 
 
1. Place complete MEM-α into the waterbath and warm to 37 C.  
 
2. Remove 1 flask of frozen cells (2 x 10
6
 cells/flask in 1 ml freezing medium) from a liquid 
nitrogen storage or the -80 C freezer. 
 
3. Transfer 5 ml of complete MEM- α medium to a 15 ml conical tube.  
 
4. Place the vial containing the frozen cells into the waterbath and allow it to warm until the 
frozen cell/medium mass initially starts to melt (you should see the frozen mass begin to glisten) 
 
5. Pipette 1 ml of complete MEM- α medium from the 15 ml conical tube onto the semi-thawed 
frozen cell mass. Pipette up and down and place medium back into the conical tube.  
 
6. Repeat until the entire 1 ml of frozen cells has been transferred into the 15 ml conical tube.  
 
7. Place the 15 ml conical tube into the centrifuge (Heraeus). Centrifuge the cell solution at 1200 
rpm for 5 minutes.  
 
8. Aspirate off the medium supernatant and re-suspend the cell pellet in 6 ml of fresh, complete 
MEM-α medium. 
 
9. Place 14 ml of complete MEM- α into two T75 flasks (VWR). Place 3 ml of the cell 
suspension into each flask and swirl gently to distribute the cells. 
 
10. Place the flasks into the incubator. Check for confluence every 24 hours and feed cells every 
48 hours.  
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A.8 Collagen hydrogel preparation and cell encapsulation protocol 
 
Supplies: 
 Collagen Type I (Cat #354249, BD Biosciences, Bedford, MA) 
 NaOH (0.4M) 
 Media  
 Cells (if needed) 
 HEPES (Cat #25-060-Cl, Corning, cellgro, Manassas, VA) 
 1X Medium 199 (M199) Buffer (Cat #10-060-CV, Corning cellgro, Manassas, VA) 
 Sodium formate (NaHCO2, Cat #71539, Sigma Aldrich, St. Louis, MO) 
 CaCl2 
 Dithiothreitol (DTT) (Cat #43815, Sigma Aldrich, St. Louis, MO) 
 Glyoxal (Cat #50649, Sigma Aldrich, St. Louis, MO) 
 
Procedure: 
 
1. The BD Biosciences collagen bottle comes in a specific concentration. Therefore, 
concentrations lower than the original concentration can be made 
 
2. Add volume of collagen solution based on the bottle concentration (collagen is viscous so 
pipette slowly and wait for a while with the tip dipped in the solution) 
 
3. Supplement the 1xM199 buffer with 0.75% NahCO2 and 0.01M HEPES. Volume of M199 
buffer mix added is 1/4
th
 of collagen solution volume 
 
4. Add the following reagents: DTT (1mM) and CaCl2 (5mM), Glyoxal (0.1mM) 
 
5. Add the volume of cells based on the number of cells required. Fill out the rest of the volume 
with media and the appropriate amount of NaOH (based on the calibration curve) 
 
Making the NaOH calibration curve 
 
1. Prepare collagen solution of multiple concentrations (1, 1.5, 2, 2.5, 3 mg/mL) with a final 
solution volume of 2 mL. Do not add any NaOH (the volume will be lesser than desired) 
 
3. Start by adding 10 uL of 0.4 M NaOH and measuring the pH with a pH probe. Make sure to 
mix the solution well before measuring pH. Keep adding more NaOH until a pH of 7.4 +/- 0.1 is 
obtained. In case the pH rises above 7.4, add 0.1M HCl instead to lower it 
 
6.  Plot the collagen concentration on the x-axis and the final NaOH volume on the y-axis to get 
the calibration curve 
 
7. Repeat process for a total solution volume of 1 mL. This is done to check the correlation 
between solution volume and NaOH volume needed for neutralization 
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A.9 Collagen hydrogel digestion protocol 
 
Supplies: 
 Collagenase Type 2 (Cat. # LS004174, Worthington Biochemical, Lakewood,NJ) 
 PBS/5%FBS 
 Sterile filter tubes (Polystyrene with nylon filter, Cat# 352235, BD Bioscience, Bedford, 
MA) 
 
Procedure: 
1. Create a 1000 U/mL stock solution of the collagenase by dissolving it in the PBS/5%FBS 
buffer. Can be used up to 7 days after preparation (Store at 4 °C) 
 
2. Remove the supernatant media from the collagen hydrogel 
 
3. Gently lift the gel out of the culture plate (with a pipette tip) and place it in a 24 well plate  
 
4. Add the collagenase solution and PBS/5%FBS buffer to give a final collagenase concentration 
of 50 U/mL 
 
5. Place the well plate on a shaker in the incubator 
 
6. Gel digestion takes between 20 – 40 mins. Pipette solution gently at regular 10 min intervals 
to facilitate digestion 
 
7. Filter solution through the sterile filter tubes and centrifuge to retrieve cells  
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A.10 Paracrine signaling inhibition protocol  
 
Supplies: 
 TGF- RI inhibitor (EMD Millipore, Cat. #616461) 
 TNF-α inhibitor (EMD Millipore, Cat. #654256) 
 MIP-1α inhibitor (Selleckchem, Cat. #S2003) 
 StemSpan SFEM  Media (Stem Cell Tech. Cat. #09650) 
 
Procedure: 
 
1. Create stock solutions of all chemicals and add to media as follows: 
 
TGF- RI:  
Stock: 5 mg powder. Dissolve in 1189 µL DMSO for 10mM final concentration. Aliquot; store 
at -20 °C 
Working concentration: 1 µM 
Add 1 µL in 10 mL of media 
 
TNF-:  
Stock: 5 mg powder. Dissolve in 794.2 µL DMSO for 10mM final concentration. Aliquot; store 
at -20 °C 
Working concentration: 2 µM 
Add 2 µL in 10 mL of media 
 
MIP-1:  
Stock: 5 mg powder. Dissolve in 973.4 µL DMSO for 10mM final concentration. Aliquot; store 
at -80 °C 
Working concentration: 7.2 nM 
Add 1 µL in 99 µL of PBS 
Then add 0.72 µL of that in 10 mL media 
 
Note: Aliquots of a higher stock concentration (100 mM) is recommended  
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A.11 Autocrine signaling inhibition protocol  
 
Supplies: 
 PDGFR, VEGFR, FGFR inhibitor (Tocris, Cat. #3335) 
 StemSpan SFEM  Media (Stem Cell Tech. Cat. #09650) 
 
Procedure: 
 
1. Create stock solutions and add to media as follows: 
 
Stock: 5 mg powder. Dissolve in 1611 µL DMSO for 20mM final concentration. Aliquot; store 
at -80 °C 
Working concentration: 1 µM 
Add 0.5 µL in 10 mL of media 
 
Note: Aliquots of a higher stock concentration (100 mM) is recommended  
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APPENDIX B: FUNCTIONAL ASSAYS AND IMAGING PROTOCOLS  
B.1 Fluorescent CMFDA/CMTPX cell staining protocol 
 
Supplies 
 CMFDA (Invitrogen, Cat # C2925)and CMTPX dyes (Invitrogen, Cat # C34552) 
 Cells 
 Media (as required) 
 DMSO (Cat. No. D2650 100ml, Sigma-Aldrich) 
 
Note: This procedure works for both cells in suspension as well as cells attached to TCPS flasks 
 
Procedure for cells in a flask 
 
1. Culture cells in a T-25 flask  
 
2. Mix the as-available dye tube with 10 µL of DMSO 
 
3. Pipette 5mL of media into a conical tube 
 
4. Add 5 µL of dye solution to the media. Mix well 
 
5. Pipette out old media from the T-25 flask. Pipette the new media into the flask  
 
6. Incubate for 20 minutes 
 
7. Following incubation, pipette out the media. Rinse twice with PBS 
 
8. Follow protocol for cell passaging (A.4) 
 
Procedure for cells in suspension 
 
1. Concentrate cells in a centrifuge tube  
 
2. Mix the as-available dye tube with 10 µL of DMSO 
 
3. Pipette 5mL of media into a conical tube 
 
4. Add 5 µL of dye solution to the media. Mix well and add to the cells  
 
5. Incubate for 20 minutes 
 
6. Following incubation, wash with PBS twice, centrifuging each time to remove the dye  
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B.2 Cell proliferation assays (CFSE and Cell trace Violet) protocol 
 
Supplies: 
 CellTrace CFSE Cell Proliferation kit (Invitrogen, Cat #C34554) 
or 
 CellTrace Violet Cell Proliferation kit (Invitrogen, Cat #C34557) 
 DMSO (Cat. No. D2650 100ml, Sigma-Aldrich) 
 
Procedure: 
 
Note: This method works for cells in suspension, typically after they have been obtained from 
the sorting facility 
 
1. Prepare a stock solution of the dye 
CFSE: Dissolve contents of one vial of dye in 18 µL DMSO for a 5 mM solution 
CellTrace Violet: Dissolve contents of one vial of dye in 20 µL DMSO for a 5 mM solution 
 
2. Final working concentration of both dyes: 1 µM.  
Note: This need not always hold and concentrations should be tested for compensation with other 
dyes for minimal spectral interference 
 
3. Centrifuge the cells at 1400 RPM and 11 minutes 
 
4. Resuspend in 400 µL PBS and place on ice 
 
5. Dilute the stock solution to 5 µM by adding 1 µL to 999 µL PBS 
 
6. Add 100 µL of this diluted dye solution to the cell solution and mix well for a final 
concentration of 1 µM 
 
7. Incubate at 37 °C. CFSE: 10 minutes; Cell Trace Violet: 20 minutes 
 
8. After the incubation period, quench the dye with 5 times the original volume of PBS/5%FBS 
 
9. Place on ice and away from light for 5 minutes (removes free dye in solution) 
 
10. For CFSE, centrifuge and resuspend again PBS for another wash for a total of two washes. 
No extra washes needed for CellTrace Violet 
 
11. Resuspend final cell solution media 
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B.3 Annexin V Apoptosis assay for flow cytometry protocol 
 
Supplies: 
 PerCp-Cy-5.5 Annexin V (BD Biosciences, Cat. # 516431) 
 Camptothecin 
 HEPES (Cat #25-060-Cl, Corning, cellgro, Manassas, VA) 
 NaCl 
 CaCl2 
 
Procedure: 
 
1. Prepare a 10X Binding Buffer solution as follows:  
 
 Wt (g) Conc (mM) 
NaCl 2.045 1400 
CaCl2 0.0693 25 
HEPES (1M) 2.5 mL 100 
dWater 22.5 mL  
Total volume 25 mL  
 
Note: Always use the Binding Buffer for this assay. PBS will not work as a high Ca
2+
 
concentration is required! 
 
2. Wash cells with PBS  
 
3. Prepare a control set (1 x 10
5
 cells) and add Camptothecin at a concentration of 2.5 µM. 
Incubate at 37 °C in the incubator for 2 hours.  
 
Note: The control step should be done 2 hours before the actual sample staining so that the 
timings match 
 
4. Resuspend sample cells in 100 µL of 1X Binding Buffer (diluted with dH2O), add 5 µL of the 
Annexin V dye and incubate at R.T. for 15 minutes in the dark 
 
5. Add 400 µL of the 1X Binding Buffer (do not wash!) and analyze cells via FACS within 1 hr  
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B.4 Multi-color flow cytometry for surface antigen expression analysis protocol  
 
Supplies: 
 Lineage cocktail from A.2 
 c-kit: APC-Cy7 (eBioscience, Cat. #47-1172-82) 
 Sca-1: PE (eBioscience, Cat. #12-5981-83) 
 CD34: APC (eBioscience, Cat. #50-0341-82) 
 FcγR: PE-Cy7 (eBioscience, Cat. #25-0161-81) 
 Annexin V from A. 11 
 Cell Trace Violet from A.10 
 Flk2: PE-Cy5 (eBioscience, Cat. #15-1351-81) 
 IL7Rα: AmCyan (BD Biosciences, Cat. #563353) 
 Sodium Azide (Cat #S2002, Sigma Aldrich, St. Louis, MO) 
 PBS/5%FBS Buffer 
 
Note 1: Work on ice at all times unless specified in another protocol 
Note 2: For analyses with fewer colors, follow protocol minus the extra/unneeded colors 
 
Procedure: 
 
1. Typically, Cell Trace Violet (B.2) would have already been added to the cells prior to culture 
 
2. Achieve a suspension of cell either by trypsinization (A.4) or collagen digestion (A.9). Ideally 
avoid trypsinization as it damages the surface antibodies. Gently pipetting the non-adherent well 
surface does well to release cells  
 
3. Centrifuge cells in polystyrene tubes (1400 RPM, 5 mins), resuspend in 100 uL of 
PBS/5%FBS with 0.1% Sodium azide and place on ice 
 
4. Prepare the following compensation controls. Need at least 1 x 10
5
 cells per control 
Note 1: For all HSC/HSPC related experiments, whole bone marrow cells cultured for the same 
time as the actual experiments will suffice 
Note 2: They only need to be done once. Make sure there is no overcompensation 
Note 3: These concentrations and times also apply to actual samples 
 
Antibody Dye Dye volume (µL) per 100 µL sample Incubation time (mins) 
Unstained Unstained 0 - 
Lineage FITC 1 30 
c-kit APC-Cy7 1 30 
Sca-1 PE 1 30 
CD34 APC 4 60 
FcγR (CD16/32) PE-Cy7 1 30 
Flk2 PE-Cy5 4 30 
IL7Rα AmCyan 4 60 
Cell Trace Violet Pacific Blue B.2 
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Annexin V PerCP-Cy5.5 B.3 
  
5. Add the CD34 and IL7Rα dye to the samples and place on ice for 30 minutes 
 
6. Create a master mix of the lineage, c-kit, Sca-1, Flk2 and FcγR dyes. Mix well and add 
cumulative amounts to each sample  
 
7. Incubate an additional 30 minutes on ice 
 
8. Wash with 1 mL of PBS/5%FBS/0.1% Sodium azide 
 
9. Centrifuge (1400 RPM, 5 mins ) and resuspend in 1X Binding Buffer 
 
10. Follow protocol A.11 for Annexin V Apoptosis stain 
 
11. Analyze via sort within 1 hr 
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B.5 Live/Dead assay to assess cell viability protocol 
 
Supplies 
 Live/Dead cytotoxicity kit (Invitrogen) 
 PBS 
 Glass Bottom Dishes (Cat #D29-20-0-N, Invitro Scientific, Sunnyvale, CA) 
 
Equipment 
 Fluorescence microscope 
 
Procedure 
 
1. To prepare the live/dead assay, prepare a 2µM solution of Calcein AM (Live) and Ethidium 
homodimer-1 (Dead) in PBS 
 
2. This can be done by adding 1 µL of and Ethidium homodimer-1 and 0.5 µL of Calcein AM in 
998.5 µL of PBS. (Scale up or down accordingly) 
 
5. Vortex well 
 
6. Add enough of the live/dead solution to cover the hydrogel in question 
 
7. Incubate at 37 °C for 30 minutes 
 
8. Transfer the hydrogel on to a Glass Bottom Dish and observe under a fluorescence microscope 
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B.6 Colony-Forming Unit (CFU) assay Protocol 
 
Supplies: 
 MethoCult® GF M3434 Methylcellulose medium with recombinant cytokines and EPO 
for mouse cells (Stem Cell Tech., Cat #03434)  
 3cc luer lock syringe (Stem Cell Tech., Cat #28240) 
16 gauge blunt-end needle (Stem Cell Tech., Cat #28110) 
 35 mm culture dishes (Catalog #27100/27150) 
 Big petri dish 
 PBS 
 StemSpan SFEM  Media (Stem Cell Tech. Cat. #09650) 
 
Equipment: 
 Light microscope (DMI4000, Leica Microsystems, Germany). 
 
Procedure: 
 
Thawing the media bottle: 
 
1. Thaw Methocult media overnight at 4 °C  
 
2. Mix contents of the bottle vigorously by shaking/vortexing. Ensure the contents of the media 
are well mixed 
 
3. Let the bottle sit for 30 – 40 minutes to allow bubbles to rise. Media should become 
transparent with the rising bubbles 
 
4. Make 4 mL aliquots of the media in 15 mL conical tubes using a 3cc luer lock syringe with a 
16 gauge blunt-end needle  
 
5. Cap tubes tightly and store at – 20 °C until use 
 
Performing the CFU assay with cell cultures 
 
1. Thaw Methocult media overnight at 4 °C 
 
2. Using the needle/syringe, vigorously mix the contents of the aliquot until even mixing is 
achieved. Let tube stand to clear out the bubbles 
 
3. In the meantime, create a cell suspension of the desired sample (either by trypsinization from 
culture A.5, collagen digestion A.9, GelMA digestion D.6 or from whole bone marrow cells A.2)  
 
4. Resuspend cells in SFEM media and make aliquots of 100 µL in micro centrifuge tubes per 
culture dish  
159 
 
Note: A high cell number will give rise to too many colonies that are extremely hard to count. 
Too few cells (<1000) won’t give a statistically reliable data. Test multiple cell densities to 
determine optimal concentration.  
 
5. Draw grid lines with a permanent marker on the back side of the 35 mm culture dishes 
 
6. Add 1 mL of the Methocult media to the micro centrifuge tubes containing the cells 
 
7. Mix contents gently with the needle/syringe  
 
8. Dispense the mixture onto the 35 mm culture dish and swirl the dish to ensure the medium 
covers the entire surface 
 
9. Label and place all the dishes in large petri dish. 
 
10. Fill a small petri dish with PBS and place it amongst the culture dishes. This ensures a 
humidified environment  
 
11. Incubate for 12 days at 37 °C with 5% CO2 and > 95% humidity 
 
Counting colonies: 
 
1. Use a 4x or 10x magnification under the light microscope to determine colony type  
 
2. Follow the grid pattern for simplified counting.  
 
Refer to the Technical Assay (version 3.1.1) for Stem Cell technologies’ Mouse Colony-
forming Cell Assays for colony type identification 
http://www.stemcell.com/~/media/Technical%20Resources/8/3/E/9/0/28405_methocult%20M.p
df 
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B.7 SCF ELISA assay protocol 
 
All supplies from RnD systems unless otherwise states 
Protocol adopted from the SCF DuoSet technical sheet 
 
Supplies:  
 Mouse SCF DuoSet, 15 Plate (Cat. #DY455) 
 Clear polystyrene microplates, 25 Pack, High Binding; Flat bottom (Cat. #DY990) 
 Substrate Reagent Pack (8 Vials Color A, 8 Vials Color B) (Cat. #DY999) 
 ELISA plate sealers, 100 pack (Cat. #DY992) 
 Tween 20 (Cat #BP337-500, Fisher Scientific, Pittsburgh, PA) 
 
Solutions: 
 PBS 
 Wash buffer: 0.05% Tween 20 in PBS 
 Reagent Diluent: 1% BSA in PBS that is 0.2 µm filtered  
 Substrate Solution: 1:1 mixture of Color Reagent A and Color Reagent B 
 Stop Solution: 2N H2SO4 
 
Reagent Preparation 
 
Bring all reagents to room temperature before use. Allow all components to sit for a minimum of 
15 minutes with gentle agitation after initial reconstitution. Working dilutions should be prepared 
and used immediately. 
 
Capture Antibody: Reconstitute with 1 mL of PBS to achieve a concentration of 72 µg/mL 
After reconstitution, store at 2 °C to 8 °C for up to 60 days or aliquot and store at -20 °C to -70 
°C for up to 6 months. Dilute to a working concentration of 0.4 µg/mL without carrier protein. 
 
Biotinylated Detection Antibody: Reconstitute with 1 mL of Reagent Diluent to achieve a 
concentration of 27 µg/mL After reconstitution, store at 2 °C to 8 °C for up to 60 days or aliquot 
and store at -20 °C to -70 °C for up to 6 months. Dilute to a working concentration of 150 ng/mL  
 
Standard: Reconstitute one vial with 500 µL of Reagent Diluent to achieve concentration of 140 
ng/mL of recombinant mouse SCF. Allow the standard to sit for a minimum of 15 minutes with 
gentle agitation prior to making dilutions. Aliquot and store reconstituted standard at -70 °C.  
 
Streptavidin-HRP (1 vial): 1.0 mL of streptavidin conjugated to horseradish-peroxidase. Store 
at 2 °C to 8 °C for up to 6 months after initial use.* DO NOT FREEZE. Dilute to the working 
concentration specified on the vial label using Reagent Diluent. 
 
Plate Preparation 
 
1. Dilute the Capture Antibody to the working concentration of 0.4 µg/mL in PBS. Immediately 
coat the 96-well microplate with 100 µL per well of the diluted Capture Antibody. Seal the plate 
and incubate overnight at room temperature. 
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2. Aspirate each well and wash with Wash Buffer, repeating the process two times for a total of 
three washes. Wash by filling each well with Wash Buffer (400 µL) using a squirt bottle, 
manifold dispenser, or autowasher. Complete removal of liquid at each step is essential for good 
performance. After the last wash, remove any remaining Wash Buffer by aspirating or by 
inverting the plate and blotting it against clean paper towels. 
 
3. Block each well of the microplate with 250 µL of Reagent Diluent. Incubate at room 
temperature for a minimum of 1 hour. 
 
4. Repeat the wash in step 2 
 
Standard Preparation 
 
1. Using the stock solution of the SCF standard prepare a 9 point standard dilution curve: 4000, 
2000, 1000, 500, 250, 125, 62.5, 31.25, 0 pg/mL in Reagent Diluent  
 
2. Ideally have triplicates but duplicates will work as well  
 
Assay Procedure 
 
1. Add 100 µL of sample or standards in Reagent Diluent or PBS, per well. Cover with an 
adhesive strip and incubate 2 hours at room temperature. 
 
2. Repeat the aspiration/wash as in step 2 of Plate Preparation. 
 
3. Add 100 µL of the working concentration of the Detection Antibody to each well. Cover with 
a new adhesive strip and incubate 2 hours at room temperature. 
 
4. Repeat the aspiration/wash as in step 2 of Plate Preparation. 
 
5. Add 100 µL of the working dilution of Streptavidin-HRP to each well. Cover the plate and 
incubate for 20 minutes at room temperature. Avoid placing the plate in direct light. 
 
6. Repeat the aspiration/wash as in step 2. 
 
7. Add 100 µL of Substrate Solution to each well. Incubate for 20 minutes at room temperature. 
Avoid placing the plate in direct light. 
 
8. Add 50 µL of Stop Solution to each well. Gently tap the plate to ensure thorough mixing. 
 
9. Determine the optical density of each well immediately, using a microplate reader set to 450 
nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength correction is 
not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. This 
subtraction will correct for optical imperfections in the plate. Readings made directly at 450 nm 
without correction may be higher and less accurate. 
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B.8 SCF Western Blot protocol 
 
Good Reference: 
http://gewesternblotting.com/resources/28999897AB-WB-HANDBOOK.pdf 
 
Reagents  
 RIPA buffer: Need ~200uL per sample 
o 150 mM NaCl 
o 1% Triton X-100 
o 0.5% sodium deoxycholate 
o 0.1% SDS 
o 50 mM Tris 
o pH = 8.0 
 Running buffer: Need ~700mL per gel (when running 1-2 gels) 
o 25 mM Tris base 
o 192 mM glycine 
o pH ~ 8.3 
o 0.1% SDS  
 Towbin’s electrotransfer buffer (10x): Need 100mL per gel 
o 25 M Tris base 
o 192 M glycine 
 Transfer buffer: Need ~1L per gel 
o 20% Methanol 
o 10% 10x Towbin’s electrotransfer buffer 
o 70% Water 
 TBS-T  
o 20 mM Tris pH 7.5 
o 0.8% w/v NaCl 
o 0.1 % v/v Tween 20 
***Use ultrapure water and filter all buffers! All buffers at RT at Sunny’s bench 
 2x Laemmli buffer (stockroom): Need ~10uL per sample 
o 2% β-mercaptoethanol 
 Blocking Buffer 1 (TBS-T + 5% non-fat milk)  
o 100mL TBS-T 
o 5g non-fat milk powder 
 Blocking Buffer 2 (TBS-T + 5% Bovine Serum Albumin)  
o 100mL TBS-T 
o 5g BSA 
 Combined protease/phosphatase inhibitors (x100; Cold room) 
 ddH2O or at least DI water 
 Protein ladder (stockroom) 
 Gel-loading pipette tips 
 Primary antibody: rabbit polyclonal Anti-SCF (Cat. #ab64677, Abcam, Cambridge, MA) 
 Secondary antibody: Goat polyclonal anti-rabbit IgG (H&L) conjugated to horseradish 
peroxidase (Cat. #ab6721, Abcam, Cambridge, MA) 
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 Clean glass bucket/container (large enough to hold entire gel) 
 Polyacrylamide gel (precast gels available at stockroom, otherwise make your own) 
 Ice 
 Plastic forceps 
 Ponceau S stain (Fisher Cat# K793-500mL) 
 Nitrocellulose membrane (Fisher Cat# RPN303E) 
 Whatman paper 
 SuperSignal West Pico Chemiluminescent Substrate kit (Cat #34077, Thermo Scientific, 
Rockford, IL) 
Supplies and equipment 
 Biorad Mini-Protean apparatus  
 Watch this video for demonstration: http://www.youtube.com/watch?v=XnEdmk1Sqvg  
   http://www.labtricks.com/2010/01/24/how-to-run-an-sds-page-gel/  
 
Procedure 
 
Day 1: Protein lysate, gel electrophoresis, transfer, primary antibody 
 
1. Have buffers ready 
2. Obtain precast gel from storeroom. Normally:10% acrylamide, however gradient gels and 
different gel percentages may be more applicable for particular target resolution (consult 
manufacturer) 
3. Prepare the 95°C heating block 
4. Thaw out the lysate (SCF or PEG-SCF) on ice. A total of 1 µg protein is sufficient  
5. Add 1 part lysate (7.5-25 uL) to 1 part 2x Laemmli buffer (7.5-25 uL) in 1.5 mL 
centrifuge tube 
Note: Adjust the amount depending on how much protein you want to load 
Loading size: Typically 20-40uL lysate + Laemilii per lane. Check precast gel 
description 
6. Heat tubes at 95 C in heating block for 5-10 min. 
7. Electrophoresis apparatus: 
 Watch video protocol: http://www.youtube.com/watch?v=XnEdmk1Sqvg  
 While tubes are heating, remove gel from fridge and rinse with water 
 Take strip off bottom and place it to the front of electrophoresis apparatus 
o If only running one gel, place a blank plastic cassette on the back side  
 Clamp everything in properly. (Red-red; black-black) 
 Pour running buffer between cassettes until gel is immersed 
 Fill container with running buffer to 2 or 4 gel marks (use 1 liter for 250 V 
transfer) 
 Remove comb from precast gels 
8. Take sample tubes. Spin down for a few seconds if you have solid pieces from 
hydrogels/scaffolds 
9. Carefully load 20-40uL lysate/Laemmli mix into each lane (behind plate) 
 Use gel-loading tips 
164 
 
 Load 5uL ladder to one lane for reference 
10. Run gel at 250V for ~0.5-1hr until all lysates (blue) arrive at the bottom 
 Make sure your band doesn’t run off the gel 
 While waiting, prepare nitrocellulose membrane by cutting it to match gel size 
 Also make sure transfer buffer is ready 
11. Turn off power and rinse gel cartridge thoroughly with DI water 
12. Carefully open gel cartridge using opening lever 
 Precast gel: Crack open at 4 sides marked by arrowheads 
13. Remove stacking gel and rinse with water 
14. Soak gels in buffer solution for 20-60 min to equilibrate (may notice shrinkage) 
15. Cut membrane and filter paper to gel size and slide at a 45⁰ angle into transfer buffer 
solution to soak for 5-10 min (15-30 min according to manual) 
16. Remove safety cover and prepare gel sandwich as follows (roll out air bubbles between 
each layer): 
To bottom platinum anode place: 
 Pre-wet extra thick (or 2 thick or 3 thin) filter paper 
 Pre-wet membrane 
 Equilibrated gel 
 Pre-wet extra thick (or 2 thick or 3 thin) filter paper 
17. Place cathode onto the stack, pressing to engage the latches with the guide post without 
disturbing the filter paper stack 
18. Place the safety cover on the unit  
19. Set the transfer parameters as 10 V for 30 min or 15 V for 15 min with max current of 
5.5mA/cm
2 
(0.35A/gel) 
 While waiting, prepare blocking buffers (5g dry milk to 100mL TBS-T and 5g 
BSA to 100mL TBS-T) vortex thoroughly 
20. Take apart assembly. Discard filter paper and gel (nothing should be left in the gel, 
indicating the transfer was successful). Nick membrane edge (top left corner) with 
scissors so you know which side the protein is on (this is the side of the membrane that 
faced the gel!) 
21. Stain with Ponceau S (1x) to check protein bands (can be re-used). Bands may not 
appear. Rinse with TBS-T to remove stain 
22. Add 20-30mL blocking buffer 1 (milk) to container. Incubate for 30min on a shaker (~50 
rpm) 
 While waiting, prepare primary antibody solution in ~5mL blocking buffer 
23. Add corresponding primary antibody in blocking buffer 2 (or as suggested by 
manufacturer) to each container 
 Primary antibodies diluted in blocking buffer can be used again. Store at 4°C or -
20°C 
24. Incubate overnight at 4°C or 2 hrs at RT on shaker. Keep remaining blocking buffer in 
fridge 
 
Day 2 (or after 2 hours): Secondary antibody, read blot using ECL (enhanced 
chemiluminescence) 
1. Wash membranes with TBS-T for 5min on shaker at RT (3x) 
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 While waiting, prepare 5-10mL secondary antibody solution (1:2500 dilution) in 
TBS-T or blocking buffer 1 from fridge 
 Make sure you use matching (anti-rabbit; anti-mouse, etc.) secondary antibody. 
2. Incubate in secondary antibody solution for 1hr at RT 
 Make sure you use matching (anti-rabbit; anti-mouse, etc.) secondary antibody. 
3. Wash membranes with TBS-T for 5min on shaker at RT (3x) 
4. Go to IGB room 124D to use ImageQuant for ECL detection 
 Make sure to bring: Your membranes in TBS-T, ECL reagents, 15mL conical 
tube, 1mL pipette with tips, plastic forceps, key to 124D 
 Make sure your membranes stay hydrated until next step 
 There should be plastic wrap and KimWipes in basement 
5. Once in basement, mix the SuperSignal West Pico Chemiluminescent Substrate kit 
reagents (1:1; make 2mL per membrane). 
6. Place saran wrap on a flat surface. Pick up your membrane with forceps then gently blot 
using KimWipes. Quickly do this for all membranes and pipette mixed ECL solution onto 
the membranes 
7. Wrap it with saran wrap and keep it in drawer at least 2 minutes 
8. Log into computer and start software 
9. Take membranes from the drawer 
10. Prepare clean saran wrap on the side. Pick up your membrane with forceps and gently 
blot using KimWipes. Place membranes on the clean saran wrap and cover it 
11. Place it in the detection chamber and detect. Expose for 30-60 sec first then adjust 
according to the output intensity (bands should not be completely black, some level of 
grey scale is needed for quantification) 
12. Save image 
13. Post-analysis: Analyze band intensity using Gel Image Analyzer or ImageJ 
 
Notes: 
Loading controls (not detailed here) 
To obtain reliable information about the expression levels of proteins on western blots (i.e. for 
publication), it is necessary to use an appropriate loading control (beta-Actin, GAPDH, etc). 
 
For best results, it may be necessary to optimize all parameters including sample loading amount, 
antibody host species/concentrations, order of target probing and stripping, and the membrane 
type and blocking reagents. 
 
RIPA: TOTAL 500mL 
pH = 8.0 NaCl 4.38g 
 Triton X-100 5mL 
 Sodium 
deoxycholate 
2.5g 
 SDS 0.5g 
 Tris base 3.03g 
Running buffer (10x): TOTAL 1000mL 
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Dilute 1:10 with ddH2O DI water 1000mL 
pH will be 8.3 Tris base 30.3g 
 Glycine 144g 
 SDS 10g 
Towbin’s electrotransfer buffer 
(10x): 
TOTAL 1000mL 
 DI water 1000mL 
 Tris base 30.3g 
 Glycine 144g 
Transfer buffer TOTAL 1000mL 
 DI water 700mL 
 Towbin’s buffer 
(10x) 
100mL 
 Methanol 200mL 
TBS-T (10x): TOTAL 1000mL 
Dilute 1:10 with ddH2O DI water 990mL 
pH will be 7.5 Tris base 24.2g 
 NaCl 80g 
 Tween20 10mL 
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APPENDIX C: MICROFLUIDIC DEVICE AND GRADIENT PROTOCOLS  
C.1 Permanent epoxy negative photoresist silicon mold with no built-in well protocol 
 
Supplies 
 3” Si wafer (#447, PO# 0128142, University Wafers, South Boston, MA) 
 SU8-2050 negative photoresist (Cat #Y111072 0500L1GL, MicroChem Corporation, 
Newton MA) 
 Isopropanol 
 Acetone 
 Polyethylene glycol monoethyl acetate (PGMEA) (Cat. #4847431, Sigma Aldrich, St. 
Louis, MO) 
 tridecafluoro-1,1,2,2-tetrahydrooctyl trichlorosilane (Silane) (Cat #SIH5841.0-5GM, 
Gelest, Morrisville, PA) 
Equipment 
 Spin Coater (G3P-8 Spin Coat, Specialty Coating Systems, Indianapolis, IN) 
 UV Source (Model #0130-040-03, Optical Associates IncSan Jose, CA) 
 2 Hot Plates (730 Series, Dataplate Digital hot plate/stirrer, Barnstead|Thermolyne 
Corporation)  
 
Procedure 
1. Turn on the yellow clean room light 
2. Sign into the log book 
3. Put on booties, frock, and cap 
4. Turn on UV exposure tool 
5. Log into UV sign-in book 
a. Must wait 30 minutes after use to turn back on 
6. Flip power switch to turn on 
a. This is the switch on the back. 
b. Wait about 15 minutes to turn on the UV light itself by flipping “start” 
7. Pre-heat the hot plates: 
a. 65°C 
b. 95°C 
c. It is better to change the aluminum foil on the hot plates to ensure that it is smooth 
d. To turn on the plates, press ENTER—plate temp—the temp you want—ENTER 
8. Spin coat: 
a. Turn on the Nitrogen (brown nob) 
b. Enter the recipe you want 
i. Our recipe is #25 
ii. First layer, follow chart for 100 microns 
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iii. Second layer, follow chart for 50 microns 
c. Check to make sure that the spin coat is clean. 
i. If not, clean the spin coat device with acetone and replace the foil 
Wafers: 
1. Helpful notes: 
a. Only place stuff on the shiny side of the wafer 
b. Before using, wash with acetone, then isopropanol, then dry with N-gun. 
c. Place the wafer as close to the center of the spin coat device as possible with the 
shiny side up. 
2. Place (estimate) 3 mL of SU-8 2050 on the spin coat 
a. Be sure to catch the tendril of SU-8 2050 
b. Wipe the bottle off after use 
3. Throw away the use towel in the flammable cabinet garbage 
 
Spin coat procedure and soft bake Part I: 
1. Turn on the vacuum pump making sure that the nozzle is pointed outward 
2. Check your spin coat protocol one more time to be safe 
3. “Start” the spin coat cycle 
4. When done, transfer to 65°C for 5 minutes 
5. Move to 95°C and leave for 15 minutes 
a. While baking, place a glass cover over to prevent dust from settling on the gel 
6. Cool the silicon plates on the metal edge of the fume hood 
7. The soft bake is now finished 
 
UV exposure #1: 
1. Place the mask over the wafer with the ink side down and place under the UV light 
2. Place the square glass cover over the mask so that it lays flat against the gel 
3. Expose for 23 seconds (or about 20 seconds) 
4. Press “expose” after putting in the respective time of exposure. 
a. Be sure to wear the UV glasses while exposing 
 
Spin coat procedure and soft bake Part II: 
1. First, check your program so that it matches the 50 micron parameters 
2. Pour on 2 mL of SU-8 2050 onto the disk and press “start” 
3. When done, transfer to 65°C for 1 minute 
4. Move to 95°C and leave for 6 minutes 
a. While baking, place a glass cover over to prevent dust from settling on the gel 
b. This soft bake will serve as the post-exposure bake for your first layer 
 
UV exposure #2: 
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1. Now, you must align the basic flow design with the herringbone mask 
2. Once you are satisfied with the alignment… 
3. Expose to UV at 80 mJ/cm² 
Post-exposure bake: 
1. 65°C for 1 minute 
95°C for 6 minutes 
a. While baking, place a glass cover over to prevent dust from settling on the gel 
 
Spin coat clean up: 
1. While baking… 
2. Rinse the chuck with acetone and wipe 
3. Replace foil 
4. Wipe down the dish ware that was used 
 
Development: 
1. Develop with Propylene glycol monomethyl ether acetate (PGMEA) 
2. Pour in about 1 cm (in height) to the beaker 
3. Set disc into solution 
4. Wait 10-15 minutes or until all SU-8 is dissolved 
5. Rinse with isopropanol 
6. Blow dry with the N-gun 
7. Rinse with PGMEA then isopropanol 
 
Clean up: 
1. Pour out liquids into the waste container 
2. SU-8 is negative photo-resistant 
a. Rinse with acetone 
3. Wipe out all glassware 
 
Silanization process 
 
1) Place the clean wafer in a degasser unit 
2) Add 2 µL of Silane into a container placed inside the unit. Leave the tip inside as well 
3) Seal the unit and pull house vacuum. Make sure that the degasser unit is completely 
sealed off  
4) Leave the degasser unit under vacuum over night or about 12 hours 
5) After the stipulated time, release the vacuum 
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C.2 Permanent epoxy negative photoresist silicon mold with built-in well protocol 
 
Supplies 
 4” Si wafer (PO# P0654119, WRS Materials, San Jose, CA) 
 Diamond-tip glass cutter 
 Super glue 
 
Procedure 
 
1. Follow all steps for C.1 until the silanization step using the master with the built-in well 
design 
 
2. Using a diamond tip glass cutter, cut out a 15 x 8 mm Si wafer 
 
3. Add a thin layer of super glue on the well pattern of the master 
 
4. Very accurately, place the wafer piece on top of the well of the master wafer. This gives a 
greater depth to the final PDMS device 
 
5. Let the super glue dry. Ensure adhesion by trying to move the wafer piece 
 
6. Proceed to the silanization step of C.1  
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C.3 Creating a PDMS device with no built-in well from the master wafer protocol 
 
Supplies 
 30g PDMS (RTV615A, Piece A, Momentive Specialty Chemicals, Columbus, OH ) 
 3g crosslinker (RTV615A, Piece B, Momentive Specialty Chemicals, Columbus, OH) 
 Glass slides 
 22 gauge needle 
 Isopropanol 
 Distilled water 
 10% Alconox solution 
 
Equipment 
 Plasma cleaner (Harrick Plasma, Ithaca, NY) 
 70° oven  
 Degasser unit 
 Vacuum pump 
 Needle punch 
 
Procedure 
 
1. Mix 30g of PDMS with 3g monomer in a plastic up. Mix until the solution becomes white and 
viscous with a lot of tiny air bubbles 
 
2. Place the cup in the degasser unit and connect it to a vacuum pump.  
 
3. Start the pump. The vacuum forces the air bubbles mixed within the PDMS solution to escape 
from the solution.  
 
4. Keep unit under vacuum until no more bubbles can be seen 
 
5. Release the vacuum and pour the PDMS solution into the Petri dish containing the Si master 
wafer 
 
6. Ensure no bubbles exist in the poured solution. Place the dish in the oven for 1 hour to cure the 
PDMS 
 
7. After 1 hour, remove the wafer from the oven.  
 
8. With a scalpel, cut the patterned part of the PDMS off the wafer. Ensure not to damage the 
wafer while doing so 
 
9. Tape the patterned side of PDMS with scotch tape. This prevents dust from settling on it 
 
10. Polish off the tip of the 22 gauge needle such that it becomes evenly round.  
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11. Using a needle punch, carefully punch holes, through the patterned side, into all the inlets 
and outlets of the devices. These are marked with tiny holes on the device 
 
12. Clean a glass slide first with the 10% alconox solution followed by distilled water and 
isopropanol. Blow dry with a Nitrogen gun 
 
13. Remove the tape from the device and place it, patterned side up, into the plasma cleaner 
along with the glass slide 
 
14. Start the vacuum pump and wait until the pressure inside goes below 500 mtorr.  
 
15. Once the desired pressure is reached, turn the plasma cleaner on high for 1 min 10 secs. 
Release the vacuum valve once midway so as to let a minuscule amount of oxygen in 
 
16. Turn off the plasma cleaner after the stipulated time, turn off the vacuum pump and release 
the vacuum inside 
 
17. Remove the glass slide and PDMS device. Place the patterned side of the device on top of the 
glass slide. Press to ensure firm bonding. Do this as quickly as possible.  
 
18. Leave the device in the oven for 1 hour to ensure complete bonding between the glass and 
PDMS 
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C.4 Gradient generation with Teflon mold protocol  
 
Supplies 
 Microfluidic device 
 Fluorescent cells (See B.1) 
Or 
 Fluorescent microbeads (Yellow/Green: Cat #F8823; Red: Cat #F8821, Life 
Technologies, Grand Island, NY) 
 Petri dish 
 High vacuum grease 
 Distilled water or sterile PBS 
 Vacuum chamber 
 Collagen solution 
 23 gauge needle  
 Non-shrinkable tubing (Cat #ATT-30, Weico, Edgewood, NY) 
 
Equipment 
 Vacuum pump 
 Harvard Syringe Pump 
 Timer 
 
Procedure 
 
1. Prepare a collagen solution of the desired density of either the beads or cells and keep it on ice 
Note: For the microbeads, prepare a 1% solution (v/v) 
 
2. Pour distilled water (for beads) or sterile PBS (for cells) in a deep welled Petri dish 
 
3. Attach one glass slide to the base of the mold using super glue. Grease the top part of the mold 
with high vacuum grease 
 
4. Using a metal wire, poke each of the 20 holes in the mold to ensure the tubes aren’t blocked 
 
5. Attach a 27 gauge needle to a 1 mL syringe. Attach a plastic tubing of the appropriate size to 
the needle 
 
6. Connect the metal tubes to the PDMS device. Connect two syringes, filled with water, to the 
inlets of the PDMS device by inserting the other end of the plastic tubes into the PDMS device 
 
7. Gently push the syringe plunger to check fluid flow through the channels and the tubes. Water 
should exit from each of the 10 inlets connected to the device and enter the cavity 
 
8. Place this assembly in the Petri dish filled with water (or PBS) such that the mold cavity is 
completely immersed in water 
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9. Place the entire assembly in the vacuum chamber and pull vacuum on the system. Bubbles will 
observed through the water surface and any interfaces 
 
10. Leave the vacuum pump on for 5 minutes, tapping the chamber intermittently, so as to 
release the bubbles on the surface 
 
11. Turn off the pump and release the vacuum 
 
12. Remove the dish from the chamber. Take care to ensure that the mold does not break the 
water surface beyond this point.  
 
13. Using two fresh syringes and 17 gauge needles pump the collagen solutions in the respective 
syringes.  
 
14. Remove the water-filled syringes attached to the device and plug the syringes containing the 
collagen solutions to it 
 
15. Load the syringes onto the syringe pump. Set the flow rate appropriately, based on the 
collagen density.  
 
16. Slide a glass slide on top of the mold so as to completely seal the mold 
 
17. Turn on the syringe pump and let the solutions flow for the desired amount of time.  
 
18. After the stipulated time, turn off the pump and detach the mold from the device.  
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C.5 Fluorescence image scanning of Teflon mold gradients protocol 
 
Equipment 
 Typhoon 9400 Image Scanner (GE Electronics) 
 ImageJ Software 
 
Procedure 
 
1. Place the generated gradient mold (with both coverslips on) on the Typhoon scanner 
 
2. Scan for the appropriate excitation and emission spectra  
 
3. After the scan, open the image files using ImageJ software 
 
4. Split the image into five regions. Using the “Measure” function, serially measure the average 
fluorescence intensity of the regions. Also measure the intensity of the standard solution  
 
5. Paste the data into Excel  
 
6. For obtaining the normalized intensity, divide the intensity of the regions by the standard 
solution intensity. This forms the basis for comparison 
 
7. Plot the average intensity as a function of position 
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C.6 Isolation of Teflon mold regions and characterization using FACS protocol 
 
Supplies 
 Metal comb  
 PBS 
 Gradient mold  
 
Equipment 
 BD LSRII Flow Cytometer  
 
Procedure 
 
1. After generating the gradient, gently slide off the top coverslip from the mold. Do this slowly 
to ensure that the gradient isn’t disturbed 
 
2. Place the metal comb into the mold cavity such that the space is equally divided into 5 parts 
 
3. Using a pipette, remove 20 µL of solution from within the cavity for each of the regions 
 
4. Mix this solution with 180 µL of PBS in a centrifuge tube. Pipette multiple times so as to 
completely dissolve the collagen 
 
5. Run the individual samples through the FACS machine 
 
6. Analyze using the FACS software 
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C.7 Creating a PDMS device with a built-in well from the master wafer protocol 
 
Supplies 
 30g PDMS (Sylgard 184 Silicone Elastomer Kit, Dow Corning, Midland, MI) 
 3g crosslinking agent (Sylgard 184 Silicone Elastomer Kit, Dow Corning, Midland, MI) 
 22 gauge needle 
 Isopropanol 
 Hydrophilic transparent polycarbonate membrane (Cat #TMTP09030, EMD Millipore, 
Billerica, MA) 
 Master Wafer 
 Blank Wafer 
 (3-Glycidoxypropyl)methyldiethoxysilane (GPTMS) (Cat #440167, Sigma Aldrich, St 
Louis, MO) 
 (3-Aminopropyl)trimethylsiloxane (APTMS) (Cat #281778, Sigma Aldrich, St Louis, 
MO ) 
 
Equipment 
 Plasma cleaner 
 70° oven  
 Degasser unit 
 Vacuum pump 
 Needle punch 
 
Procedure 
 
1. Mix 30g of PDMS with 3g monomer (10:1) in a plastic up. Mix until the solution becomes 
white and viscous with a lot of tiny air bubbles 
 
2. Place the cup in the degasser unit and connect it to a vacuum pump.  
 
3. Start the pump. The vacuum forces the air bubbles mixed within the PDMS solution to escape 
from the solution.  
 
4. Keep unit under vacuum until no more bubbles can be seen 
 
5. Release the vacuum and pour the PDMS solution into the Petri dish containing the Si master 
wafer. Similarly, add the PDMS solution to the blank wafer as well 
 
6. Ensure no bubbles exist in the poured solution. Place the wafers in the oven for 1 hour to cure 
the PDMS 
 
7. After 1 hour, remove the wafers from the oven.  
 
8. With a scalpel, cut the patterned part of the PDMS off the wafer. Ensure not to damage the 
wafer while doing so 
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9. Tape the patterned side of PDMS with scotch tape. For the blank wafer, tape the wafer side of 
the PDMS. This prevents dust from settling on it 
10. Polish off the tip of the 22 gauge needle such that it becomes evenly round.  
 
11. Using a needle punch, carefully punch holes, through the patterned side, into the two inlets of 
the devices. These are marked with tiny holes on the device 
 
12. Cut the blank PDMS into two. Place the taped side of the patterned and blank PDMS on top 
of each other. With a scalpel, cut out a slab corresponding to the well on the master PDMS 
 
13. Remove the tapes and place the PDMS pieces, tape side up, into the plasma cleaner  
 
14. Cut out membrane pieces of adequate area and place them in the plasma cleaner 
 
15. Start the vacuum pump and wait until the pressure inside goes below 500 mtorr.  
 
16. Once the desired pressure is reached, turn the plasma cleaner on high for 1 min 10 secs. 
Release the vacuum valve once midway so as to let a minuscule amount of oxygen in 
 
17. Turn off the plasma cleaner after the stipulated time, turn off the vacuum pump and release 
the vacuum inside 
 
18. Remove PDMS pieces and the membrane. Place the PDMS in a 1% solution of GPTMS (in 
dH2O) and the membrane in a 1% solution of APTMS (in dH2O) and incubate at R.T. for 20 
minutes 
 
19. Wash all pieces with dH2O, place on a lint-free cloth to tap gently to remove any water 
 
20. Place the membrane on the patterned side of the PDMS and place the blank PDMS on top of 
the membrane such that the well aligns with the slab carved out of it. This creates a trough to 
enable media supplementation to cells underneath the membrane 
 
21. Let sit in the oven at 65 °C overnight  
 
22. Autoclave before use  
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C.8 Gradient generation with built-in well protocol 
 
Supplies 
 Microfluidic device 
 Fluorescent cells, beads or protein-conjugated polymer 
 23 gauge needle  
 Non-shrinkable tubing (Cat #ATT-30, Weico, Edgewood, NY) 
 
Equipment 
 Harvard Syringe Pump 
 Timer 
 
Procedure 
 
1. Prepare the desired polymer solutions (See D.4 for GelMA polymer preparation) in a micro 
centrifuge tube 
 
2. Load the 1 mL syringe connected to the tubing on to the syringe pump  
 
3. Withdraw the polymer solution from the micro centrifuge tube at a speed of 100 µL/min 
 
4. Insert the ends of the tubing into the inlets of the PDMS device  
 
5. Infuse at a speed of 100 µL/min until the solution is halfway through the well 
 
6. Stop the pump. Due to high viscosity, the solution keeps flowing. Detach tubing once well is 
filled 
Note: If the solution is not viscous, run the pump until well is completely filled 
 
7. In case of GelMA hydrogels, polymerize the solution with the membrane side up by placing 
under UV light (10 mW/cm
2
) for 25 seconds. (See D.4 for complete polymerization process) 
 
8. For cell cultures, add media into the trough created by the blank PDMS and place in the 
incubator  
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C.9 Built-in well gradient gel cell retrieval and region isolation protocol 
 
Supplies 
 Scalpel 
 Blade 
 Glass slide 
 Ruler and Pen 
 Sharp tipped forceps 
 Spatula 
 
Procedure 
 
1. On a white sheet of paper, mark out two main lines 15 mm apart and make 5 divisions 3 mm 
apart 
 
2. Remove the microfluidic device from the incubator and aspirate supernatant media from the 
trough 
 
3. With a scalpel, cut out the membrane from all four sides 
 
4. Using the forceps, peel off the membrane off the device. The gel should be inside the PDMS 
well 
 
5. Using a spatula, gently lead the gel onto a glass slide. Ensure it is flat and horizontal 
 
6. Place the glass slide on the marked paper such that the gel aligns with the two main lines 
 
7. With a blade, cut gel into sections along the other marked divisions 
 
8. Use the regions as required 
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APPENDIX D: POLYMER SYNTHESIS, FUNCTIONALIZATION AND 
PHOTOPOLYMERIZATION PROTOCOLS 
D.1 Gelatin Methacrylate (GelMA) synthesis protocol 
 
Supplies 
 Porcine Gelatin Type A, 300 bloom (Cat #G2500, Sigma Aldrich, St. Louis, MO) 
 Methacrylic anhydride (Cat #64100, Sigma Aldrich,  St. Louis, MO) 
 PBS 
 Dialysis tubing (12,000 – 14,000 MW) (Cat #21-152-8, Fisher Scientific, Pittsburgh, PA) 
 
Equipment 
 Magnetic stirrer and hot plate 
 Lyophilizer 
 
Procedure 
 
1. Prepare a 10% (w/v) solution of gelatin in PBS and stir at 60 °C until the gelatin has fully 
dissolved 
 
2. Add Methacrylic anhydride dropwise, stirring the solution continuously. 
 20% methacrylic anhydride (v/v) yields roughly 85% degree of functionalization 
 10% methacrylic anhydride (v/v) yields roughly 60% degree of functionalization 
 
3. Allow the reaction to run for 1 hour  
 
4. Dilute the reaction with five-fold volume of dH2O 
 
5. Pre-soak dialysis tubing in water for 20 minutes.  
 
6. Clip one end of the tubing with the heavier clips and pipette the reaction solution. Leave 
enough space for expansion due to dialysis. Clip the top end and place the tubing in water 
 
7. Dialyze for a minimum of 7 days, changing water daily and maintaining the solution at 60 °C 
with constant stirring  
 
8. After dialysis, pipette the solution into 50 mL conical tubes and freeze at -20 °C, followed by 
lyophilization until all the water has been removed. Store the dried GelMA for further use 
 
9. Check degree of functionalization via NMR spectroscopy 
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D.2. Lithium acylphosphinate (LAP) photoinitiator protocol  
 
Supplies 
 2,4,6-trimethylbenzoyl chloride (Cat #682519) 
 dimethyl phenylphosphonite (Cat #149470) 
 lithium bromide (Cat #213225) 
 2-butanone (Cat #360473) 
 
All reagents purchased from Sigma Aldrich, St. Louis, MO) 
 
Equipment 
 Hot plate and stirrer  
 Schlenk line with Argon gas  
 
Procedure 
 
1. 2,4,6-trimethylbenzoyl chloride was added drop wise to an equimolar amount of continuously 
stirred dimethyl phenylphosphonite at room temperature and under argon.  
 
2. The reaction mixture was stirred for 18 hours after which a fourfold excess of lithium bromide 
in 2-butanone was added and heated to 50 °C to form a solid precipitate.  
 
3. The mixture was cooled to ambient temperature then filtered and washed 3 times with 2-
butanone to remove unreacted lithium bromide.  
 
4. Excess solvent was subsequently removed by vacuum, leaving behind a white residue which is 
LAP 
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D.3. Functionalization of SCF with Polyethylene glycol (PEG) protocol  
 
Supplies 
 3500 MW PEG-NHS Ester (Cat #ACLT-PEG3500-NHS, JanKem Technology, Plano, 
TX), store at -20 °C 
 Recombinant Murine SCF (Cat #250-03, Peprotech, Rocky Hill, NJ)  
 PBS with a pH of 8.0  
 10K MW Pierce Concentrator PES (Cat #88513, Thermo Scientific, Waltham, MA) 
 
Note: Handle the protein carefully and gently. Avoid vigorous agitation via vortexing 
 
Procedure 
 
1. Create a 1 mg/mL stock solution of the PEG-NHS ester in pH 8 PBS (total volume need not 
exceed 100 uL)  
 
2. Mix the ester with SCF at a molar ratio of 24:1  
 
Calculation: 
 
For 50 µg of SCF, moles = 50/18300 = 0.002732 µmole 
Therefore, 24 excess of the ester = 24 x 0.002732 x 3500 = 229.5 µg 
 
3. Let mixture react for 1 hour. Pipette at intervals to assure mixing  
 
4. Separate the unreached ester using the 10K MW Pierce concentrator (follow manufacturer 
instructions)  
 
5. Resuspend final protein solution in 1% BSA and determine concentration via ELISA. This is 
referred to as PEG-SCF 
 
6. Make aliquots and store at -80 °C until further use  
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D.4 GelMA hydrogel synthesis (cellular and acellular) protocol  
 
Supplies 
 GelMA (See D.1) 
 LAP photoinitiator (See D.2) 
 UV Lamp 
 PBS 
 Cells 
 Plastic well mold  
 Glass slides 
 
Procedure 
 
1. Dissolve GelMA in PBS to create a 6.5% (w/v) solution. UV sterilize the GelMA prior to 
adding the PBS  
 
2. Stir at 60 °C until all the GelMA is dissolved. Place in the incubator at 37 °C until further use 
 
3. For cellular gels, resuspend cells in PBS and store on ice until further use 
 
4. Create a 5% stock solution of LAP in sterile PBS  
 
5. Mix the components to yield a 5% GelMA, 0.1% PI solution. Adjust to final volume using 
PBS.  
 
6. In case of cellular gels, add cell solution to the mixture and mix well 
 
7. Using a 3D printer, print a plastic mold containing 6 wells that are 7 mm in diameter and 700 
µm in thickness. Sand down the surface to give a final thickness of 500 µm 
 
8. Wrap two glass slides with parafilm, sandwich the mold between them and clip the 
arrangement tight with binder clips  
 
9. Pipette the pre-polymer solution into the wells and place under UV light for 15 seconds (10 
mW/cm
2
) 
 
10. Gently separate the glass slides (add PBS at the edges to facilitate separation) and remove the 
gels  
 
11. Place in media/PBS immediately  
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D.5 SCF time-release profile in GelMA hydrogels protocol  
 
Supplies 
 PEG-SCF (See D.3) 
 Soluble SCF 
 Plate reader 
 
Procedure 
 
1. Instead of cells, add the PEG-SCF or soluble SFC at the desired concentrations (100 or 400 
ng/mL)  
 
2. Follow protocol D.3 to make the GelMA hydrogels 
 
3. Place the gels in 500 µL PBS and place it in the incubator  
 
4. Collect PBS at intervals of 12hours, 2days, 4days and 7 days, replacing it with fresh PBS 
every time  
 
5. Store the collected PBS at -80 °C 
 
6. After all the solutions for all the samples have been collected, perform the ELISA assay 
(protocol B.7) to determine individual SCF concentrations in each sample  
 
7. Calculate the initial amount of SCF added to the gels and plot the % of SCF released (or 
retained) in the samples based on ELISA  
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D.6 GelMA gels digestion protocol  
 
Supplies: 
 Collagenase Type 2 (Cat. # LS004174, Worthington Biochemical, Lakewood,NJ) 
 PBS/5%FBS 
 Sterile filter tubes (Polystyrene with nylon filter, Cat# 352235, BD Bioscience, Bedford, 
MA) 
 
Procedure: 
1. Create a 1000 U/mL stock solution of the collagenase by dissolving it in the PBS/5%FBS 
buffer. Can be used up to 7 days after preparation (Store at 4 °C) 
 
2. Remove the supernatant media from the GelMA hydrogel and wash once with PBS 
 
3. Add the collagenase solution and PBS/5%FBS buffer to give a final collagenase concentration 
of 50 U/mL 
 
4. With a scalpel, cut the gel into small pieces for faster digestion 
 
5. Place the well plate on a shaker in the incubator 
 
6. Gel digestion takes between 40 – 60 mins.  
 
7. Filter solution through the sterile filter tubes and centrifuge to retrieve cells  
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